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INTRODUCTION 
 
1. PHYSIOLOGICAL ASPECTS OF MAMMARY GLAND DEVELOPMENT 
AND INVOLUTION 
 
 The mammary gland is a highly dynamic and complex tissue with a 
fundamental function: to provide nutrition and immunological protection to 
mammalian offspring by means of milk production (Ward & German, 2004). 
Considering the complex biochemical mechanisms of milk production and 
secretion, lactation appears to have evolved gradually, becoming a highly 
specialized skin gland that initially, like other skin glands, was part of the 
protective epithelial body barriers. Corroborating this hypothesis, milk is rich in 
enzymes such as xanthine oxidoreductase (XOR), lysozyme and other 
molecules with antimicrobial and protective effects. This composition strongly 
suggests that the mammary gland evolved from the innate immune system, 
as a mucus skin gland protecting the newly evolving mammalian skin from 
infectious disease (figure 1) (Vorbach et al, 2006).  It has also been 
hypothesized that lactation, as it is known today, evolved as an inflammatory 
response to tissue damage and infection and that inflammatory molecules 
became key regulators of lactation. This way, the nutritional value of milk 
evolved subsequently from its immunological function (Shahani et al, 1973). 
 
 In fact, as it will be exposed further on, mammary gland evolutionary 
steps share many common mechanisms with inflammatory responses 
(Vorbach et al, 2006). These pro-inflammatory changes, more evident during 
post-lactational involution, are an adequate environment to allow tumour 
progression, given an oncogenic event (Lyons et al, 2011). 
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Figure 1. Proposed evolution of the mammary gland from a mucus secreting 
epithelial gland. Mammary glands presumably evolved as mucus-secreting 
skin glands. The evolution of additional functions resulted in the secretion of 
fat droplets, α-lactalbumin and lactose. Consequently, the mammary gland 
evolved from a protective immune organ into a reproductive organ unique to 
the class mammalia. Adapted from (Vorbach et al, 2006). 
  
1.1 MAMMARY GLAND ANATOMY 
  
Mammary gland structure consists of a compound tubulo-alveolar gland 
embedded within an irregular connective tissue that undergoes a series of 
changes from conception to senescence (Stingl et al, 2005). It consists of 15 
to 25 lobes, each of which is drained by a collecting duct that terminates in the 
nipple. The collecting duct has several branches which end in the basic 
functional unit of the breast – named the terminal ductal-lobular unit (TDLU) 
(figure 2). The TDLU is composed of a small segment of terminal duct and a 
cluster of ductules (acini), which are the actual secretory units. The functional 
structures are surrounded by a varying amount of fat and collagenous tissue. 
The main arterial supply is from the internal mammary and lateral thoracic 
arteries. The venous drainage is mainly by branches of internal thoracic veins, 
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but anatomical variations have been described. The most important lymphatic 
drainage is to the axilla, while less of the lymph flow is drained via internal and 
posterior intercostal lymphatics.  
 
As mentioned above, the breast is affected by physiologic changes in 
morphology and function throughout life-time from menarche to menopause, 
during each menstrual and pregnancy/lactation cycles. These changes are 
regulated by hormonal activity, mainly prolactin (PRL), oestrogen (E) and 
progesterone (Pg). At menarche, the main events include development and 
growth of ductal and lobular units. During pregnancy and lactation, a 
remarkable rise in hormone levels induces growth and secretory activity of the 
breast. Post-menopausally, the breast undergoes involution characterized by 
atrophy of the parenchymal structures (Tavassoli, 1992). The modifications 
observed with each menstrual cycle and pregnancy/lactation cycles have 
been the basis of studies that prove that mammary gland initially develops 
from multipotent embryonic progenitors which give rise to lineage-restricted 
stem cells with renewal potential that ensure the homeostasis the gland 
(Villadsen et al, 2007). Microscopically, the normal breast structure is 
classified into two tissue compartments:  a stratified epithelium, derived from 
embrionary ectoderm, which consists of ducts and alveoli that contain milk-
producing cells; and the mesodermally-derived stroma, also known as 
mammary fat pad which main components are adipocytes, although it also 
contains fibroblasts, cells from the haematopoietic system, extracellular matrix 
(ECM), blood vessels and neurons (Hennighausen & Robinson, 2005)A small 
part of the ducts at the nipple is lined by squamous epithelium (Tavassoli, 
1992). In the normal breast, the stratified epithelium consists of two different 
cell populations, epithelial and myoepithelial, which origin is now believed to 
be the lineage restricted stem cells (Van Keymeulen et al, 2011). These cells 
can be differentiated with immunohistochemical staining using antibodies 
against cytokeratin (CK) and myosin respectively (figure 2 A).  
 
  The epithelial cells are luminal secretory and ductal cells, which undergo 
functional differentiation in pregnancy to produce milk. The myoepithelial cells 
encase the luminal cells, are contractile and participate in the delivery of milk 
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in response to oxytocin stimulation (Hennighausen & Robinson, 2005).  It has 
been hypothesized that the generation of cellular heterogeneity in breast 
lesions depends on the underlying developmental program of the normal 
breast, and that breast carcinoma heterogeneity could arise from the 
neoplastic transformation of either an epithelial or myoepithelial cell, or even 
from a lineage restricted stem cell (Gusterson et al, 1982; Van Keymeulen et 
al, 2011).  
 
 
Figure 2. Mammary gland structure from a macroscopic and microscopic point 
of view (A). Adapted from (Bosch et al, 2010; L Tabar, 1998). 
 
  As for the changes that the mammary gland undergoes throughout the 
life spam of a mammal, it is important to differentiate distinct stages within 
normal development from embryonic stage to the final involution process 
during menopause. There are two characteristics that make this organ unique; 
the first is that most of its development takes place post-natally. While the 
primordia of the gland are formed early in embryogenesis as derivatives of the 
epidermis, growth of the gland proceeds rather slowly until puberty when the 
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parenchyma starts to extend and fill the mammary fat pad (Robinson et al, 
1999). The second characteristic is that its structure changes periodically in a 
female’s reproductive life with successive cycles of proliferation, differentiation 
and apoptosis. In fact, these changes take place in each menstrual cycle, but 
the terminal functional differentiation is reached only during pregnancy and 
lactation when the development of alveoli reaches its final differentiation stage 
and synthesis of specific milk proteins takes place. This is followed by 
subsequent massive apoptosis of epithelial tissue with weaning. These 
dramatic changes have placed the mammary gland one of the most important 
physiological models to study proliferation and apoptosis at a molecular level.  
 
On the other hand, mammary gland developmental program shares 
striking similarities with breast carcinogenesis program. In fact, as it will be 
specified later on, pregnancy and post-partum related breast cancer is a 
disease with increasing incidence and worse prognosis, and preliminary data 
seem to point to the special physiologic environment in mammary gland 
during pregnancy and specially involution, as the main reason for this 
aggressiveness. Before going into detail on the parallelisms between 
mammary gland physiologic changes and carcinogenesis, it is important to lay 
out the different stages in mammary gland development and the molecular 
pathways underlying them. Focus will be placed on the mouse model, as it is 
the most studied and there is evidence that it is a good surrogate to human 
physiology. 
 
1.2 STAGES IN MAMMARY GLAND DEVELOPMENT 
 
Mammary development occurs in three distinct and differentially 
regulated stages: embryonic, pubertal and adult. The adult phase can be 
further subdivided in pregnancy/lactation development, involution post-
weaning and involution during menopause.  
 
1.2.1 Embryonic Stage 
 
 The first morphological indication of mammary development in most 
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mammalian embryos is the appearance of a localized thickening on the 
ectoderm or epidermis. In many mammals, the formation of the individual 
gland buds is preceded by the elevation of an epidermal mammary crest and 
a milk line that runs along most of the length of the trunk. This milk line then 
fragments and regresses except for the individual gland buds that may form 
(anteriorly, in the thoracic region as in primates and elephants, posteriorly in 
the inguinal region as in most ungulates, or all along the trunk as in pigs).  In 
the mouse embryo, bilateral mammary lines are formed on the ectoderm 
between embryonic day 10 and 11. From a morphological point of view, 
epidermal cells become columnar and multilayered, defining a ridge that 
protrudes above and below the plane of the single-layered primitive epidermis 
(Hens & Wysolmerski, 2005). From a molecular point of view, the specification 
of the mammary line is dependent on the activation of the canonical Wnt/β-
catenin  and the fibroblast growth factor (Fgf) pathway, which acts in parallel 
to Wnt (Chu et al, 2004; Mailleux et al, 2002). The second step in mammary 
gland morphogenesis is the placode formation which can be observed by 
embryonic day 11.5. The same signalling pathways are implicated in this step 
(Wnt and Fgf) together with the transcription factor Gata3 (Asselin-Labat et al, 
2007; Eblaghie et al, 2004; Hens & Wysolmerski, 2005; Mailleux et al, 2002). 
The third step is the bud formation. The size of the bud slowly increases until 
a circumscribed epithelial ball is formed within the epidermis by embryonic 
day 15. In this step Wnt signalling also seems to take an important role (Chu 
et al, 2004; Hens & Wysolmerski, 2005). During this period, the epithelial bud 
is surrounded by layered mesenchymal cells which constitute the primary 
mammary mesenchyma. The interaction between epithelial cells and the 
underlying mesenchyma is crucial for further development of the gland. 
Another factor that plays an important role in the epithelial-mesenchyma 
interaction, is the parathyroid hormone related protein (PthrP) (Foley et al, 
2001) which is also necessary for the mammary mesenchyme to induce the 
nipple formation from the overlying epidermis (Foley et al, 2001; Wysolmerski 
et al, 1998). The final step is the formation of the rudimentary ductal tree. This 
initial branching is hormone independent (Hennighausen & Robinson, 2001). 
A primary sprout grows out on embryonic day 16. Continued proliferation until 
the end of gestation leads to formation of a small ductal tree that consists of 
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10 to 15 branches arising from the single duct that emanates from the nipple 
(Robinson et al, 1999). The genes that regulate this phase are PthrP and its 
down stream effectors, along with Wnt which seems to be crucial for the 
outgrowth of the initial ducts from the bud (Cowin & Wysolmerski, 2010; Hens 
& Wysolmerski, 2005).  A graphical summary of the embryogenic stages of 
mammary gland development can be seen in figure 3. 
 
Figure 3. Mammary gland formation in the embryonic and adult phase. After 
placode appears, the mammary bud develops through cell proliferation. This 
bud is surrounded by mesenchymal cells and will grow into rudimentary ductal 
tree. Most of the develoment of the gland is done post-natally with puberty, 
reaching the final differentiation state with pregnancy and lactation E: 
Embryonic day. (Cowin & Wysolmerski, 2010; Gjorevski & Nelson, 2011). 
 
1.2.2 Pubertal Development 
 
 Post-natally, the mammary gland grows isometrically with body growth 
until puberty, when the influence of E and Pg cause massive ductal elongation 
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and branching. In fact, the changes observed in the mammary gland during 
puberty, pregnancy, lactation, menopause, and each menstrual cycle are all 
correlated to physiologically varying amounts of circulating oestradiol in the 
blood stream (Petersen et al, 1987). Puberty is a striking stage of mammary 
morphogenesis. Prompted by elevated levels of ovarian hormones, the ends 
of the growing ducts form the terminal end buds (TEB) in rodent anatomy, or 
TDLU in the human equivalent, which are the functional units of the gland. It is 
important to highlight that these are the sites where most breast tumours arise 
and the postulated site for stem cell niche (Hilakivi-Clarke, 2007). TEB contain 
two main cell populations, the cap cells which will give rise to myoepithelial 
cells; and the inner body cells that give rise to luminal cells of the mammary 
epithelium. It was thought that mammary stem cells gave rise to a common 
progenitor that would split into the two lineages mentioned (Siegel & Muller, 
2010) but a recent study points out to the existence of two different lineage-
restricted progenitors (Van Keymeulen et al, 2011). The TEB invade the fat 
pad and bifurcate at regular intervals generating the ductal tree. In the mature 
mouse the entire fat pad is filled with a system of primary and secondary 
ducts with side branching that form and disappear with each menstrual cycle, 
and TEB are replaced by terminal end ducts.  
 
As specified, E and Pg play a crucial role in postnatal mammary gland 
development. Their function is exerted by means of their receptors (oestrogen 
receptor, ER and progesterone receptor, PgR) that are expressed in most 
epithelial cells (Hennighausen & Robinson, 2005). With every menstrual cycle 
proliferation and apoptosis occur in response to E. The mechanisms by which 
steroid hormones stimulate mammary epithelium growth are controversial. 
Among the specific hormone receptors involved, two ER have been 
discovered, ERα and ERβ. The first is predominant in breast tissue and is 
required for normal ductal elongation and outgrowth during puberty 
(Bocchinfuso et al, 2000). ER acts as a transcription factor which becomes 
activated upon ligand binding; translocates to The nucleus where jt joins the 
specific DNA sequences known as Estrogen Regulatory Elements (ERE) and 
activates gene transcription (Eroles et al, 2010). Additionally, binding of E to 
the ER can be modulated by Pg. There are also two known isoforms of PgR, 
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A and B, which are encoded by two transcripts derived from the same gene, 
but it is PgR B that is required to carry out the proliferative effect of Pg on 
mammary epithelial cells. Pg is essential for the expansion of the alveolar 
compartment while its contribution to ductal elongation and branching is minor 
(Hennighausen & Robinson, 2005). There are other transcription factors that 
play an important role in mammary gland postnatal development, namely 
GATA-3 which expression is, at this point, restricted to the luminal epithelial 
cells and is absent from the myoepithelial compartment. Its function is 
essential for ductal elongation. (Kouros-Mehr et al, 2006; Siegel & Muller, 
2010). It has been demonstrated that the numbers of proliferative and 
apoptotic events vary during the menstrual cycle and that these variation 
occur also in a cyclic manner, but these variations do not depend solely on 
steroid hormone fluctuations, since other factors such as several Bcl-2 family 
proteins change during the menstrual cycles (Navarrete et al, 2005). 
 
1.2.3  Adult Stage: Preganancy and Lactation 
 
The final step in proliferation and differentiation of the mammary gland is 
reached with pregnancy and lactation. During pregnancy, the branched ductal 
system, that expanded during puberty, further develops into a lobuloalveolar 
compartment. Among the transcription factors that regulate this process NF-
κB is known to play a crucial role (Cao et al, 2001). The ducts branch into 
decreasingly smaller ductules, which terminate in lobules. Lobules are 
composed of alveoli, which consist of secretory epithelial cells that undergo 
functional differentiation with parturition. Hence, the number of epithelial cells 
increases by approximately 100 fold in response to several hormones and 
signalling factors. The hormones that play an essential role in this step of 
breast development are E, Pg, growth hormone (GH), glucocorticosteroids, 
insulin and PRL, being the most important Pg and PRL (Hennighausen & 
Robinson, 2005).  ER has a critical role in ductal elongation and PgR directs 
lobuloalveolar development during pregnancy (Siegel & Muller, 2010). In early 
stages of pregnancy, PgR positive cells are lined closely to the proliferating 
cells, which implies that the proliferative effect of PgR is mediated in part in a 
paracrine fashion (Brisken et al, 1998; Pang & Hartmann, 2007). After 
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parturition, progesterone withdrawal is a potent lactogenic trigger (Pang & 
Hartmann, 2007). During pregnancy PRL is involved in the maintenance of 
the corpus luteum in the early stages, to ensure the secretion of E and Pg, 
and in mammary gland development. After this initial stage, both functions of 
PRL are carried out by placental lactogens, until birth, when PRL will take 
over again.  
 
The most dramatic event in the lactation cycle, lactogenesis, occurs at 
parturition when there is a sudden increase in the secretory activity of the 
mammary gland. Lactation has been artificially subclassified in two stages in 
order to better understand the process: the first stage represents the stage of 
pregnancy when the mammary epithelial cells differentiate into lactocytes 
(secretory mammary epithelial cells) with the capacity to synthesize unique 
milk constituents such as lactose, casein, α-lactalbumin, fatty acids etc. The 
second stage is the initiation of copious milk secretion. These two stages are 
known as secretory differentiation and secretory activation, respectively 
(Anderson et al, 2007). It is believed that along with PRL secretion from the 
hypophysis, the Pg withdrawal after birth triggers secretory activation. Also, 
the glucocorticoid receptors that are present in the cytosol of mammary 
epithelial cells, when bound to glucocorticoids, translocate to the nucleus and 
act synergistically with PRL-activated transcription factors to enable the 
synthesis of milk proteins, such as, casein and α-lactalbumin. The main 
regulatory factors that account for this final functional differentiation are known 
to be GATA3, ELF-5, AKT and STAT5. 
 
1.2.4 Post-lactational Mammary Gland Involution 
 
Post-lactational involution is the process following weaning of the litter by 
which the mammary gland undergoes massive cell death and tissue 
remodelling in order to return to a virgin-like state. The physiology and 
genetics of apoptosis are easily studied in the mouse mammary gland where 
most of the epithelium is removed within 6 days of weaning. The study of the 
mechanisms underlying this process has been possible using a forced 
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weaning model in which the pups are removed in day 10-11 after birth, which 
is the peak of lactation. This precipitates a synchronous involution and allows 
the study of the molecular mechanisms that take place and their 
morphological counterpart (Watson, 2006). This model has permitted to 
elucidate that there are two phases in post-lactational involution: a reversible 
first phase that lasts 48h; and a second irreversible phase that initiates the 
remodelling program and returns the gland to a pre-pregnant state (Lund et al, 
1996). Each phase is characterized by specific gene expression.  
 
In the first phase of involution after weaning, milk stasis induces 
apoptosis. This phase is triggered by local factors and lasts approximately 
48h. The influence of local factors on apoptosis initiation has been proved 
using a teat-sealing technique. Milk accumulation triggers increased 
expression of the death-inducing bax gene through a yet-undefined 
mechanism. The same stimuli mediate loss of STAT5a and 5b 
phosphorylation disrupting the principal pathway for prolactin signalling (Li et 
al, 1997b; Marti et al, 1997). It is thought that milk stasis promotes apoptosis 
through loss of polarization of luminal cells.  
 
 As for the regulatory pathways and the genes that are up-regulated 
during this first phase of involution, two studies (Clarkson et al, 2004; Stein et 
al, 2004) have revealed that there are four distinct gene expression profiles in 
the first 4 days of involution that partially overlap one another: a rapid but 
transient increase in gene expression 12h after weaning (group1); a rapid 
activation, which peaks at 12 h and is sustained for up to 4 days (group2); a 
delayed induction of gene expression that is not maximal until 24 h but is also 
sustained for at least 96h after weaning (group3); and a gradual increase in 
expression, that peaks at the last time point of the array analysis, 96 h 
(group4). It is noticeable from these microarray studies that there is a clear 
up-regulation of acute phase response (APR) genes (Pensa et al, 2009). 
Different genes are expressed in quite distinct patterns with some being 
expressed early (within 12h) and others later, during the second phase. Group 
1 contains transcripts for the death receptor (DR) ligands and class II APR 
genes. This cluster also contains genes activated by NF-κB. Gene cluster 2 is 
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characterized by a profile of STAT3 regulated genes, and it contains 
transcripts for inflammatory (il-1β) and anti-inflammatory regulators (slpi - 
secretory leukocyte protease inhibitor) and also acute phase proteins (APP) 
such as orosomucoid 2. The CAAT/enhancer binding protein transcription 
factor (C/EBP) δ, that has been shown to regulate involution (Thangaraju et 
al, 2005) and the class I APR (Poli, 1998) are in this cluster also. The third 
group of transcripts has a similar profile to group 2 but peaks at 24h. Genes 
expressed in this profile include cd14 and C/ebpβ. CD14 could have a dual 
role as a suppressor of bacterial infection and as a mediator of the 
phagocytosis of shed cells (Devitt et al, 1998). The fourth group has a gradual 
and sustained increase in expression level from 24h onwards. The 
predominant genes in this group are associated with innate immunity, 
antimicrobial defence and inflammation and include immunoglobulins, 
complement components, some class II APP that are regulated by STAT3 
alone (Alonzi et al, 2001). The regulator of phagocytosis, mfge8, has also this 
expression profile. Loss of MFGE8 results in deregulated phagocytosis during 
involution, tissue scarring, and failed lactation in subsequent pregnancies 
(Atabai et al, 2005; Hanayama & Nagata, 2005) emphasizing the importance 
of efficient clearance of dead cells for tissue remodelling and function. In 
addition to immunoglobulins, a range of soluble innate defence factors are 
expressed at high levels during involution, including antimicrobial factors that 
may protect from mastitis (Clarkson et al, 2004; Sordillo & Streicher, 2002). 
The striking outcome of these studies is the association of involution with an 
inflammatory and acute phase response. Among the regulatory pathways that 
control mammary gland involution from the early phases, STAT3, the NF-κB, 
TGF-β and phosphatidil inositol 3 kinase (PI3K)/AKT pathways are the most 
important and will be explained later on in more detail (Clarkson et al, 2004).  
 
1.2.5 Mammary Gland Involution During Menopause 
 
The last phase in mammary gland development is the final involution 
that takes place during menopause. Lobular involution is a distinct process 
from post-lactational involution. Unlike the dramatic cell death and remodelling 
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following weaning, lobular involution is associated with a gradual decrease in 
the complexity and extent of ductal epithelium with age. This stage, that 
implies both lobular and ductal regression (Howard & Gusterson, 2000),  
appears to be an irreversible process in which the number and size of acini 
per lobule are reduced and the intralobular stroma is replaced with collagen 
(Hutson et al, 1985; Radisky & Hartmann, 2009) whereas the glandular 
epithelium and interlobular connective tissue regress to be replaced by fat 
(Howard & Gusterson, 2000). Hence, the mammary tissue is no longer 
functional. The timing and extent of lobular involution can vary considerably 
among individual women (Hutson et al, 1985).  
 
A large study has noted that the extent of lobular involution is associated 
with a significantly reduced risk of breast cancer (Milanese et al, 2006). While 
this finding is consistent with the widespread understanding that lobules (or 
TDLUs) are the anatomic substructure that gives rise to breast cancer, this 
study points to the fact that progressive degrees of involution are associated 
with reduced cancer risk. Completion of involution around age 50 coincides 
with the well-recognized slowing in the rate of increase of breast cancer at 
that age, raising the possibility that lobular involution is contributing to the 
decrease breast cancer risk (Baer et al, 2009; Henson et al, 2006).  
 
2. MOLECULAR MECHANISMS CONTROLING MAMMARY GLAND    
DEVELOPMENT IN THE LACTATION/INVOLUTION CYCLE 
 
2.1 LACTATING MAMMARY GLAND 
 
As it has been previously specified, the final step in mammary gland 
development and differentiation is reached with pregnancy and lactation. 
Lactation, being the most differentiated state, is mainly regulated by PRL, 
secreted by the hypophysis. PRL mediates its function via its receptor 
(PRLR), a transmembrane protein of the class I cytokine receptor family 
(Boutin et al, 1988).  This family includes the GH receptor, interleukin (IL) 
receptors, erythropoietin (EPO), granulocyte colony-stimulating factor (G-
CSF), granulocyte– macrophage CSF (GM-CSF), leukaemia inhibitory factor 
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(LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF) and the more 
distantly related interferon (IFN) receptors (Watson & Burdon, 1996). PRLR is 
associated with a Janus kinase (JAK) and a Signal Transducer and Activator 
of Transcription (STAT) factor. The Stat family member that is activated down 
stream of PRLR during lactation is STAT5. Briefly, ligand binding (PRL) 
induces dimerization of one or more of the receptor chains, which brings 
together two JAK. The proximity of the receptor chains plus their associated 
JAKs results in tyrosine cross-phosphorylation of both JAKs and specific 
residues on the receptor. The phosphorylated tyrosine residues on the 
receptor recruit STAT5 protein, which in unstimulated cells exist as monomers 
in the cytosol. A transient association of the STAT with the receptor results in 
tyrosine phosphorylation of the STAT, which oligomerizes with at least 
another STAT protein through specific SH2 (Src-homology 2) domain-
phosphotyrosyl interactions and becomes activated. Activated STAT5 
translocates to the nucleus and binds to DNA specific Gamma Activated 
Sequence (GAS) sites (TTCCNGGAA) activating transcription. Activated 
JAK2 may also associate with the SH2 domain of SRC homology collagren 
protein (SHC), which then interacts with GRB2 (an adaptor protein) following 
tyrosine phosphorylation, thereby activating the mitogen activated protein 
kinase (MAPK) pathway. Figure 4 schematically depicts this molecular 
pathway.  
  
 STAT5 is a transcription factor that was originally identified by its role in 
activation of transcription of milk-protein genes in response to PRL activation 
(Wakao et al, 1994). Now, it is known to be encoded by two different genes, 
giving rise to STAT5a and STATb; and to participate in a plethora of signalling 
pathways (Ihle, 2001). Stat5a deficiency in mice results in the loss of 
mammary gland development and consequently in lactation failure (Liu et al, 
1997a). The deletion of Stat5b alone results in a phenotype with similarities to 
that observed in GH receptor deficient mice (Udy et al, 1997). Deleting both 
Stat5a/b results in a phenotype that is identical to that observed in PRLR 
deficient mice and is consistent with the concept that all the physiological 
functions mediated by PRL require STAT5a/b (Teglund et al, 1998). 
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Figure 4. Prolactin signal transduction pathways. A schematic representation 
of the pathways that have been implicated in prolactin signal (PRL) 
transduction. GAS: TTCCNGGAA  (Watson & Burdon, 1996). 
 
Activation of STAT5 is a crucial switch in mammary gland development 
during pregnancy and lactation. It is essential for inducing proliferation and 
differentiation of the ductal and alveolar luminal cells, and it is also necessary 
to allow survival and function of these cells during lactation. These different 
functions are carried out by this transcription factor throughout pregnancy. A 
murine model in which the two stat5 genes were deleted at different time 
points showed that loss of stat5 prior to pregnancy prevented epithelial 
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proliferation and differentiation. Deletion of stat5 during pregnancy, after 
mammary epithelium had entered Stat5-mediated differentiation, resulted in 
premature cell death, indicating that at this stage epithelial cell proliferation, 
differentiation, and survival require STAT5 (Cui et al, 2004). 
 
PRL activates STAT5 via the PRLR-JAK2 tandem (see figure 4), hence 
PRL is essential for alveolar proliferation in early pregnancy (Ormandy et al, 
1997). Still, it is not the only participating mechanism in mammary gland 
development during pregnancy. In fact, studies have identified human 
epidermal receptor (HER) 4 as another mediator in STAT5 activation that 
affects the functional differentiation of luminal cells after the proliferative 
phase mediated by PRLR (Long et al, 2003). STAT5 target genes have 
known roles in cell proliferation, survival, differentiation and, of course, milk 
synthesis. The following table summarizes the main target genes and their 
known function, inferred from mouse models: 
 
Table 1. STAT5 target genes during lactation. 
 
Target gene Function 
Receptor activator of 
nuclear factor κB (NF-
κB)- ligand (Rank-L)  
Alveolar development during pregnancy during 
later steps. Important for differentiation. It 
activates NF-κB activity, which in turn activates 
Cyclin D1 expression (Fata et al, 2000).  
NF-κB It is not a direct target of STAT5, but it is indirectly 
activated via Rank-L. Its abrogation allows for 
expansion of mammary epithelium but it is unable 
to differentiate. Hence, mice that lack NF-κB 
function in the mammary epithelium cannot lactate 
(Cao et al, 2001).   
Cyclin D1 Both a target gene of STAT5 and NF-κB. Loss of 
this gene leads to under-proliferation of alveolar 
cells, which are also unable to differentiate (Fantl 
et al, 1995). 
INTRODUCTION 
 
 
19 
Connexin-26 Component of GAP junctions which are essential 
for polarization of the luminal cells and formation 
of junction between them. This process is crucial 
for the establishment of functional alveoli 
(Ormandy et al, 2003).  
Whey Acidic Protein 
(WAP)  
β-casein 
Milk proteins (Miyoshi et al, 2001).  
 Member of transcription 
factor family ETS (ELF5) 
Participates in alveolar proliferation and 
differentiation. Its absence allows for alveolar bud 
formation but not for its proliferation and 
maturation (Zhou et al, 2005).  
 
Another transcription factor that needs to be briefly mentioned for its 
implication in mammary gland development during pregnancy is GATA3. As in 
earlier developmental steps, GATA3 is a key regulatory factor that allows 
alveolar differentiation of mammary progenitor cells during pregnancy. Its 
deletion at this stage of mammary gland development results in impairment of 
lobuloalveolar development, resulting in a lactation-deficient phenotype 
(Asselin-Labat et al, 2007). ELF-5 has a pivotal role in alveolar differentiation 
and secretion (Choi et al, 2009). Still, the functional relationship between 
GATA3 and STAT5/ELF-5 has not yet been elucidated (Siegel & Muller, 
2010).  
 
2.2 MOLECULAR SIGNALLING DURING MAMMARY GLAND INVOLUTION 
AFTER WEANING 
 
When lactation ends, the excess of epithelium that developed and 
differentiated to produce milk has no further function, hence, those cells are 
no longer needed and the mammary gland regresses to a pre-pregnant state 
in order to prepare for the next pregnancy.  As referred to earlier, mammary 
gland involution occurs in two phases. In the first, the main mechanism by 
which the surplus epithelial cells disappear is apoptosis, and during the 
INTRODUCTION 
 
 
20 
second phase the mammary gland undergoes a profound remodelling, with 
degradation of basal membrane and extracellular matrix and a concomitant 
loss of the lobular-alveolar structure.   
2.2.1 Mechanisms of Cell Death 
 
Before explaining in more depth the mechanisms involved in this first 
phase of involution, it is important to explain briefly the mechanisms by which 
a cell can die. Dying cells enter a process that is reversible until a “point of no 
return” is trespassed, still, this point is yet to be specifically defined from a 
biochemical point of view. A number of morphological criteria can be used to 
define cell death: i) cell has lost plasma membrane integrity. This can be 
determined by the incorporation of dyes such as propidium iodide (PI) or 
trypan blue in in vitro models; ii) the cell has undergone fragmentation into 
what is referred to as apoptotic bodies; iii) the dead cell or its fragments are 
engulfed by adjacent cells in vivo. 
 
Although there are many ways for a cell to die, only the main four will be 
referred to, and focus will be placed on apoptosis, since, it is the main event in 
this first phase of involution. For a more extensive review, see the 
recommendations of the Nomenclature Committee on Cell Death 2009 
(Kroemer et al, 2009). 
 
I) APOPTOSIS 
The term was coined in the year 1972 by Kerr et al to describe a specific 
type of cell death that involved conversion of scattered cells into small round 
masses of cytoplasm that contained specks of condensed nuclear chromatin 
(Kerr et al, 1972). During apoptosis the morphological features that can be 
observed are: rounding-up of cells, retraction of pseudopodes, reduction of 
cellular and nuclear volume (pyknosis), nuclear fragmentation (karyorhexis), 
minor modifications of organelles, plasma membrane blebbing and 
engulfment by phagocytes in vivo (Baehrecke, 2002; Barkla & Gibson, 1999). 
As for the biochemical features, apoptosis can be defined through the 
determination of activation of proapoptotic Bcl-2 family proteins (such as BAX 
and BID), the activation of caspases, mitochondrial transmembrane potential 
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dissipation, mitochondrial membrane permeabilization, DNA fragmentation 
and plasma membrane rupture (Kroemer & Martin, 2005; Kumar, 2007; 
Lamkanfi et al, 2007). It is important to point out that none of these features 
are definitory per se of apoptosis and that there are different types of 
apoptosis that are triggered through different biochemical routes. Apoptotic 
cell death is activated by extrinsic, receptor mediated, or intrinsic, 
mitochondria mediated, signalling pathways both converging in the activation 
of caspase 3. However, it should be kept in mind that not all forms of 
apoptotic cell death induce activation of caspase 3 and not all forms of 
apoptotic cell death involve caspases (Orrenius et al, 2003). 
 
Caspases are the main effectors of apoptosis. They are a family of 
proteases that depend on a cystein nucleophile to cleave motifs possessing 
aspartic acid (aspase) hence the term caspase (Thornberry & Lazebnik, 
1998). Caspases are produced as inactive zymogens that have a large and a 
small subunit preceded by an N-terminal prodomain. Two aspartic cleavage 
sites are processed sequentially and the large and small subunits associate to 
provide the active site for the enzyme. The active caspase is a tetramer of two 
heterodimers that contains two active sites (Thornberry et al, 1997).  
 
Besides, in the apoptosis intrinsic pathway there are various types of 
proteins essential to the process. One of these protein families is the BCL-2 
family that constitutes a critical intracellular checkpoint. It includes both 
proapoptotic and antiapoptotic regulators that are classified according to the 
homology they share within four conserved regions named BCL-2 homology 
(BH). The antiapoptotic members share an homology in all four of the BH 
domains 1-4. This subgroups includes BCL-2, BCL-XL, BCL-W, A1 and MCL-
1. The multidomain proapoptotic members (BAK, BAX and BOK) conserve 
BH1-3 and when activated they undergo a conformational change, 
oligomerize and allow the permeabilization of the mitochondrial outer 
membrane allowing the release of intermembrane space proteins such as 
cytochrome c that has an important role in apoptosis. The third subtype of 
BCL-2 family members (BAD, BID, BIK, BLK, HRK, BNPI3 and BIM-L) only 
contain homology in one domain, BH3. They are also proapoptotic and they 
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work upstream of the other BCL-2 members. They respond to specific signals 
and result in the activation of BAX and BAK and thereafter the rest of the 
apoptotic cascade. The function of antiapoptotic members is to bind and 
sequester the BH3 only molecules to prevent the activation of apoptosis 
effectors BAX and BAK (Danial & Korsmeyer, 2004). This cell death pathway 
has other control proteins such as inhibitor of apoptosis proteins (IAPs) and 
second mitochondrial activator of caspases (Smac). Once free, cytochrome c 
binds to Apoptosis Protease-Activating Factor-1 (APAF-1) which becomes 
competent to recruit procaspase-9 in the presence of ATP. This cytochrome 
c/Apaf-1/procaspase-9 complex is known as the apoptosome. Procaspase-9 
bound to Apaf-1 is capable of self-processing into caspase-9, which leads to 
the activation of procaspase-3 (Danial & Korsmeyer, 2004; Orrenius et al, 
2003). The apoptosome function is also regulated by the oncoprotein pro-
thymosin-α (Pro-T) and the tumour suppressor putative HLA-DR-associated 
protein (PHAP).  
 
The extrinsic pathway occurs through the activation of death receptors 
(DR) such as Fas/CD95, which, following ligand binding undergoes a 
conformational change and assemble on its cytoplasmic domain a signalling 
complex known as the DISC (Death Inducing Signalling Complex) (Muzio et 
al, 1996). Procaspase 8 is then recruited and it is believed that high local 
concentrations of this procaspase lead to autoproteolitic activation and 
subsequent activation of caspase-3 and 7. Fas-induced apoptosis can follow 
two pathways depending on the type of cell: in type I cells, which are 
refractory to BCL-2, caspase-8 activates procaspase-3, which cleaves target 
proteins, leading to apoptosis. In type II cells BCL-2 can block Fas-mediated 
cell death, therefore a mitochondrial amplification loop is needed; caspase-8 
cleaves BID, which, in turn, induces the translocation, oligomerization and 
insertion of BAX and/or BAK into the mitochondrial outer membrane (see 
figure 5 for details) (Orrenius et al, 2003; Scaffidi et al, 1998). 
 
When the apoptotic cascade has been initiated and caspases activated, 
DNA degradation is one of the endpoints of the process. This phenomenom 
first occurs at A/T rich regions to produce 50 to 200kb DNA fragments. It has 
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been described that a caspase activated DNase (CAD) is normally kept 
inactive by its inhibitor DNA fragmentation factor-45 (DFF-45) that is cleaved 
by caspases 3 and 7, hence eliminated, leaving CAD to degrade DNA (Liu et 
al, 1997b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Graphical representation of the main apoptotic pathways. The 
extrinsic, receptor-mediated apoptosis pathway and the intrinsic, 
mitochondria-mediated pathway (Orrenius et al, 2003). 
 
Apoptotic cell death terminates with the phagocytosis of the dead cell. 
The most important signal used by the apoptotic cell in order to activate 
phagocytosis is the exposure of phosphatidylserine on the outer cell surface 
(Savill & Fadok, 2000). This will stimulate phagocytic activity through several 
receptors, including CD91, CD14, CD36, αvβ3 integrin, phosphatidilserine 
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receptor and scavenger receptors (Fadok et al, 2000; Savill et al, 1992). 
Phagocytosis also favors DNA degradation via DNase II within the lysosomes 
of the phagocytes. In addition to engulfment of apoptotic cells, macrophages 
are important regulators of proinflammatory responses. It is important to 
achieve suppression of proinflammatory factors during apoptotic cell 
clearance as well as to abrogate the initiation of any immune reaction against 
self peptides. Defects in clearance of apoptotic cells may create a 
proinflammatory ambiance that may predispose to autoimmune disorders and 
facilitate cancer progression (Danial & Korsmeyer, 2004).  
 
II) NECROSIS 
Morphologically characterized by gain in cell volume, swelling of 
organells and plasma membrane rupture that leads to release of noxious 
cellular constituents. This process generates exudative inflammation in the 
surrounding tissue. The decision of the cell to die by necrosis or apoptosis is 
thought to depend on the nature and the severity of the insult and to day, 
there is no consensus on the biochemical changes that may identify 
unequivocally necrosis, which is still defined largely by the absence of 
apoptotic or autophagic markers, although some processes have been 
implicated in necrotic cell death. These phenomena include mitochondrial 
alterations, lysosomal changes, increased Ca2+ concentration in cytosol and 
activation of non-caspase proteases such as calpains and cathepsins 
(Kroemer et al, 2009; Orrenius et al, 2003). Recently it has been 
demonstrated that necrosis can also participate in a physiological process 
such as post-lactational mammary gland involution. It has been demonstrated 
that during this process there is increased lysosomal membrane  permeability 
and an increase in the cytosolic concentration and activity of the cysteine 
peptidases cathepsins B and L. This new concept of physiological necrosis is 
starting to be known as necroptosis (Kreuzaler et al, 2011; Luke & Silverman, 
2011).  
 
III) AUTOPHAGY 
Characterized by the sequestration of cytoplasmic material within 
autophagosomes for bulk degradation by lysosomes (Kroemer et al, 2009). 
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Autophagosomes are two-membraned and contain degenerating cytoplasmic 
organelles of cytosol (Levine & Klionsky, 2004; Levine & Kroemer, 2008). The 
fusion between an autophagosome and a lysosome to form autolysosomes 
marks the completion of the autophagic  pathway. This type of cell death, 
unlike apoptosis, has little or no association with phagocytes (Baehrecke, 
2005). It also lacks chromatin condensation and is accompanied by massive 
autophagic vacuolization of the cytoplasm (Kroemer et al, 2009). 
 
IV) CORNIFICATION 
This is a very specific form of programmed cell death that occurs in the 
epidermis. It leads to the formation of cornecytes (dead keratinocytes 
containing specific proteins such as keratin, loricrin, SPR and involucrin; and 
lipids). It is considered the terminal differentiation program of keratinocytes, 
necessary for skin function (mechanical resistance, elasticity, water 
repellence and structural stability). 
 
2.2.2 Mechanisms Implicated in Post-Lactational Involution  
 
2.2.2.1 Signalling Pathways Implicated in Mammary Gland Involution 
 
I) LIF/STAT3 
Apoptosis is induced in the mammary gland within 12h of the end of 
suckling and increases(Chapman et al, 1999) sharply during the first phase of 
involution (Lund et al, 1996). The initiation of involution is characterized by 
changes in the activity of two members of the STAT family of transcription 
factors. The phosphorylation status, and thereby the activity, of the 
transcription factors STAT5 and STAT3 changes rapidly at the onset of 
involution (Liu et al, 1996). STAT5a and STAT3 have reciprocal patterns of 
phosphorylation with levels of STAT5a decreasing and STAT3 increasing at 
the beginning of involution. These changes can be detected within 12h after 
weaning of the pups (Li et al, 1997b; Liu et al, 1996). In the mammary gland, 
STAT5 phosphorylation and activation can be induced by PRL, epidermal 
growth factor (EGF), and GH whereas it is known that, in vivo, the factor that 
activates STAT3 during involution is leukaemia inhibitory factor (LIF) which is 
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induced 30 fold during weaning (Gallego et al, 2001; Kritikou et al, 2003; 
Schere-Levy et al, 2003). STAT3 is critical for the initiation of apoptosis and 
involution and its absence reduces dramatically the number of apoptotic cells 
but it does not abolish apoptosis entirely (Chapman et al, 1999). Alterations in 
the levels of apoptosis have been demonstrated in stat3 transgenic mouse 
models where the impairment of its function leads to a significant decrease in 
the level of apoptosis at day 2. However, there is not a complete absence of 
programmed cell death at either day 2 or 6 of involution, implying that the 
regulation of apoptosis is not entirely dependent on the presence of STAT3 
(Chapman et al, 1999; Humphreys et al, 2002).  
 
As already mentioned, STAT3 acts as a transcription factor, some of its 
target genes being already identified. The STAT3 target genes have diverse 
functions and many have been validated as important regulators of involution 
in their own right. Table 2 summarizes some of the principal STAT3 
transcripts which are also proapoptotic or antiiflamatory mediators (Clarkson 
et al, 2006). 
 
Table 2. Summary of STAT3 target genes in mammary gland during involution 
after weaning (Clarkson et al, 2006). 
 
Gene title Gene 
symbol 
Pro-
apoptotic 
Inflammation/acute 
phase response 
B-cell leukemia/lymphoma 3 Bcl3 * * 
CCAAT/enhancer binding protein 
(C/EBP), beta Cebpb  * 
CCAAT/enhancer binding protein 
(C/EBP), delta Cebpd * * 
FBJ osteosarcoma oncogene Fos *  
insulin degrading enzyme Ide *  
interferon activated gene 204 Ifi204 *  
oncostatin M receptor Osmr  * 
phosphatidylinositol 3-kinase, regulatory Pik3r1 *  
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subunit, polypeptide 1 (p85 alpha) 
purine-nucleoside phosphorylase Pnp *  
secretory leukocyte protease inhibitor Slpi  * 
MAD homolog 1 (Drosophila) Smad1 *  
signal transducer and activator of 
transcription 3 Stat3 * * 
X-box binding protein 1 Xbp1 *  
 
Once STAT3 is phosphorylated, it translocates to the nucleus where it 
activates the transcription of oncostatin M receptor (OSMR). Oncostatin M 
(OSM) is a cytokine normally produced by macrophages, and the ligand for 
OSMR that, when active, will take over LIF’s function and activate STAT3 
(Watson & Brown, 2008), thereby establishing a positive feedback-loop. 
Conversely, OSMR activation results in STAT5 dephosphorilation (Tiffen et al, 
2008). These data further confirm the importance of the STAT5/STAT3 switch 
in mammary gland involution. OSMR-KO mice exhibit a delayed second 
phase involution, which correlates with the involution trigger function of 
STAT3 (Tiffen et al, 2008).  
 
Other STAT3 targets that are known to have a role in involution include 
CAAT/enhancer binding protein (C/ebp)δ ̀, a transcription factor involved in the 
acute phase response and that when deleted, delays mammary gland 
involution (Thangaraju et al, 2005) and SOCS3, a negative regulator of 
STAT3 that when knocked down accelerates involution (Sutherland et al, 
2006). Additional targets of interest include slpi; Pi3kr1, that encodes three 
regulatory subunits of the p85α gene which bind to the p110 catalytic subunits 
of class I PI3K (Abell et al, 2005); Insulin-like growth factor (IGF) binding 
protein 5 (igfbp-5) (Chapman et al, 1999); and stat3 itself. 
 
As explained, many of the transcriptional targets of STAT3 are 
inflammatory mediators and APR genes. This inflammatory response is 
required for efficient clearance of apoptotic mammary epithelium during 
involution. STAT3 functions in a non-cell autonomous manner to modulate the 
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mammary microenvironment during mammary gland involution. APR proteins 
display a range of functions related to acutely protecting the host from a 
variety of damages. Some of these proteins activate complement and 
phagocytic cell functions, others have anti-oxidant activity. Serum Amyloid A 
(SAA) has been implicated in inducing leukocyte migration (Urieli-Shoval et al, 
2000) and Complement components impact on chemotaxis, opsonization, 
vascular permeability and dilation, while fibrinogens are important players in 
hemostasis, tissue repair and wound healing (Kushner, 1993). STAT3 plays a 
major role in the induction of both class I and class II APR genes, and with it, 
in the orchestration of inflammatory responses. Interestingly, it is also a key 
factor mediating anti-inflammatory responses (AIR) depending on the specific 
cell type (Poli V, 2003). The fact that STAT3 is up-regulating all these APR 
proteins strongly suggests that this transcription factor plays two distinct roles 
in mammary gland involution- promotes apoptosis on one side and on the 
other it protects the tissue from excessive damage, guiding remodelling.  
 
II) NF-κB 
 Another key regulator in mammary gland involution process is NF-κB. 
NF-κB is a group of dimeric transcription factors with roles in immunity, 
inflammation, proliferation and apoptosis. These were first identified based on 
their interaction with the immunoglobulin light –chain enhancer in B cells and 
they are present in all cells (Sen & Baltimore, 1986). The group is formed by 
seven distinct proteins that can form a variety of dimers, not all of which are 
active (Barnes & Karin, 1997). These proteins include: NF-κB1 (p105 and 
p50), NF-κB2 (p100 and p52), RelA (p65), RelB and c-Rel.  
 
In non-stimulated cells, most NF-κB dimers are retained in the cytoplasm 
by binding to inhibitory IκB proteins, except for the dimers formed by p105 
and p100, which are inactive and contain intrinsic IκB-like moieties. In 
response to pro-inflammatory stimuli, such as tumour necrosis factor (TNF) or 
interleukin 1β (IL-1β), that interact with the death receptors (DR) such as 
CD95/Fas, TNF-related apoptosis-inducing ligand (TRAIL) receptors TRAIL-
R1/-R2 and TNF-R1, the serine/threonine-specific IκB kinase (IKK) complex, 
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composed of the IKK1/α and IKK2/β catalytic subunits and the IKKγ/NEMO 
regulatory subunit, is activated. This results in IκB phosphorilation (p-IκB) and 
its eventual ubiquitin-mediated degradation in the proteasome. This leads to 
the unmasking of NF-κB nuclear localization signal (NLS) permitting the 
nuclear entry of NF-κB dimmers (Ghosh & Karin, 2002). Of the two catalytic 
subunits, IKK2/β is the most critical for the IκB degradation, forming the core 
of what is known as the classical activation pathway. On the other hand, 
IKK1/α activation by NF-κB inducing kinase (NIK) is required for the inducible 
processing of the inactive p100 protein to its active form p52, thus forming the 
core of the alternative pathway (Senftleben et al, 2001). Figure 6 shows 
schematically both activation pathways of NF-κB, the canonical and the 
alternative.  
 
NF-κB is both expressed and active throughout different stages of 
mammary gland development. Its activity is high during pregnancy, when it 
regulates epithelial proliferation and branching (Baxter et al, 2007; Cao et al, 
2001) but is found to be inactive during lactation, since it inhibits STAT5-
mediated gene transcription, which is fundamental in this developmental 
stage (Clarkson et al, 2000; Geymayer & Doppler, 2000). However, during 
involution, NF-κB is reactivated as early as 1h after pup-removal, and its 
activity increases significantly at 24h, peaking at 72h (Clarkson et al, 2000). It 
regulates apoptosis and involution after weaning probably through the 
canonical pathway activated by DR ligands- TNFα and (TNF)-like weak 
inducer of apoptosis (TWEAK) (Watson, 2006). This means that its activation 
during involution is through the canonical pathway. NF-κB activation allows it 
to translocate to the nucleus where it binds to specific DNA  sites, activating 
the transcription of target genes. As for the profile of the target genes of NF-
κB, it correlates well with APR genes, (Clarkson & Watson, 2003) as it has 
been previously described for STAT3. Hence, it is possible that both 
transcription factors cooperate in the induction of an immune related response 
during involution.  
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Figure 6. NF-κB signalling. On ligand interaction with surface receptors, one 
of two NF-κB activation pathways can be elicited. Canonical signalling 
depends on IKK2/β and IKKγ/NEMO and induces the transcription of genes 
that regulate inflammation and cell survival. The interaction of these ligands 
with the TNFR1 results in activation of caspase mediated apoptosis via 
caspases 8 and 3. Furthermore, IKK2/β is also required indirectly for TWEAK 
transcription.The non-canonical NF-κB activation is mostly involved in the 
regulation of B-cell development (Baxter et al, 2006; Baxter et al, 2007; 
Bollrath & Greten, 2009).  
 
Among these NF-κB target genes, table 3 summarizes some of them, 
and it can be observed that many of these NF-κB regulated genes partake in 
pro-inflammatory responses. 
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Table 3. Transcriptional targets of NF-κB signalling. The biological outputs of 
NF-κB signalling are mediated by the transcriptional gene products it turns on. 
CD40L, CD40 ligand; c-FLIP, cellular Fas-associated death domain-like IL-
(Wong & Tergaonkar, 2009). 
 
 
Since NF-κB is mostly related with anti-apoptotic signalling, its activation 
during the first phase of mammary gland involution might seem contradictory, 
given that the luminal epithelium undergoes massive apoptosis. In fact, initial 
in vitro studies with a mammary gland epithelial cell model showed that NF-κB 
suppressed cell apoptosis (Clarkson et al, 2000). Later studies have shown 
that NF-κB and its upstream regulator IKK2/β also promote apoptosis during 
involution (Connelly et al, 2010). Also, IKK2/β has been found to regulate 
FOXO3a and with it, TWEAK expression, via an Akt dependent process 
(figure 6) (Baxter et al, 2006). Thus, both IKK2/β and NF-κB are essential in 
early involution for induction of the extrinsic pathway of cell death. It is also 
noteworthy that DR ligands (TNFα, Fas Ligand and TRAIL) are NF-κB target 
genes (Baetu et al, 2001; Kasibhatla et al, 1998; Trede et al, 1995) which 
Function  Transcriptional target 
Cytokines/chemokines IL-8, IL-6, TNF-α, IL-1b, GM-CSF, MIP-1a, MCP-
1 and Rantes 
Antimicrobial effectors Defensins, NO and O2• 
Enzymes NOS2, COX-2 and PLA2 
Immunoreceptors B7.1 and MHC class I 
Transcription factors GATA3, STAT4 and IRF1 
Growth 
factors/modulators 
IL-2, GM-CSF, CD40L, Cyclin D1, VEGF, IL-6 
and c-myc 
Regulators of 
apoptosis  
A1, c-IAPs, c-FLIP, Bcl-xl and Bcl-2 
Cell adhesion 
molecules 
ICAM-1, VCAM-1 and E-selectin 
Invasion/angiogenesis Maspin, VEGF and MMP-9 
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have been demonstrated to be very important in early activation of apoptosis 
in mammary gland involution (Baxter et al, 2006).  
 
III) TGFβ pathway 
The Transforming Growth Factor beta (TGFβ) family is conformed by a 
group of regulatory cytokines that regulate the expanding systems of epithelial 
and neural tissues, the immune system, and wound repair. Most members of 
this cytokine family exist in variant forms (e.g., TGFβ1, β2, and β3). The 
bioactive cytokine molecule is a dimer composed of a polypeptide chain that 
is cleaved from a precursor by enzymes. The active dimer signals through the 
coupling of two pairs of receptor serine/threonine kinases known as the type I 
and type II receptors, respectively (Massague, 2008). Upon binding TGFβ, the 
type II receptors phosphorylate and activate the type I receptors that then 
propagate the signal by phosphorylating Smad transcription factors. Once 
activated, the receptor substrate Smads (RSmads) shuttle to the nucleus and 
form a complex with Smad4, a binding partner common to all RSmads (Shi & 
Massague, 2003). Smad4-RSmad complexes associate with additional DNA-
binding cofactors in order to achieve binding with high affinity and selectivity 
to control the expression of hundreds of target genes in a given cell 
(Massague, 2008). 
 
Currently, there are three known mammalian isoforms of TGFβ, namely 
TGFβ1, TGFβ2 and TGFβ3 (Pelton et al, 1990; Roberts & Sporn, 1992). 
These have been shown to be expressed at different stages of mammary 
gland development, although none of these transcripts is detected in lactating 
glands (Pelton et al, 1990; Robinson et al, 1991). TGFβ1 and 3 have been 
demonstrated to inhibit ductal outgrowth (Daniel et al, 1989; Silberstein & 
Daniel, 1987). Also, TGFβ3 has been proved to be a local mammary-derived 
signalling factor synthesized in response to milk stasis that induces apoptotic 
cell death during the first phase of involution. In fact, TGFβ3 expression 
increases as early as 8h after pup removal and its absence in mammary 
tissue results in normal development but delay in apoptosis during early 
involution (Nguyen & Pollard, 2000). As explained before, TGFβ3 signalling is 
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mediated by the Smad pathway. Indeed, Smad3-KO mice show reduced 
apoptosis upon forced weaning (Yang et al, 2002). It is worth noting that one 
of the transcriptional targets of TGFβ3 that shows increased abundance 12-
24h after weaning is the ZIP-protein TGFβ3-stimulated clone 22 (Tsc-22) 
which has been associated with apoptosis and is down-regulated in various 
types of cancers (Kawamata et al, 2004; Shostak et al, 2003; Uchida et al, 
2000). 
 
IV) PI3K/AKT 
IGFs and their signalling axis, the PI3K/AKT/mTOR pathway, have a 
significant role in cellular functions such as growth and cell survival, 
proliferation, division, metabolism, apoptosis and migration capabilities. It has 
also been studied as a major pathway involved in regulation of mammary 
gland involution. When IGF-1 interacts with its receptor (IGF-1R) it facilitates 
the phosphorylation of tyrosine residues in the intracellular domain of the 
receptor. This will allow for the phosphorylation of tyrosine and serine 
residues of the insulin receptor substrate (IRS) and Src. The consequence of 
this series of phosphorilations is the activation of the MAPK and 
PI3K/AKT/mTOR pathways (Baserga et al, 2003). 
 
IGF pathway is regulated in many critical points, from ligand availability 
to negative feedback mechanisms exerted by mTOR (Wan et al, 2007) and is 
activated under normal conditions when the supply of nutrients is appropriate 
and it promotes the synthesis of lipids, proteins and glycogen. In case of 
energy shortages, however, the kinase pathways are activated by adenosine 
monophosphate kinase (AMPK) leading to the inhibition of earlier biosynthetic 
processes (Towler & Hardie, 2007). Figure 7 depicts graphically this pathway 
and its regulators. 
 
The IGF/PI3K pathway is involved in mammary gland involution 
regulation, since it has been proved that when overexpressed, involution is 
delayed (Hadsell et al, 1996; LeRoith et al, 1995; Moorehead et al, 2001; 
Neuenschwander et al, 1996) and PTEN, a negative regulator of the pathway, 
enhances apoptosis in the mouse mammary gland epithelium (Dupont et al, 
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2002). The activation of this pathway converges into the activation of the 
critical survival kinase AKT. 
 
Figure 7. PI3K/AKT/mTOR and AMPK pathways. The activation of the 
membrane tyrosine kinase receptors (RTK) such as the IGF1R causes 
activation of intracytoplasmic effectors. AKT is activated via PI3K and has 
multiple targets, including mTOR, which promotes protein synthesis and cell 
growth. Cellular energy sensor AMPK and LKB1 exert the opposite effect, 
inhibiting mTOR. The RTK activation also leads to the activation of other 
routes such as the MAPK and STAT3. Adapted from (Baserga et al, 2003; 
Eroles et al, 2011). 
 
 In a mouse mammary context, levels of akt mRNA have been reported 
to increase slightly during pregnancy and more dramatically during lactation, 
decreasing sharply as the gland begins to involute (Schwertfeger et al, 2003). 
AKT protein levels also halve by 48h of involution and this decrease in total 
Akt corresponds to an even greater reduction in activated (phosphorylated) 
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AKT (Abell et al, 2005; Schwertfeger et al, 2001; Strange et al, 2001). This 
coincident downregulation of AKT survival signalling correlates with the initial 
apoptotic phase of involution. Beyond mere correlation, the importance of 
shutting down this pathway at involution has been demonstrated by 
mammary-specific overexpression of AKT in transgenic mice. Two 
independent studies expressing constitutively active AKT observed delays in 
post-lactational involution and delayed onset of apoptosis, consistent with 
AKT antiapoptotic role (Hutchinson et al, 2001; Schwertfeger et al, 2001). 
 
The IGFR/PI3K/AKT pathway is down-regulated during the lactation-
involution apoptotic transition by two mechanisms, the loss of cell-matrix 
integrity and the upregulation of IGFBPs. Indeed, as it has been mentioned 
before, IGFBP-5 is a transcriptional target of STAT3; therefore, with the 
activation of the latter, there is an increase of IGFBP-5 within the first 24h of 
involution (Gilmore et al, 2000; Strange et al, 2001; Tonner et al, 1997; 
Tonner et al, 1995). This binding protein sequesters IGF which cannot interact 
with the IGF-1R thus preventing IGF-mediated survival in the first phase of 
mammary gland involution. Furthermore, inactivation of the central player of 
this pathway, AKT, has many known effects that favor apoptosis. AKT exerts 
its effects through the phosphorylation of different substrates, which results in 
the activation or inhibition of its targets. Caspase 9, a crucial apoptosis 
initiation caspase, is inactivated by AKT mediated phosphorylation (Cardone 
et al, 1998). Also, phosphorylation of the fork-head transcription factor 
FOXO3a, prevents its translocation to the nucleus were it activates the 
transcription of pro-apoptotic factors such as FasL and Bim (Brunet et al, 
1999; Dijkers et al, 2000). AKT also targets BAD, which, after 
phosphorylation, undergoes degradation so it cannot exert its function of 
sequestering anti-apoptotic members of its own family such as BCL-2 and 
BCL-X (Baxter et al, 2007). AKT also affects the NF-κB pathway via 
degradation of IκBα (Kane et al, 1999). 
 
Beyond the first 48h after weaning, when mammary tissue starts the 
remodelling stage, AKT becomes activated again. This would be in line with 
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the intense activity observed in the mammary gland at this point in order to 
reassemble its structure to get ready for the next pregnancy. It is intriguing 
that the apoptotic process is triggered in certain alveolar cells yet the 
neighboring cells survive and integrity of the alveolar wall is maintained. It is 
possible that an over-riding survival signal is initiated in these surviving cells, 
most likely pAKT. Interestingly, AKT is a component of the NF-κB, PI3K, 
STAT3 and TGFβ pathways, suggesting AKT is a master sentinel that 
regulates early involution of the mammary gland. (Baxter et al, 2007) 
 
Taken together, the four pathways described co-operate in a precisely 
orchestrated manner to allow for the apoptosis of the excess epithelial cells in 
the first phase of involution. This first phase will trigger the second, which is 
predominantly characterized by the extensive remodelling of the tissue. With 
it, mammary gland will be ready for a new pregnancy/lactation cycle once the 
process is terminated.  
 
2.2.2.2 Effectors of Mammary Gland Tissue Remodelling in the Second 
Stage  
 
I) Role of Metalloproteases 
The second, irreversible stage of postlactational involution begins at 
approximately 48 h after weaning. A gradual reduction of circulating hormones 
during the first stage is necessary for progression to this stage (Feng et al, 
1995; Li et al, 1997b). Here, there is glandular collapse, re-differentiation of 
adipocytes, and remodelling of the ductal epithelium. During this phase there 
is a substantial expression of serine and matrix metalloproteases (MMPs) 
which contribute to the degradation of the basement membrane, phenomenon 
that will also convey in further apoptosis of luminal cells and the overall 
involution of the mammary gland (Green & Lund, 2005). MMPs represent a 
continuously growing family of endopeptidases classified into subfamilies 
based on their substrate specificity and domain homology (Benaud et al, 
1998).  
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During this second phase of involution, MMP-2, MMP-3, MMP-9 and 
MMP-11 are expressed, together with urokinase-type plasminogen activator 
(uPA) which is a serine protease (Li et al, 1994; Lund et al, 2000; Talhouk et 
al, 1992). The expression of these MMPs is localized to myoepithelial cells 
and stromal fibroblasts surrounding the degenerating ducts and alveoli. It is 
noteworthy that tissue inhibitors of MMPs (TIMPs) are overexpressed during 
the first phase of involution, and as involution progresses, their levels 
diminish, and hence, MMPs become increasingly activated (Talhouk et al, 
1992; Talhouk et al, 1991). The patterns of expression of TIMPs and MMPs 
correlate with the loss of cellular differentiation, extensive tissue remodelling 
and cell death (Lund et al, 1996). Also, the critical balance between TIMPs 
and MMPs provides a mechanism to coordinate the transition between the 
first stage of mammary involution and the second, which, as already 
described, has to do with removal of matrix proteins and of the remaining cell 
debris generated in the first phase, adipocyte differentiation and remodelling 
of the epithelial ductal tree (Green & Streuli, 2004). 
 
The various MMPs are expressed sequentially throughout involution. 
MMP-2 is the first to be both expressed and activated following weaning, this 
is followed by MMP-3, uPA and MMP-9 (Benaud et al, 1998; Lund et al, 2000; 
Talhouk et al, 1992). The sequential expression of MMPs suggests that these 
enzymes may have different functions, or, more likely, they may play a role in 
an activation cascade, whereby one MMP is first secreted and then activated, 
participating thereafter in the activating cleavage of the other MMPs.  
 
II) Cathepsin D 
Another family of proteases involved in the second phase of involution 
is the cathepsin family. This family of proteases is among the most studied 
lysosomal hydrolases that degrade proteins at an acidic pH. They can be 
divided into three subgroups according to their active-site amino acid. 
Cathepsins B, C, H, F, K, L, O, S, V, W have a cysteine in their active site. 
Cathepsins D and E have aspartic acid and cathepsin G has a serine. 
Cathepsins function primarily as endopeptidases within endolysosomal 
compartments, although some have exopeptidase activity. Apart from their 
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function in the protein turnover, they can also perform specific functions 
playing a role in processes such as neovascularisation, antigen presentation, 
cell growth and tissue homoeostasis (Liaudet-Coopman et al, 2006). Given 
the acidic pH found within the lysosomes, it is not surprising that all 
cathepsins are optimally active at acidic pH and, although they are still highly 
active at neutral pH, raising the pH usually results in the irreversible folding 
which reduces their lifetime in the cytosol. However, during cell death 
acidification of the cytosol is common and so loss of cathepsin function upon 
release from lysosomes is likely to be diminished resulting in cleavage of 
cytosolic substrates (Lagadic-Gossmann et al, 2004).  
 
Cathepsins are thought to modulate involution through three 
mechanisms: i) lysosomal mediated cell death (necroptosis); ii) autophagy 
and iii) extracellular remodelling.  And even though studies are still not 
conclusive about the specific roles that each member of the cathepsin family 
may play specifically during this physiological process, RNA profiles show a 
rise in the expression of cathepsins B, K, S, L, and D. Interestingly, although 
the expression of these endopeptidases can start rising as early as 12h after 
weaning, the expression is maximal after the 48h time point. It is also 
important to keep in mind that these proteases have to undergo specific post-
translational modifications in order to become activated, therefore, it is 
plausible that the increased expression does not correlate exactly with an 
increased activity (Clarkson et al, 2004; Watson & Kreuzaler, 2009). 
 
Human Cathepsin D is an endopeptidase that belongs to the aspartic 
peptidase family A1. It is found in lysosomes of most human cells and its 
fundamental function is to catalyse the hydrolysis of peptidic bonds in 
peptides and proteins (Fusek & Vetvicka, 2005). Its expression is regulated by 
steroid hormones, growth factors IGF-1, TNF-α, EGF and by retinoic acid 
(May et al, 1993; Scarborough et al, 1991; Sheikh et al, 1996; Wang et al, 
2000). It is synthesized in the form of pre-pro-cathepsin (412 aminoacids Aa) 
and it is translocated to the endoplasmic reticulum via a signal sequence. In 
the endoplasmic reticulum, the pre-pro form is further processed and loses 
the signal sequence, thus leading to the generation of pro-cathepsin D. The 
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Aa sequence of pro-cathepsin D determines its post-translation modifications: 
particle rugosity, formation of disulphate bridges, N-glycosylation and 
phosphorylation. 
 
It is within the endoplasmic reticulum that the pro-cathepsin D undergoes 
glycosilation mainly with mannose oligosaccharide chains (Gieselmann et al, 
1983; Kussendrager et al, 1972). After synthesis and glycosilation, it is 
transported to the Golgi apparatus where the terminal mannose residues 
undergo phosphorylation to mannose-6-phosphate (M6P) (Cantor et al, 1992; 
Cantor & Kornfeld, 1992). By means of these M6P residues, pro-cathepsin D 
is transported to primary lysosomes (Sahagian, 1984). Once in the primary 
lysosome, with the acid environment (pH= 4.5-5.5), the pro-cathepsin 
undergoes further changes in its way to be a fully functional peptidase, 
cathepsin D. These changes consist in a series of proteolytic transformations 
and autocatalytic activation. The cleavage of the bond between the 
aminoacids in position 64 (Glu) and 65 (Gly) releases a 44 Aa propeptide and 
transform pro-cathepsin D into a 348 Aa active single-chain form. The ultimate 
form of cathepsin D consists in a mature two chain protein obtained after the 
cleavage of the Ala204-Tyr205 bond and other cleavages on the carboxyl and 
amino terminus of the heavy and light chains respectively. The heavy chain, 
of 196 Aa residues is bound to the light chain of 141 Aa through hydrophobic 
bonds.  The maturation process is schematized in the figure 8 (Hasilik & 
Neufeld, 1980; Minarowska et al, 2008; Richo & Conner, 1991). 
 
When active, cathepsin D cleaves non-terminal peptide bonds in a 
polypeptide chain, hence the term endopeptidase. The cleaved bonds are 
normally formed by carboxyl groups of hydrophobic amino acids, specially 
aromatic. The catalytic site of cathepsin D is constituted by two Asp acid 
residues in positions 32 and 231(Fusek & Vetvicka, 2005); and the proteolitic 
activity of both the mono-chain and the double-chain forms is the same. 
 
As already mentioned, its main function is to carry out intracellular 
digestion within the lysosomal compartment. Acidic pH is required for the 
activity of cathepsin D to degrade proteins in lysosomes with an optimum pH 
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of 3.5-5.5 in contrast to other proteases such as serine proteases and MMPs. 
It has also been shown that it can activate precursors of biologically active 
proteins in pre-lysosomal compartments of specialized cells (Diment et al, 
1989). It is apparently also involved in the processing of antigens, hormones 
and neuropeptides. Cathepsin D is also required in certain epithelial cells for 
tissue remodelling. Still, cathepsin D seems to play a role in a plethora of 
other physiological processes regardless of its proteolytic function. In fact, 
cathepsin D deficient mice die prematurely from massive destruction of 
lymphoid organs and progressive atrophy of the intestinal mucosa, suggesting 
essential functions of this protease in tissue homeostasis (Saftig et al, 1995).  
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Proteolytic modification of cathepsin D from its pre-pro form to the 
mature double-chain form. The amino-terminal end is on the left hand side. . 
PS – signalling peptide, EP - endopeptidase, AP - aminopeptidase, EPc – 
cysteinyl endopeptidase, CP - carboxypeptidase, - hydrophobic bond 
(Minarowska et al, 2008) 
 
Cathepsin D is constitutively expressed in nearly all cells, but, as it has 
been stated before, it is up-regulated in a hormonally dependent fashion 
(Cavailles et al, 1993). When cathepsin D is looked at in normal breast, in a 
quiescent state, mammary epithelial cells secrete minimal levels of pro-
cathepsin D (Capony et al, 1989). But, since the physiological function of the 
mammary gland is lactation, when studying cathepsin D expression, post-
translational modifications and functions during lactation and weaning, quite a 
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different picture is drawn.  For example, pro-cathepsin D is secreted at 
relatively high levels into human, bovine and rat milk and it is thought to be 
activated by the low pH of the new-born digestive tract, playing a role in 
digestion (Benes et al, 2008; Margaryan et al, 2010). Also, the secretion of 
activated single-chain cathepsin D from the basal side of the epithelial cells 
toward the basement membrane has been identifed. There it is thought to 
process PRL to generate a bioactive fragment with anti-angiogeninc and pro-
apoptotic properties (Castino et al, 2008; Hilfiker-Kleiner et al, 2007; Lkhider 
et al, 2004; Piwnica et al, 2006). 
 
During weaning, its principal role is as an endopeptidase, and it is 
thought to have a role in the remodelling of the mammary gland stroma and 
also in the lysosomal mediated cell death, recently coined as necroptosis. It is 
of note that cathepsin D undergoes distinct protein processing at different 
stages of mammary gland development, and this customized processing 
results in differential enzymatic activity best fitting particular stages of 
development. In fact, at the onset of involution, the glycosilation pattern 
changes; and it reverts back to the original pattern by day 4 of involution 
(Margaryan et al, 2010). All in all, the complex post-translational modifications 
of this peptidase are far from being totally figured out, and changes can have 
an impact in its function throughout a dynamic process such as post-
lactational involution.  
 
2.2.2.3 Nitric Oxide and its implications in Cellular Signalling during 
Mammary Gland Involution 
 
Nitric Oxide (NO) is a highly reactive molecule with low molecular 
weight, uncharged, soluble in both aqueous and hydrophobic environments 
and highly diffusible. It is the best example of a reactive molecule 
demonstrating both cytotoxic and cytoprotective properties (Wink et al, 1998). 
NO was first identified in the 1980’s as Endothelium-Derived Relaxation 
Factor (EDRF), a substance generated by the endothelium that caused 
vascular relaxation and also the active component of nitorvasodilators 
(Ignarro, 1990). Conversely, NO was found to be generated by macrophages 
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participating in the anti-tumour and anti-pathogen response (Granger & Hibbs, 
1996; Nathan & Hibbs, 1991). These initial observations led to an explosion of 
NO research, which has revealed the importance of this diatomic molecule in 
nearly every tissue in the body. 
 
I) Formation  
The chemical biology of NO divides its potential reactions into two 
categories: direct and indirect (Wink et al, 1993). The direct effects of NO are 
those chemical reactions that occur fast enough to allow NO to directly react 
with a biological target molecule. The indirect effects require that NO reacts 
with oxygen or superoxide anion to generate reactive nitrogen species (RNS) 
which subsequently react with the biological targets. The direct effects 
normally occur at low concentrations and the indirect effects occur at much 
higher concentrations. These indirect effects can be further categorized into 
oxidative stress (when the oxidation of the target molecule increases) and 
nitrosative stress (which implies the addition of a nitrosonium group NO+) 
(Thomas et al, 2008). Figure 9 briefly summarizes the chemical reactions NO 
undergoes in order to become a reactive species.  
 
Although there are alternative mechanisms to generate NO, such as 
acidification or reduction of nitrite, the vast majority of mammalian NO is 
derived enzymatically from NO synthase (NOS). This family of enzymes 
converts arginine to citrulline and NO in an NADPH and O2 dependent 
process. There are three NOS isoforms that provide a wide range of 
concentration and temporal NO profiles. Two of these are constitutive 
(NOS1/nNOS neuronal and NOS3/eNOS endothelial) and one is inducible 
(NOS2/iNOS) (Stuehr et al, 2004). These isoforms are differentially regulated 
at numerous levels including transcription, translation, post-transcriptional and 
biochemical (Bredt, 1999; Fulton et al, 2001). There are two main differences 
between these isoforms, the duration of NO generation and the local 
concentration of NO that can be produced. Calmodulin dependency is 
important for the constitutive forms of the enzyme where calcium fluxes and 
phosphorylation through protein-protein interactions regulate their activity, 
providing a transient NO output (Mayer et al, 1989). In contrast, NOS2 has 
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calmodulin as a subunit, being thus permanently activated and capable of 
generating NO for long periods of time (Nathan & Xie, 1994). The enzymatic 
activity of NOS is tightly controlled depending on the substrate and co-factor 
availability, as well as the rate of electron transfer. Hence, in the presence of 
sufficient co-factors (NADPH, FMN, BH4, FAD), the NOS activity is dependent 
on the arginine and oxygen availability (Ghosh & Salerno, 2003). 
Furthermore, NOS enzymes are also known to form complexes with their 
targets, e.g. NOS2 regulates cyclooxigenase-2 (COX-2) activity in 
inflammatory settings (Kim et al, 2005).  
 
 
 
 
 
 
 
 
II) Effects 
Many in vitro studies using NO donors have demonstrated that different 
concentrations of NO exert different biological effects. For example, when 
cultured cells are exposed to NO for defined periods of time, various proteins 
were found to be sensitive to distinct concentrations of NO (Thomas et al, 
2006). At sustained NO levels of 10-30nM, phosphorylation of ERK occurs. At 
30-60nM NO, AKT is phosphorylated (Pervin et al, 2007; Prueitt et al, 2007; 
Ridnour et al, 2004; Thomas et al, 2004). When NO reaches a concentration 
of 100nM, HIF-1α is stabilized (Thomas et al, 2004) and at 400nM NO, p53 is 
Figure 9. Summary of the formation of RNS. The 
balance between oxidation and nitrosation 
chemistry depends on the flux of NO. In the case of 
the auto-oxidation in hydrophobic environments, 
NO2 is first generated, but as levels of NO2 
increase there is rapid formation of N2O3 
(equations 1 and 2), ultimately forming nitrite in 
water (equation 3). ONOO- is formed from the 
NO/O2- reaction (equation 4). Finally, the reaction 
rates of NO with these RNS are nearly diffusion 
controlled, facilitating the rapid conversion from an 
oxidative to a nitrosation profile (equation 5). 
eq=equation (Thomas et al, 2008). 	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phosphorilated and acetylated, inducing cell cycle arrest and even an 
apoptotic response. When the concentration is above 1µM NO, mitochondria 
respiration is inhibited (Borutaite & Brown, 2006; Cleeter et al, 1994).  
 
As for the achievable NO in vivo concentrations, it was very important to 
establish whether NO can achieve the higher concentrations in vivo that seem 
to mediate some biological effects on a Petri dish. Several studies have 
demonstrated that µM levels of NO can occur in vivo in an inflammatory 
microenvironment (Carcillo et al, 2003; Lee & Lee, 2005; Stadler et al, 1994).  
These high NO concentrations are achieved through production by 
macrophages which play an important part in the immune and inflammatory 
responses (Hanahan & Weinberg, 2011). Macrophages can generate different 
concentrations of NO that serve their different functions (Espey et al, 2000). 
Interestingly, the amount of NO generated by activated macrophages 
depends on how they are stimulated. And not only on animal models (the 
above are examples of septic models), there are also some examples in 
humans that µM NO levels may be achieved. Samples from ulcerative colitis 
found phospho-p53 co-localized with NOS-2. Also, in colorectal cancer there 
is a correlation between NOS2 and HIF-1α which indirectly suggests NO 
concentrations  above 100nM (Yu et al, 2006).  
 
In addition to concentration, temporal aspects of NO exposure are 
important. Certain proteins respond immediately to NO exposure, for example 
activated HIF-1α that is stabilized and accumulates as long as the minimum 
threshold of NO concentration is available, but when NO levels fall below this 
threshold, protein levels of HIF-1α disappear (Thomas et al, 2004). In 
contrast, phosphorylation of p53 by NO takes several hours, but it sustains 
long after the NO exposure has ceased. Therefore NO responders are 
categorized into various categories, namely immediate, delayed, transient and 
sustained (Thomas et al, 2008). Having established that endogenously 
generated NO provides a spectrum of biological responses based on 
concentration and duration of NO exposure, it is important to point out, once 
more, that endogenously generated NO ranges from basal levels in 
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endothelial cells (< 1nM) to that generated by fully activated macrophages 
(>1µM). This wide range of concentrations combined with its unique chemical 
reactivity, makes NO a very versatile signal transduction agent.  
 
As said before, NO at high concentrations exerts its functions through 
the reaction with O2 or superoxide to generate reactive nitrogen oxide species 
(RNS) that subsequently react with biological targets, inducing nitrosative 
modifications. Nitrosative modifications are selective processes that target 
precise molecular sites in proteins or lipids for gain or loss of function, in a 
manner somewhat analogous to the better-known phosphorylation or 
acetylation signal transduction mechanisms (White et al, 2010). In proteins, 
with the exception of heme-iron binding, these modifications manifest in two 
main forms, namely S-nitrosylation of cysteine thiols and nitration of tyrosine 
residues. S-nitrosylation occurs through the covalent attachment of a diatomic 
nitroso group to a reactive thiol sulfhydril in a redox-dependent fashion (Hess 
et al, 2005). Tyrosine nitration results from the covalent addition of a triatomic 
nitro group (NO2) to the phenolic ring of tyrosine residues (Ischiropoulos, 
2003). Both S-nitrosylation and tyrosine nitration may arise from the protein 
interactions with NO or RNS. Another important modification induced by NO is 
S-Glutathionylation. Briefly, the GSH/GSSG redox system maintains cellular 
proteins in a reduced state. Normaly, S-nitrosylated proteins are rapidly 
reduced by GSH (the reduced form of glutathione) and GSH can be S-
nitrosylated to S-nitrosoglutathione (GSNO) which is also an effective agent 
for the direct transfer of NO to other thiols by transnitrosylation. In addition, 
glutathione could potentially replace the NO on S-nitrosylated proteins, 
converting them into an S-glutathionilated form (Singh & Gupta, 2011). Figure 
10 provides an overview of the chemical reactions NO is involved in, from 
synthesis to biological effects.  
 
Although non-enzymatic dependent, protein nitrosative modifications are 
very selective processes. This is corroborated by the relatively small number 
of tyrosine and cysteine residues that seem to be the target of nitrosative 
adducts (Stamler et al, 2001). It has also been established that the local 
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environment of the residue plays a major role on whether it will react with 
RNS (Souza et al, 1999; Stamler et al, 1997). Protein nitrosative modifications 
are negatively regulated by denitrosylalting and denitrating enzymes such as 
S-nitrosoglutathione reductase, thioredoxin, protein disulfide isomerase and 
xanthine oxidase (Liu et al, 2001; Nikitovic & Holmgren, 1996; Trujillo et al, 
1998). Still, there is not so much information about possible denitrating 
enzymes.  
 
 
 
III) Nitrosative modifications in intracellular signalling 
Nitrosative modifications play an important role in different signalling 
pathways. Generally speaking, and with respect to the main hubs that are 
activated during mammary gland involution, nitrosative modifications have 
been found to take an active part in regulation of cell signalling in the NF-κB 
and AKT pathways. Indeed, nitration of the 181 tyrosine residue in IκBα is 
consistent with the disruption of the interaction of the IκBα -p50 complex. 
Disrupting these interactions results in dissociation of the IκBα/NF-κB 
complex, and the latter becomes activated (Yakovlev et al, 2007). 
Furthermore, NF-κB has been proved to activate NOS2 transcription during 
mammary gland involution (Zaragoza et al, 2005), which could establish a 
feed-back loop where nitrosative modifications are required to activate this 
important hub in the involution process. Controversially, it has also been 
reported that RNS can negatively regulate NF-κB via S-nitrosylation of a 
Figure 10. Chemistry of NO. NO is 
synthesized endogenously from L-
arginine, NADPH and Oxigen. NO 
freely diffuses creating concentration 
gradients across subcellular 
compartments. Redox or additive 
reactions convert NO to NO species, 
which in turn, dictate the biological 
effects of NO. Adapted from (Singh & 
Gupta, 2011). 	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cysteine residue within IKKβ, which inhibits IκB phosphorylation preventing 
NF-κB nuclear translocation (Hess et al, 2005). Taken together, these data 
suggest that nitrosative stress may serve as both stimulatory and inhibitory 
effects on the NF-κB signalling pathway, depending on the prevailing 
posttranslational protein modifications. It is thus conceivable that, in acute 
inflammatory settings, S-nitrosylation of IKKβ could serve as a negative 
feedback control of the NF-κB dependent inflammatory response, but in a 
more persistent state of inflammation, tyrosine nitration could supersede the 
S-nitrosylation effect and exacerbate the inflammatory response.  
 
In AKT pathway regulation, there has been an important amount of work 
covering the role of NOS2, nitrosative modifications and insulin resistance. 
For example, obese NOS2-KO mice are protected from developing insulin 
resistance (Perreault & Marette, 2001). Importantly, NOS2 is induced in 
skeletal muscle and adipose tissues of type 2 diabetic subjects, and its 
expression correlates with insulin resistance and obesity (Engeli et al, 2004).  
In vitro work has shown that exposure to ONOO- can induce tyrosine nitration 
of IRS-1, consequently impeding tyrosine phosphorylation and activation of 
downstream insulin-signalling intermediates (Nomiyama et al, 2004). Also, 
ONOO- can induce tyrosine nitration of AKT, which can blunt its kinase activity 
(Zhou & Huang, 2009).  
 
All in all, NO has been proved to be a particularly interesting and rich 
signalling mediator, and since it is produced in pro-inflammatory settings, its 
specific role in mammary gland involution should be further characterized.  
 
3. FROM MAMMARY GLAND INVOLUTION TO BREAST CANCER 
 
Having reviewed all the different pathways involved, it is clear that 
mammary gland involution after weaning is a well orchestrated and complex 
process which is finely tuned by different signals. Following lactation and the 
weaning of pups, the mammary gland undergoes a sequential chain of events 
that end up with the gland returning to a pre-pregnant like state.  
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A deeper study into the molecular mechanisms involved in the regulation 
of mammary gland involution reveals different biological processes 
overlapping at the same time. Cell proliferation occurs not only during virgin 
development and pregnancy as thought at first, but also during mammary 
gland involution with a peak of DNA synthesis at 48h after weaning (Wiesen & 
Werb, 2000). On the other hand, the induction of inflammatory APR genes in 
mammary gland has been described as early as 24h after pups withdrawal 
(Stein et al, 2007). Concomitant induction of inflammatory, apoptotic and 
proliferative regulatory signals could represent conflicting messages for cells. 
However, under physiological conditions, a fine balance among these 
responses will condition tissue homeostasis, and therefore cell proliferation or 
apoptosis resolution will depend upon which side the balance is tilted.  
  
In this sense, although the molecular mechanisms involved in the 
inclination to a particular biological process remain elusive, it is not unusual to 
find common regulatory proteins for the above mentioned processes 
(Aggarwal et al, 2009; Reuter et al, 2010; Shaulian, 2010). Most of these 
proteins have been identified as oncogenes or transcription factors 
persistently activated during neoplasic transformation, a circumstance that 
adds an increased interest for health purposes.  Indeed, a deeper analysis of 
the main hubs that control mammary gland involution, namely STAT3 and NF-
κB, shows that they not only modulate cell death and proliferation, but are 
also involved in tumour development and progression by the induction of an 
inflammatory environment in some way similar to that one observed in the 
involuting mammary gland of mice (Chariot, 2009; Torres et al, 2011). In fact, 
it has been suggested that deregulation of post-lactational involution may act 
to facilitate tumour formation (Lyons et al, 2011; Radisky & Hartmann, 2009). 
The elevated incidence of breast cancer associated with pregnancy has been 
suggested to be influenced by the tumour microenvironment developed in 
mammary gland after weaning (Lyons et al, 2011). Furthermore, in agreement 
with the tumour-promoting potential of the involuting mammary gland, it has 
INTRODUCTION 
 
 
49 
been described that up to 81% of the genes regulated by NF-κB during 
involution have been related with carcinogenic processes (Torres et al, 2011).  
 
3.1 INVOLUTION AS A PRO-INFLAMMATORY PROCESS- THE CANCER 
LINK 
As it has been explained earlier, the induction of pro-inflammatory 
cytokines, by both STAT3 and NF-κB, is an important event that takes place 
in the early stages of mammary gland involution. This might seem 
inexplicable, since involution after weaning is not a process associated 
clinically with inflammation (Stein et al, 2007). This could be partially 
explained because phagocytosis of apoptotic cells can activate a regulatory 
mechanism that down-regulates pro-inflammatory cytokine production (Fadok 
et al, 1998; Monks et al, 2005). It has been suggested that the chemokine/ 
cytokine pro-inflammatory signature is a natural consequence of the Stat3/NF-
κB activation and that this would promote an unwanted cellular infiltrate that 
required sequestering through additional anti-inflammatory mechanisms 
regulated by physiological programs (Clarkson et al, 2004; Stein et al, 2004). 
In fact, in stat3-KO mice, mastitis is a common event and although this has 
not been associated with infection, it results in a massive infiltration of 
lymphocytes (Chapman et al, 1999).  
 
Data from several studies have established that wound-healing 
programs are activated during mammary gland involution after lactation ends, 
and these programs entail macrophage activation (Clarkson et al, 2004; 
McDaniel et al, 2006; Schedin et al, 2004; Schedin et al, 2007; Schedin et al, 
2000; Stein et al, 2004). Many genes involved in macrophage recruitment and 
activation are up-regulated at the RNA and protein levels during involution 
(Clarkson et al, 2004; Stein et al, 2004). 
On the other hand, components of chronic inflammation are common in 
the microenvironment of many cancers, such as breast and colon (Balkwill et 
al, 2005). In cancer-related inflammation, immune cell infiltration is associated 
with high chemokine and cytokine signalling, protease mediated tissue 
remodelling and angiogenesis (Hanahan & Weinberg, 2011; Mantovani et al, 
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2008; Mantovani et al, 2007). Thus, physiologic gland regression after 
pregnancy can be a tumour promoting microenvironment, and a subset of 
breast cancer diagnosed within 5 years of a recent pregnancy is associated 
with a poor prognosis (Lyons et al, 2011; Schedin, 2006). This will be further 
explained in the discussion section.  
  
Macrophages’ presence in breast cancer pathology studies has been 
amply correlated with poor prognosis of this disease. In fact, tumour 
associated macrophages (TAM), have been linked to significant increased 
relapse rate and worse over-all survival with hazard ratios of 2.79 and 9.43 
respectively (Leek et al, 1996). While the concept of tumour promoting 
immune cells might seem contradictory, many studies have looked into the 
role of TAMs as tumour favouring and it has been well established that 
macrophages can play a tumour suppressor and a promoter role, depending 
on the specific cytokine milieu (Goede et al, 1999; Lee et al, 1997; Leek et al, 
1996).This dual role is due to macrophages’ multifunctional nature since they 
perform diverse functions, such as the secretion of various pro-angiogenic 
factors, including various cytokines and matrix-degrading enzymes. Among 
the pro-tumorigenic factors and cytokines expressed by macrophages are: 
VEGF (Leek et al, 1994), urokinase (uPA) which is involved in ECM 
degradation, invasion and metastasis (Hildenbrand et al, 1999; Xu et al, 
1997), MMP-9 (Davies et al, 1993; Naylor et al, 1994) and lysosomal 
proteases such as cathepsin D (Lipponen, 1996), although for the latter, it is 
the expression in tumour cells which has been correlated with metastasis, so 
the role of TAM-derived cathepsins in cancer progression remains unknown 
(Lah et al, 2000; Lipponen, 1996). 
 
At a more specific level, macrophages are also a very important source 
of NO. It has been explained before that during inflammatory responses, the 
levels of NO can reach µM concentrations. In fact, generation of NO by NOS2 
is a cardinal feature of inflamed tissues (Hussain et al, 2000; Jaiswal et al, 
2000). As for the role of NO and nitrosative modifications in cancer 
development and cancer progression, contradictory reports exist (Ridnour et 
al, 2008). Earlier studies have described that NO is a critical component of the 
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immune response of macrophages (Hibbs, 1991). Other studies showed that 
lack of NOS2 could lead to tumour development (Hussain et al, 2004). Recent 
studies have shown a correlation between NOS2 and worse prognosis in 
breast cancer and melanoma (Ekmekcioglu et al, 2006; Prueitt et al, 2007). 
To date, there is substantial evidence implicating NO in cancer development 
as it can act as an endogenous mutagen (Wink et al, 1991), a pro-angiogenic 
factor (Jenkins et al, 1995), an enhancer of oncogene expression and an 
inhibitor of apoptosis (Ambs et al, 1998; Li et al, 1997a). 
 
As it occurs in physiological processes, NO concentration and time of 
exposure play an important role in biological effects in pathological contexts. 
In MCF-7 cells, levels below 50nM NO increase cGMP-mediated ERK 
phosphorylation, intermediate levels (>100nM) lead to HIF-1α stabilization, 
and high NO (>300nM) are associated with p53 phosphorilation (Thomas et 
al, 2004).  Hence, at NO levels of 100nM or lower, pro-survival responses are 
favoured in a neoplastic context.  However, the pro-survival effects of NO are 
lost at concentrations above 400nM (Hofseth et al, 2003; Wang et al, 2003), 
this has been the biological rational for the development of NO donating 
drugs, since it is believed that high NO concentrations will result in cell death, 
but this issue will be discussed later. Figure 11 represents the mechanisms of 
action of NO on tumour cells. Given the capacity of macrophages to produce 
NO, it can be said that these immune system cells are responsible, at least in 
part, of NO output in tumour microenvironment (Ridnour et al, 2008). As 
referred to before, several studies have shown that patient survival decreases 
with enhanced NOS2 expression in the tumour (Ekmekcioglu et al, 2006; 
Glynn et al, 2010; Prueitt et al, 2007). These and other studies have 
established tumour development as persistent, non-healing wounds, with pro-
inflammatory features and abundance of tumour associated macrophages 
(TAMs) implying worse prognosis (Chang et al, 2005; Leek et al, 1996; 
Whalen, 1990). All in all, data suggests that there is a link between 
inflammation and cancer progression (Lyons et al, 2011) and NO production 
seems to play a role in this setting.  
 
INTRODUCTION 
 
 
52 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Diagram summarizing NO action on cancer cells. NO can influence 
tumour development in a time and concentration dependent manner. (Singh & 
Gupta, 2011) 
 
3.2 STAT3 AS A BREAST CANCER-PROMOTING FACTOR 
 
 STAT3’s role as the regulator of a pro-apoptotic program in normal 
mammary gland development is in apparent contradiction to its documented 
pro-survival functions in mammary tumour progression (Guo et al, 2006; Zhou 
et al, 2007). A potential explanation may lie in recent work demonstrating that 
the involuting mammary gland is a particularly good microenvironment for 
promoting mammary tumour metastasis (McDaniel et al, 2006; Schedin et al, 
2007). Recently published data suggests that the proinflammatory functions of 
STAT3 during mammary gland involution may also have a critical role in 
mammary tumour progression. In vivo work with mice expressing the ErbB2 
oncogene (HER2) has demonstrated that STAT3 dependent pro-inflammatory 
program is required for the metastatic phase of tumour progression. This work 
showed that STAT3 was not essential for tumour onset but STAT3 ablation 
implied significant decrease in metastasis occurrence. The analysis of gene 
expression profile of these stat3-defficient HER2 tumours revealed that the 
acute inflammatory response was dramatically impaired because the reduced 
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expression of STAT3 targets: C/Ebpδ, OsmR, SAA1, SAA2 (Ranger et al, 
2009). What is intriguing is that STAT3 uses this same regulatory network for 
either promoting mammary gland involution and tumour progression. Hence, 
since STAT3 in involution modulates microenvironment, its role in tumour 
progression is probably to also alter the tumour microenvironment (Siegel & 
Muller, 2010). 
  
3.3 NF-κB CANONICAL ACTIVATION AND MAMMARY TUMORIGENESIS 
 
NF-κB plays a key role in regulating inflammatory response (Lin & Karin, 
2007), and, as already explained, during mammary gland involution it can 
exert both pro-survival and pro-apoptotic signals in mammary epithelial cells. 
As for the role in carcinogenesis, NF-κB family members are over-expressed 
or activated in breast cancer cell lines, primary human breast tumours and 
other malignancies (Dejardin et al, 1995; Sovak et al, 1997). Still, many efforts 
are being made to elucidate the specific role of NF-κB in mammary epithelial 
cell vs inflammatory cell in tumour progression. In fact, a work published 
recently shows that NF-κB induced activation in epithelial mammary cells 
promotes tumour on-set, growth, angiogenesis and the infiltration of TAM. 
Also, its inhibition resulted in reduction of epithelial-mesenchymal transition, 
breast tumour stem cell expansion and heterotypic signalling in which 
epithelial cells recruited TAM (Liu et al, 2010).  
 
Furthermore, in vitro investigations concerning activation of NF-κB in 
human breast cancer cells have established NF-κB as a provider of 
resistance to cytotoxic agents. It has been demonstrated that expression of 
the NF-κB inhibitor IκBα increases cancer cell sensitivity to paclitaxel, a key 
chemotherapeutic agent in breast cancer treatment (Patel et al, 2000). Also, 
doxorubicin increases NF-κB activity in vitro and inhibition of the pathway also 
increases cells sensitivity to this agent (Tapia et al, 2007). In vivo work in 
transgenic mice has proved that inhibition of NF-κB signalling leads to 
increased tumour latency and decreased tumour burden (Connelly et al, 
2011). This data indicates that, in addition to the NF-κB role as an inducer of 
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the inflammatory response, its activation in epithelial cells contributes actively 
to tumour progression and it could be a potentially effective therapeutic target.  
 
3.4 CATHEPSIN D AS A PROGNOSTIC FACTOR IN BREAST CANCER 
 
The role of cathepsin D in cancer remains to be elucidated, but it has 
been published in numerous occasions that increased cathepsin D expression 
correlates with tumour aggressiveness, metastasis and poor survival (Liaudet-
Coopman et al, 2006), and this is also true for breast cancer (Ferrandina et al, 
1997; Rochefort, 1992; Westley & May, 1999). A meta-analysis of studies on 
node negative breast cancer and a complete study on 2810 patients have 
confirmed the value of high concentrations of cathepsin D as a marker of 
aggressiveness (Ferrandina et al, 1997; Foekens et al, 1999). As for the 
specific role this protease plays in carcinogenesis, many reports have 
established cathepsin D as a mitogenic factor, a stimulator of angiogenesis 
and a pro-metastatic factor.  
 
Different mechanisms have been proposed as responsible for the 
mitogenicity of cathepsin D. On one hand, its catalytic activity has been 
implicated in the proteolytic activation of growth factors, rendering cathepsin D 
an indirect role in mitosis activation (Briozzo et al, 1991; Rifkin et al, 1997). 
Nevertheless, it is pro-cathepsin D that seems to play a major role in 
activation of mitosis. Various studies have demonstrated the growth 
stimulating effects of both pro-cathepsin D and its 44 Aa activation peptide on 
the proliferation of breast cancer cells (Fusek & Vetvicka, 1994; Vashishta et 
al, 2005; Vetvicka et al, 1999). In fact, this mitogenic function is thought to be 
mediated by the activation peptide of pro-cathepsin D through its interaction 
with a yet unknown cell surface receptor (Benes et al, 2006; Fusek & 
Vetvicka, 1994). It is hypothesized that the signal formed by interaction of the 
membrane receptor with the activation peptide is transmitted to the cell 
nucleus where it affects the expression of genes involved in cell proliferation, 
apoptosis and invasion. In fact, in in vitro studies with recombinant pro-
cathepsin D activation peptide and breast cancer cell lines, a series of genes 
involved in these processes where found to be either up or down-regulated. 
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For example, NF-κB2 (p49/p100), BCL-2 binding component 3 (PUMA) and 
cell division cycle 42 (CDC42) were found to be up-regulated. These genes 
are implicated in cell cycle progression, survival, angiogenesis, invasion, anti-
apoptotic activity and regulation of cell motility and adhesion. Also, treatment 
with activation peptide enhances the invasiveness of breast cancer cells 
(Benes et al, 2006). So it seems that cathepsin D’s role in cancer progression 
is more related with a paracrine function, where either the pro-cathepsin D or 
its activating peptide interact with a yet unknown receptor. This interaction 
would activate a signalling pathway (possibly MAPK) and finally activate 
transcription of genes that regulate cell cycle progression, mitosis, 
angiogenesis and cell migration (Laurent-Matha et al, 2005). In fact, the direct 
involvement of enzymatic activity of the mature form of cathepsin D in growth 
and invasiveness of breast cancer cells has not been established (Liaudet-
Coopman et al, 2006). 
 
In line with the concept that every physiologic process is extremely well 
regulated, so is the complex processing of cathepsin D. As mentioned before, 
cathepsin D processing varies during the different stages of mammary gland 
development (Margaryan et al, 2010). These finely regulated changes could 
be deregulated during cancer progression, and render a plausible explanation 
for the apparent change in the role of cathepsin D in this pathological setting.  
 
Having reviewed the major aspects of mammary gland involution, the 
genetic program that mammary cells recruit during the involution process after 
lactation, the pro-inflammatory environment created and the signalling 
pathways activated, it is clear that this physiological process has to be very 
well orchestrated. The pro-apoptotic and pro-survival signals are well 
modulated in order to not send equivocal messages that could favour an 
oncogenic event or its progression. Intriguingly, most of the mechanisms that 
partake in the post-lactational remodelling process have also been related in a 
way or another with tumour development and progression. This warrants the 
need for better understanding the mechanisms that regulate this process, in 
order to be able to also understand how they become de-regulated and allow 
for cell transformation and cancer development. 
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1. Our group has previously established that NOS2 expression is induced 
by NF-κB during weaning as early as 8 hours after litter removal 
(Zaragoza et al, 2005). NOS2 has been implicated in many pro-
inflammatory processes, inducing higher and steadier levels of NO 
than those obtained with NOS1 and NOS3. This, added to the previous 
works that define mammary gland involution after weaning as a pro-
inflammatory model, gave rise to question exactly which role did NO 
exert in this setting. Hence, our first objective is to establish the role of 
NO as a signalling molecule in the involution process, specifically in the 
regulation of two of the main pathways implicated in post-lactational 
involution, STAT3 and NF-κB. 
 
2. NO has been characterized as a highly reactive molecule that 
produces reactive nitrosative species. NO can play contradictory 
signalling roles depending on concentration and temporal exposure. In 
general, lower NO concentrations promote cell survival and 
proliferation, while higher levels trigger cell cycle arrest, apoptosis and 
senescence (Thomas et al, 2008). More specifically, it has been shown 
that NO can induce a series of nitrosative post-translational 
modifications on proteins and lipids that play a key signalling 
mechanism in cell physiology, with a clear role in pathophysiology 
(White et al, 2010). In proteins, these modifications manifest in two 
main forms, either as S-nitrosylation of cystein thiols or as nitration of 
tyrosine residues. The second objective is to further explore the 
possible role of specific protein nitrosative modifications in mammary 
gland involution and how these post-translational modifications affect 
protein function. 
 
3. Pregnancy is associated with a reduction in a woman’s lifetime risk of 
developing breast cancer (Albrektsen et al, 1994; MacMahon et al, 
1973; Rosner et al, 1994). However, studies in breast cancer incidence 
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have demonstrated a transient increase in breast cancer risk in the 
years immediately following pregnancy (Albrektsen et al, 2005; Chie et 
al, 2000; Lambe et al, 1994). Hence, pregnancy might both suppress 
and promote breast cancer, since, the initial effect of any completed 
pregnancy is an increased risk, but a crossover to long-term protection 
is seen in women of younger maternal age, and high parity (Lord et al, 
2008). One of the hypotheses to explain this increased risk in breast 
cancer associated with pregnancy postulates that mammary gland 
involution, which goes hand-in-hand with a terminated pregnancy 
implies the activation of certain mechanisms that resemble pro-
tumorigenic, wound-healing and pro-inflammatory micro-environment 
(Schedin, 2006).  NO is one of the molecules induced in pro-
inflammatory environments, and it has been proved to have deleterious 
or pro-survival effects in different cancer cell lines depending on dose 
and time of exposure (Thomas et al, 2008). The third objective is to 
explore in an in vitro luminal breast cancer model the specific pathway 
activation that NO can induce at high concentrations. The main aim of 
the third objective is to find which physiological mechanisms studied in 
the previous two objectives are recruited by transformed mammary 
epithelial cells when exposed to high NO concentrations. 
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1. ANIMAL HUSBANDRY AND TISSUE EXTRACTION 
 
Pregnant Wistar rats (Harlan), wild-type (WT) control mice and knock out 
NOS2 (NOS2-KO) mice (Taconic, Ejby, Denmark) were used. Mice were 
C57BL/6 and the genotype of the NOS2-KO strain was verified by PCR, using 
DNA obtained from tail samples taken at the end of the experiments. Animals 
were kept in individual cages in a controlled environment (12 hour light/12 
hour dark cycle) and they received water and food ad libitum. They were 
cared for and handled in conformance with the NIH (National Institutes of 
Health) guidelines and the Guiding Principles for Research Involving Animals 
and Humans approved by the Council of the American Physiological Society. 
The Research Committee of the School of Medicine (University of Valencia) 
approved the study protocol. After parturition, the litters were maintained with 
at least ten pups in the case of rats and seven pups in the case of mice. 
 
At the peak of lactation (days 9–11), mice were divided into groups as 
follows: control or weaned animals from which the litter was removed 6, 24, 
48 and 72h before sacrifice. The rats were divided into different groups at the 
peak of lactation (days 12-14): control lactating rats (n=8) or weaned rats from 
which pups were removed 12 days after delivery to initiate involution. 
Mammary tissue samples were collected at the indicated times after weaning 
(at least three rats for each condition were used). . The animals were 
anaesthetized with sodium pentobarbital (60mg/kg body weight in 0.9% NaCl 
intraperitoneal; Braun Medical, Rubi, Spain) and killed immediately after 
removing the inguinal mammary glands that were snap-frozen in liquid 
nitrogen and stored at −80ºC for further analysis. 
 
2. CELL CULTURE 
 
The cell line used for the in vitro assays was the MCF-7 cell line, 
initially obtained from a metastatic pleural effussion of an invasive ductal 
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carcinoma oestrogen and progesteron receptor positve, HER-2 negative, was 
obtained from the ATCC. 	  
Cells were grown in 6cm diameter plates with DMEM media supplemented 
with 2nM glutamine, 100U/mL of penicilin and 100µg/mL streptomycin and 
10% fetal bovine serum. The in vitro experiments were carried out when the 
plates were at 70% confluence.  
The nitration experiments were carried out using 3-Morpholinosydnonimine 
hydrochloride SIN-1 (sigma-aldrich) in different concentrations and in a time-
dependent manner.  
 
2.1 CELL VIABILITY ASSAY WITH MTT 
 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a 
yellow tetrazole), is reduced to purple formazan in living cells.  The media was 
removed from the 6mm cell plates (control and SIN-1 treated MCF-7 cells) 
and the plates were washed twice with warm (37°C) phosphate buffer saline 
(PBS). Then, 3mL of MTT (1mg/mL of DMEM media, filtered through 0.2µm) 
were added and plates were incubated for 1h. The solution was mixed once 
during incubation time. The MTT solution was aspirated and the plates were 
washed once with PBS 1x. 2mL of N-propanol were added and the plates 
were incubated for 30 minutes under mild agitation and protected from light. 
1mL of the N-propanol was collected onto a microcentrifuge tube and 
centrifuged for 2min at 12000g. Finally, the centrifuged N-propanol was 
diluted 1:4 and absorbance was read in a Shimadzu UV-160 
spectrophotometer at 560nm. 
 
3. MILK PRODUCTION 
 
Milk production was measured as previously described by Sampson and 
Jansen  with a simple mathematic method that allows estimation of daily milk 
yield in the well-nourished dam from pup weight and weight gain (Sampson & 
Jansen, 1984). Briefly, the following equation relating pup milk yield to pup 
weight and weight gain was used to estimate milk production:  
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yield = 0.0322 + 0.0667 (weight) + 0.877 (gain) 
Where yield is daily yield per pup (g·day–1·pup–1), weight is pup weight (g), 
and gain is daily pup weight gain (g/day).  
 
4. TISSUE PREPARATION AND HISTOPATHOLOGY 
 
Inguinal mammary glands from lactation and weaned wild-type and 
NOS2-KO mice were embedded in paraffin after removal and fixation in 4% 
(w/v) paraformaldehyde. Tissue sections of 5-7µm were cut and haematoxilin 
and eosin stained for histological studies.  
 
5. QUANTIFICATION OF SERUM PROLACTIN LEVELS 
 
On day 10 of lactation, blood from WT NOS2-KO  (n=3 for each 
condition) was collected and centrifuged at room temperature at 3500 rpm 
during 20min. The supernatant (plasma) was collected and kept at -20°C until 
use. Measurement of prolactin levels in plasma was conducted using an 
enzyme immune assay (EIA) commercial kit (SPIbio). The EIA is based on the 
competition for limited specific rabbit anti-prolactin sites between sample 
prolactin and prolactin labelled with acetylcholinesterase AChE (tracer). Once 
the sample prolactin and the tracer are bound to the rabbit anti-prolactin 
antibody, the mixture is placed in a well that contains mouse monoclonal anti-
rabbit antibody attached. The plate is then washed and Ellman’s Reagent 
(enzymatic substrate for AChE plus chromogen) is added. The AChE tracer 
prolactin reacts with the Ellman’s reagent and forms a yellow compound. The 
intensity of colour is determined with spectrophotometry (reading between 
405 and 414nm) and it is proportional to the amount of tracer bound to the 
well and inversely proportional to the sample prolactin present in the well 
during the immunological incubation.  
 
In this experiment, the plasma collected and kept at -20°C was thawed 
and centrifuged at 1600g and room temperature for 20min to eliminate any 
fibrin remaining. Following the manufacturer’s instructions, the plate was 
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washed 5 times with the provided specific wash buffer. For prolactin 
determination a standard curve was used with prolactin concentrations 
ranging from 0.39 ng/µL to 25 ng/µL.  In each well either 50µL of standard or 
50µL of sample were pipetted followed by 50µL of prolactin tracer. Finally, 
50µL of prolactin antiserum was added to every well and the plate was 
incubated at room temperature for 20 hours. After incubation, the plate was 
washed 5 times with the wash buffer and 200µL of Ellman’s reagent pipetted 
to each well and incubated once more in the dark, at room temperature and 
shaking. The reading was performed using the Multiskan FC plate reader 
(Thermo Scientific) between 405 and 414nm.  
 
6. COLORIMETRIC AND FLUOROMETRIC DETERMINATION OF NITRITE 
CONCENTRATION  
 
Nitrite levels where measured with a colorimetric assay kit (Cayman 
Chemical Company) following the instructions of the manufacturer. Briefly, 
100µL of cell culture media from cells treated with different concentrations of 
SIN-1 were collected and plated in a 96 well plate. 50µL of Griess Reagent 
R1, followed by 50µL of Griess Reagent R2 were added to each well. The 
plate was incubated for 10min at room temperature for color-development. 
Then, absorbance was measured with a Multiskan FC plate reader (Thermo 
Scientific) at 540nm.  
 
Since this colorimetric method was not sensible enough to measure 
nitrite concentration in vivo on mammary tissue, a fluorimetric method was 
used. The method is based on the reaction of 2,3-diaminonaphthalene 
(Sigma-Aldrich) with nitrite under acidic conditions to form 1-(H)-
naphthotriazole, a fluorescent product. Samples from control lactating and 
24h weaned mice were prepared by homogenizing 0.1g of tissue in 500µL of 
50 mM Tris/HCl pH7.5 followed by a centrifugation at 12000g for 20min to 
avoid proteins interfering with the determination. The supernatant obtained 
was filtered using a 30KDa molecular mass cut-off filter (Microcon YM-30; 
Millipore). An aliquot of 10µL of freshly prepared 2,3-diaminonaphthalene 
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(0.05mg/mL in 0.62M HCl) was added to 100µL of the supernatant obtained in 
the previous step and mixed immediately. After a 10 minute incubation at 
20°C protected from light, the reaction was stopped with 5µL of 2.8M NaOH. 
Formation of the 2,3-diaminonaphthotriazole was measured using the 
SPECTRAmax GEMINI XS Microplate Spectrofluorometer (Molecular 
Devices, Inc.  Sunnyvale, CA. USA), with excitation wavelength at 365nm and 
emission read at 450nm. White opaque 96-well plates (Bibby Sterilin Ltd.) 
were used for optimal measurement of fluorescence intensity. 
 
7. MOUSE GENOTYPING 
  
In order to determine the mice genotype, tails were cut and incubated 
over night at 65°C in TESNA buffer (100mM Tris/HCl pH7.5; 10mM EDTA; 2% 
SDS and 10mM NaCl) together with 0.5mg/mL proteinase K. The product was 
then transferred onto a new micro-centrifuge tube and 1 volume of 
Phenol:Chloroform:Isoamyl Alcohol (25:24:1) was added. The mixture was 
centrifuged for 15min at 12000g at room temperature using a  MIKRO 200 
centrifuge (Andreas Hettich GmbH & Co.KG; Tuttlingen, Germany). The 
aqueous phase was transferred into another tube and 500µL of isopropanol 
where added followed by a second centrifugation at 12000g for 15 more 
minutes. The pellet obtained was washed with 750µL of 80% ethanol and 
centrifuged again at 12000g for 15min. The pellet was finally resuspended in 
65µL of preheated (65°C) H20.  
 
The PCR was carried out as follows: 
The previously obtained DNA was diluted 1:10 in H20. The PCR 
master-mix was made for a final reaction volume of 30µL: DNA (2µL of the 
dilution), 1x Buffer PCR (Invitrogen, Carlsbad, USA), 2mM MgCl2, 0.2mM 
dNTP mixture, 0.8µL of oligonucleotide A for NOS2, 0.4µL of oligonucleotide 
B for NOS2 and 0.4µL of oligonucleotide D for NOS2, 0.15µL of Taq 
polymerase (Invitrogen, Carlsbad, USA) and Diethyl Pyrocarbonate (DEPC) 
water. The use of three oligonucleotides was due to the fact that NOS2-KO 
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mice did have the gene, but in a truncated form, hence the primer forward for 
WT and KO was different.  
 
Table 4. Oligonucleotides for NOS2 amplification: 
 
 
 
 
 
The PCR was performed with the Gene Amp PCR system 2700 (Applied 
Biosystems) and the PCR conditions were as follows: 95°C (1min); [95°C 
(30s); 63°C (30s); 72°C (30s)] repeat for 40 cycles; 72°C (10min); 4°C(∝).  
 
The amplification product was then loaded onto a 1.5% agarose/TAE 
(40mM Tris, 20mM Acetic acid, 1mM EDTA) gel with DNA loading buffer (30% 
glycerol, 0.25% bromophenol blue) and ethidium bromide (Sigma-Aldrich). 
The reading was performed using an image analyzer system UVIdoc 
(UVITEC Limited, Cambridge, UK). 
 
8. RNA EXTRACTION 
 
Total RNA from mammary tissue or cell pellets was extracted using 
TRIzol reagent (Invitrogen Life Technologies). Briefly, 50-100mg of tissue or 
cell pellets obtained from 6cm diameter plates at 70% confluence at were 
homogenized at 4°C with 1mL of TRIzol reagent using either a 29G syringe in 
the case of cells or the Ultra-Turrax® T25 basic (IKA®-Werke GmbH & Co. 
KG. Germany) in the case of the tissue samples. The mixture was centrifuged 
at 12000g and 4°C during 10min in order to eliminate debris, and the 
supernatant kept. After a 5min incubation at room temperature, 200µL of 
chloroform per mL of TRIzol used were added. Incubation for 2-3min on 
bench top was followed by a new centrifugation a 12000g and 4°C for 15min. 
The aqueous phase was transferred to a new ultracentrifuge tube and 500µL 
of isopropyl-alcohol per mL of TRIzol were added, incubating for 10min at 
NOS A ATCAGCCTTTCTCTGTCTCC 
NOS B GGCTTTCTGTCTGTTCTCTC 
NOS D-28 GCCTGAAGAACGAGATCAGCAGCCTCTG 
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room temperature. Then a new centrifugation at 12000g and 4°C was 
performed and the pellet obtained was washed with ethanol 75% (1mL per mL 
of TRIzol used) and centrifuged, this time at 7500g for 5min. The ethanol was 
eliminated and the RNA isolated resuspended in 200µL of Ultrapure RNAse 
free water. After this isolation, an additional column purification (RNeasy, 
Qiagen) was performed following the intructions of the manufacturer. RNA 
quantity and purity were determined using the NanoDrop ND-2000 (NanoDrop 
Technologies), and RNA integrity was assessed by determining the RNA 
28S/18S ratio using RNA 6000 Nano Labchips in an Agilent 2100 Bioanalyzer 
(Agilent Technologies). 
	  
9. REAL-TIME RT-PCR 
 
RNA (500ng) was reverse-transcribed into cDNA at 25ºC for 10min and 
37ºC for 2h using a high capacity cDNA reverse transcription kit (Applied 
Biosystems). The cDNA products were amplified by qPCR using the 
GeneAmp Fast PCR Master Mix (Applied Biosystems). All reactions were 
carried out in triplicate. Quantitative real-time PCR was run in the 7900HT 
Fast Real-Time PCR System. Pre-developed Taqman primers were 
purchased from Applied Biosystems (see table 5 below).  
 
Table 5. Summary of the Taqman probes purchased from Applied 
Biosystems. 
 
GENE NAME TaqMan PROBE 
Human 18s rRNA 4319413E 
Mouse NOS2 Mm01309902_m1 
Mouse Whey Acidic Protein (wap) Mm00839913_m1 
Mouse Bcl-3 Mm00504306_m1 
Mouse Metallo-Protease 2 (mmp-2) Mm00439506_m1 
Mouse Metallo-Protease 9 (mmp-9) Mm00442991_m1 
Mouse beta casein (Csnb) Mm04207885_m1 
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Mouse Leukemia inhibitory factor (lif) 
 
Mm00434762_g1 
Mouse Cathepsin D (ctsd) Mm00515586_m1 
Rat Cathepsin D (ctsd) Rn00592528_m1 
Human Metallo-Protease 9 (MMP-9) Hs00234579_m1 
 
Results were normalized according to 18s rRNA quantification in the 
same sample reaction. The threshold cycle (CT) was determined, and then the 
relative gene expression was expressed as follows:  
 
Fold change (relative amount) = 2– Δ (Δ Ct) 
Where ΔCt = Ct target – Ct housekeeping, and Δ( Δ Ct) = ΔCt treated – ΔCt 
control 
 
10. RT-PCR ARRAY FOR NF-κB SIGNALLING PATHWAY 
 
The effect of weaning on the expression of 84 genes associated with 
NF-κB-mediated signal transduction were examined using mouse NF-κB 
signalling pathway RT2 Profiler PCR array (SuperArray Bioscience) according 
to the manufacturer's instructions. In brief, 1µg of total RNA of control and 
48 hour weaned mammary glands from WT and NOS2-KO mice was 
converted into cDNA using the RT2 First Strand Kit (SABiosciences). This 
cDNA was then added to the RT2 SYBR Green/ROX qPCR Master Mix 
(SABiosciences). Next, each sample was added to Mouse NF-κB Signalling 
Pathway PCR Arrays (catalogue number PAMM-025). All steps were carried 
out according to the manufacturer's protocol for the 7900 HT Fast Real-Time 
PCR System. PCR amplification was conducted with an initial 10 minutes step 
at 95°C followed by 40 cycles of 95°C for 15 s and 60°C for 1min. The 
fluorescent signal from SYBR Green was detected immediately after the 
extension step of each cycle, and the cycle at which the product was first 
detectable was recorded as the cycle threshold (Ct). Data normalization was 
based on correcting all Ct values for the average Ct values of several 
constantly expressed housekeeping genes present on the array. The relative 
gene expression was expressed as follows: Fold change (relative amount) = 
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2– Δ (Δ Ct) 
Where ΔCt = Ct target – Ct housekeeping, and Δ( Δ Ct) = ΔCt treated – ΔCt 
control 
 
11. ChIP (CHROMATIN IMMUNOPRECIPITATION) ASSAY 
 
Chromatin from mammary gland extracts was fixed and 
immunoprecipitated as previously described (Borras et al, 2003). Briefly, 
mammary tissue samples were excised and immersed in PBS, pH7.4, and 1% 
(v/v) formaldehyde for 10min to cross-link the chromatin, and the reaction was 
stopped by adding glycine to a final concentration of 0.125M. After 
centrifugation at 1500g for 5min, the cell pellet was resuspended in cell lysis 
buffer (85mM KCl, 0.5% Nonidet P40, 5mM Hepes, pH8.0) supplemented with 
a protease inhibitor cocktail (Sigma), incubated on ice for 15 min and 
centrifuged at 3500g for 5min to pellet the nuclei. The pellet was resuspended 
in nuclear lysis buffer (10mM EDTA, 1%SDS, 50mMTris/HCl, pH8.1) at a ratio 
of 1:1 (v/w) relative to the initial tissue weight, incubated on ice for 10min, 
aliquoted in 1mL fractions and stored at −80°C until use for ChIP assay. 
Cross-linked chromatin (1mL of each sample) was sonicated on ice with 15 
pulses of 10s at 38% amplitude with 50s stops, in a Vibra-Cell VCX-500 
sonicator. The sonified chromatin was centrifuged at 14000g for 10min and 
the supernatants, containing soluble chromatin fragments were kept. 
Chromatin concentration was determined diluting 5µL of the chromatin 
samples 1:200 (v/v) in 1% SDS. The measurement was performed in quartz 
cuvets using the UV-160 UV-visible recording spectrophotometer (Shimadzu, 
Minnesota, USA) at 260nm. 
The units of chromatin were calculated using the formula: 
 
Absorbance260 x 1000/5=Units of chromatin/mL 
 
In order to determine if sonicated chromatin was properly size-
fractioned, 4.5U of the sonified chromatin were diluted in H2O up to a final 
volume of 100µL, treated with RNase (Sigma-Aldrich) and incubated for 
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30min at room temperature. 0.4µg/µL Proteinase K (Roche) and 0.01% SDS 
were added followed by over night incubation at room temperature. The 
chromatin was then purified using the PCR purification kit QIAquick® DNA 
(QIAGEN, Hilden, Germany) following the instructions by the manufacturer. 
The purified DNA was stained with ethidium bromide and then loaded onto a 
1.5% agarose/TAE (40mM Tris, 20mM Acetic acid, 1mM EDTA) gel with DNA 
loading buffer (30% glycerol, 0.25% bromophenol blue). The reading was 
performed using an image analyzer system UVIdoc (UVITEC Limited, 
Cambridge, UK). The average size of the chromatin fragments obtained was 
∼500bp. 
 
The chromatin fragments were diluted 10-fold in dilution buffer (165mM 
NaCl, 0.01%SDS, 1.1%Triton X-100, 1.2mM EDTA, 16.7mM Tris/HCl, pH8.0) 
supplemented with protease inhibitor cocktail. The diluted chromatin fractions 
were precleared by adding 30µL/mL Protein A/G–agarose (Amersham 
Biosciences; previously blocked for 1h with 500µg/mL tRNA and 1mg/mL 
BSA) and incubated for 4h at 4°C on a rotating plate. The suspensions were 
then centrifuged at 14000g for 30s to remove non-specifically bound 
chromatin fragments. Aliquots from the supernatant (equivalent to 50µg of 
DNA) were taken, incubated with 2µg of specific antibodies against the NF-κB 
p65 and p50 subunits (both from Santa Cruz Biotechnology), and left 
overnight at 4°C under rotation. The samples were then incubated with 50µL 
of blocked ProteinA/G–agarose under rotation for an additional period of 4h. 
The immunocomplex was recovered by centrifugation at 14000g for 30s and 
washed twice with low-salt buffer (150mM NaCl, 0.5% deoxycholate, 0.1% 
SDS, 1% Nonidet P-40, 1mM EDTA, 50mM Tris–HCl), twice with high-salt 
buffer (500mM NaCl, 0.5% deoxycholate, 0.1% SDS, 1% Nonidet P-40, 1mM 
EDTA, 50mM Tris–HCl), twice with LiCl buffer (250mM LiCl, 0.5% 
deoxycholate, 0.1% SDS, 1% Nonidet P-40, 1mM EDTA, 50mM Tris–HCl) 
and finally twice with TE buffer (0.25mM EDTA, 10mM Tris–HCl).  (Sandoval 
et al, 2004). 
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An aliquot of the cross-linked chromatin was treated as above, but in 
the presence of an unrelated antibody (IgG); the first supernatant, after 
preclearing with ProteinA/G–agarose, was saved as the Input fraction. The 
immunoselected chromatin was eluted from the ProteinA/G–agarose in two 
consecutive steps by adding 50µL of elution buffer (1%SDS, 100mM 
NaHSO3) each time, with 30s of vigorous vortexing. The two supernatants 
were combined (IP (immunoprecipitated) fraction) and incubated at 65°C 
overnight to reverse formaldehyde cross-links. The DNA from all samples was 
purified with a PCR purification kit QIAquick® DNA (QIAGEN, Hilden, 
Germany) and used for PCR analysis of the target genes. 
After DNA purification, input, immunoprecipitated, and unrelated antibody 
fractions were analyzed by PCR with the appropriate primer pairs to amplify 
the promoter of the target gene MMP-9 (Primer forward for MMP-9 promoter 
region: 5’- GTGAACACGGTGGCTGAAA-3’. Primer reverse for MMP-9 
promoter region: 5’-CAGGCTCTTTGAAGCAGGATT-3’).  
 
The PCR was performed with the NETZYME® DNA Polymerase using 
the Gene Amp PCR system 2700 (Applied Biosystems) and the PCR 
conditions were as follows:  
 
93°C (2min); [93°C (30s); 58°C (30s); 72°C (30s)] repeat 37 cycles; 72°C 
(10min); 4°C(∝).  
 
The amplification product was then loaded onto a 1.5% agarose/TAE 
(40mM Tris, 20mM Acetic acid, 1mM EDTA) gel with DNA loading buffer (30% 
glycerol, 0.25% bromophenol blue) and ethidium bromide (Sigma-Aldrich). 
The reading was performed using an image analyzer system UVIdoc 
(UVITEC Limited, Cambridge, UK). 
 PCR fragments were size fractionated by 1.5% agarose/TAE gel 
electrophoresis and stained with ethidium bromide. The reading was 
performed using an image analyzer system UVIdoc (UVITEC Limited, 
Cambridge, UK).  
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12. PROTEIN EXTRACTION 
 
Cell pellets collected from 6cm diameter plates at 70% confluence or 
freeze-clamped tissue (0.1g) were homogenized in 1mL of RIPA buffer 
(1.8mM NaH2PO4, 8.4mM Na2HPO4, 0.1 % (w/v) SDS, 1.0% (v/v) TritonX 100, 
0.1M NaCl, 0.5% sodium deoxycholate, 1mM PMFS) supplemented with 
2µL/mL of protease inhibitor cocktail and 5µL/mL of phosphatase inhibitor 
cocktail (both from Sigma) at 4⁰C using a 29G syringe in the case of cells and 
an Ultra-Turrax® T25 basic (IKA®-Werke GmbH & Co. KG. Germany) for 
tissue. After homogenization, the sample was incubated for 1h at 4⁰C  in a 
rotating device followed by centrifugation at 4°C and maximum speed 
(14000g) for 30min.  
  
The supernatant containing the total protein extract was collected and 
normalized for protein concentration using a Bradford-based assay (Bio-Rad 
protein assay) following instructions from the manufacturer. This assay 
involves the addition of an acidic dye (Coomassie® Brilliant Blue G-250 dye) 
to protein solution, and subsequent measurement at 595 nm with a 
spectrophotometer or microplate reader. Comparison to a standard curve 
provides a relative measurement of protein concentration. The absorbance 
maximum for the acidic solution shifts from 465nm to 595nm when binding to 
protein occurs. The Coomassie blue dye binds to primarily basic and aromatic 
amino acid residues, especially arginine, and a differential color change of the 
dye occurs in response to various concentrations of protein. The BSA protein 
standard was prepared with a range of 0.05µg/µL to 0.5µg/µL dilutions. 2µL of 
each standard and sample was pipetted into separate microtiter plate wells 
and 200µl of diluted dye reagent was added to each well. The sample and 
reagent were mixed using a microplate mixer followed by 5min incubation at 
room temperature. Absorbance was measured with a Multiskan FC plate 
reader (Thermo Scientific) at 595 nm. 
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13. WESTERN BLOTTING 
 
Same amounts of protein (15µg) were denatured with Laemli buffer 5x 
(0.3M Tris/HCl pH6.8, 50% glycerol, 10% SDS, 0.05% bromophenol blue, 
25% β-mercaptoethanol) at 95°C for 5min and loaded in SDS-PAGE gels for 
electrophoresis (concentration of bis-tris acrylamide varied from 8% to 15% 
depending on the molecular weight of the protein to be determined. After 
electrophoresis (electrophoresis buffer 0.25M Tris/HCl pH8.6, 1.92M glycine 
and 1.0% SDS), the proteins were eletroblotted onto a nitrocellulose 
membrane (Protran®, Whatman, Kent, UK) in transfer buffer (0.25M Tris 
pH8.6, 1.92 M glycine and 20% methanol). The membranes with the 
transferred proteins were blocked for one hour with 5% BSA in TBS-T (0.25M 
TrisHCl pH 7.5, 0.15M NaCl, 0.1% (v/v) Tween 20) followed by addition of a 
primary antibody. For all antibodies, the membranes were incubated over-
night at 4°C with shaking; following four washes with TBS-T. 
 
The blots where then incubated with the secondary antibody conjugated 
to horseradish peroxidase for 60min at room temperature. Finally, the blots 
where washed with TBS-T and detection was carried out using the 
chemiluminescent luminol reagent (Amersham™ ECL™ Western Blotting 
Detection Reagent. GE Healthcare UK Limited). The processor Curix60 
(AGFA) was used for film development. The intensity of the bands was 
measured by densitometry using Image J, a public domain Java image 
processing program. Equal loading was confirmed by reprobing the blot 
against either α-tubulin or β-actin and by Ponceau staining. The antibodies 
and their source, as well as the concentration used for blotting are specified in 
the table below. 
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Table 6. List of primary and secondary antibodies for western blotting.  
 
14. TWO-DIMENSIONAL ELECTROPHORESIS 
 
Mammary gland tissue from lactating controls and 72h weaned rats was 
homogenized in rehydration buffer from Bio-Rad Laboratories (8M urea, 2% 
3-[(3-Cholamidopropyl) dimethylammonio]-1 propanesulfonate (CHAPS), 
50mM dithiothreitol (DTT), 0.2% Bio-Lyte® 3/10 ampholyte and 0.001% 
Bromophenol Blue). After cleaning up the samples with a ReadyPrep 2-D 
Protein ORIGIN DILUTION   
β-actin Rabbit monoclonal 1:2500 Abcam (ab8227) 
α-tubulin Mouse monclonal 1:1000 SantaCruz Biotechnology (sc-5286) 
ER-alpha Mouse monoclonal 1:1000 SantaCruz Biotechnology (sc-
73479) 
Cathepsin D Rabbit polyclonal  1:1000 SantaCruz Biotechnology (sc-
10725) 
Cathepsin D Rat monoclonal 1:1000 R&D Systems clone 204712 
(MAB1029) 
Cathepsin D Mouse monoclonal 1:1000 Calbiochem clone BC011 (IM03) 
Anti-nitrotyrosine Mouse monoclonal 1:1000 Upstate biotechnology clone 1A6 
(#05-233) 
STAT3 Rabbit polyclonal 1:1000 Upstate Biotechnology (#06-596) 
p-STAT3 (Tyr 705) Rabbit polyclonal 1:1000 Cell Signalling Technology (#9131) 
STAT-5 Rabbit polyclonal 1:1000 SantaCruz Biotechnology (sc-1081) 
p-STAT5 (Tyr694) Rabbit monoclonal 1:1000 Cell Signalling Technology (#9314) 
AKT Rabbit polyclonal 1:1000 Cell Signalling (#9272) 
p-AKT (Ser 473) 
(D9E) 
Mouse monoclonal 1:1000 Cell Signalling (#4060) 
IκB-β Rabbit polyclonal  1:1000 SantaCruz Biotechnology (sc-945) 
IκB-α Rabbit polyclonal 1:1000 SantaCruz Biotechnology (sc-371) 
Anti-Rabbit 
Immunoglobulins/ 
HRP 
Polyclonal Goat  1:5000 DAKO Cytomation P0448 
Anti-Mouse 
Immunoglobulins/ 
HRP 
Polyclonal Goat  1:5000 DAKO Cytomation P0447 
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Cleanup kit (Bio-Rad Laboratories), 500µg of tissue lysates were loaded on to 
precast immobilized pH gradient strips (IPG strips; pH5–8; Bio-Rad 
Laboratories) and subjected to isoelectric focusing (IEF) two-dimensional 
PAGE. The IEF conditions were those recommended by the manufacturer for 
the type of strip used. Second-dimension gels contained 8% acrylamide. 
Simultaneously, proteins were resolved by two-dimensional PAGE and then 
electrophoretically transferred on to nitrocellulose membranes (Protran®) or 
visualized using silver or Coomassie Blue staining. Membranes were probed 
with a 1:1000 dilution of anti-nitrotyrosine antibody as described above. Spots 
corresponding to nitrated proteins were excised manually from Coomassie 
Blue-stained gels and identified by MS. 
 
15. PROTEIN IDENTIFICATION BY MASS SPECTROMETRY 
 
Protein preparation and tryptic digestion: 
Protein spots corresponding to weaned mammary gland lysates 
recovered from two-dimensional gels were precipitated with 20% 
trichloroacetic acid (TCA) on ice and, after centrifugation at 20000g for 30min, 
the pellet was washed with cold acetone. The same procedure was performed 
in the case of human cathepsin D (25µg) treated with 20µM ONOO− or with 
1.2M NaOH, in order to identify the nitration site of the enzyme. Precipitated 
proteins were resuspended in 25mM ammonium bicarbonate and digested 
with 12.5ng/µl trypsin for 12h at 37 °C. 
 
LC (liquid chromatography)–ESI (electrospray ionization)-MS/MS 
(tandem MS) analysis: 
MS/MS analysis was performed as previously described (Munoz et al, 
2008). Microcapillary reversed-phase LC was performed with a CapLC™ 
(Waters) capillary system. Reversed-phase separation of tryptic digests was 
performed with an Atlantis, C18, 3µm, 75µm×10cm Nano Ease™ fused silica 
capillary column (Waters) equilibrated in 5% acetonitrile and 0.2% formic acid. 
After injection of 6µL of sample, the column was washed for 5 min with the 
same buffer and the peptides were eluted using a linear gradient of 5–50% 
acetonitrile in 45min at a constant flow rate of 0.2µL/min. The column was 
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coupled online to a Q-TOF Micro (Waters) using a PicoTip nanospray 
ionization source (Waters). The heated capillary temperature was 80°C and 
the spray voltage was 1.8–2.2kV. MS/MS data were collected in an 
automated data-dependent mode. The three most intense ions in each survey 
scan were sequentially fragmented by CID (collision-induced dissociation) 
using an isolation width of 2.0 and a relative collision energy of 35V. Data 
processing was performed with MassLynx 4.1. Database searching was 
carried out with ProteinLynx Global Server 2.1 (Waters) and Phenyx 2.2 
(GeneBio) against Uniprot knowledgebase release 12.3 consisting of 
UniprotKB/Swiss-Prot release 54.3 and UniprotKB/TrEMBL release 37.3 with 
285335 and 4932421 entries respectively. The search was enzymatically 
constrained for trypsin and allowed for one missed cleavage site. Data were 
then manually inspected and the results were only accepted when the 
molecular mass and pI of the identified protein were coincident with the 
electrophoretic mobility of the corresponding spot in two dimensions. 
 
16. IMMUNOPRECIPITATION 
 
16.1 IMMUNOPRECIPITATION OF CATHEPSIN D USING SEPHAROSE 
BEADS 
 
Protein A–Sepharose and Protein G–Sepharose beads(GE Healthcare 
UK Limited) (50:50 v/v) were blocked with bovine serum albumin 1µg/µL for 
4h. 1mg of proteins obtained from tissue lysates from lactating and weaned 
mammary glands were precleared with the blocked sepharose beads during 
1h at 4°C.  The samples with the beads were centrifuged at 12000g for 5min. 
The supernatant was incubated first with either cathepsin D antibody from 
Santa Cruz Biotechnology or with an unrelated antibody also from Santa Cruz 
Biotechnology overnight at 4°C, and then with Protein A–Sepharose and 
Protein G–Sepharose (50:50v/v) beads for 4h at 4°C on a rotating device. 
Pellets were collected by centrifugation at 14000g for 1min at 4°C. The 
supernatants from the samples incubated with the unrelated antibody were 
taken to be used as INPUT, and each pellet was subsequently washed three 
times with 50mM Tris/HCl pH8.0. After washing the sepharose beads, the 
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immunocomplexes were eluted by boiling in the Laemli buffer for 5min and 
then subjected to SDS/PAGE immunoblotting as described previously.  
 
16.2 PEPSTATIN A AFFINITY PURIFICATION OF CATHEPSIN D 
 
Homogenates from weaned mammary gland (500µg of whole extract 
proteins) were incubated for 15h at 4°C with pepstatin A–agarose-coated 
beads (Sigma) previously washed with in 20mM citrate phosphate buffer 
pH7.0. Then the mixture was centrifuged at 20000g for 5min and the pellet 
was washed with the citrate phosphate buffer. Finally, the pellet was 
resuspended and denatured in 30µL of Laemli buffer prior to Western blot 
analysis. 
 
17. IN VITRO PROTEIN NITRATION 
 
Peroxynitrite (ONOO−) was purchased from Calbiochem (La Jolla, USA), 
diluted in 1.2M NaOH and stored in an oxygen-free atmosphere at −80°C until 
use. Prior to experimentation, the concentration of ONOO− was measured by 
the increase in molar extinction coefficient (ε) at 302nm (ε302 1.670M−1·cm−1) 
in 1.2M NaOH (Radi et al, 1991). Recombinant cathepsin D (20µg) from 
human liver (Sigma) or 50µg of protein from control lactating mammary gland 
homogenates were incubated with 0–500µM ONOO− in assay buffer (pH3.5; 
from the cathepsin D assay kit). The incubation was carried out in the 
presence or absence of 30µM epicatechin (Sigma-Aldrich, Steinheim, 
Germany) and in the presence and absence of pepstatin A (Sigma). 
Epicatechin is used as a nitration inhibitor due to its action as a potent 
scavenger of ONOO−. Pepstatin A is a specific inhibitor of cathepsin D. The 
reaction was performed by placing a small aliquot of ONOO− into a test tube 
containing the sample, immediately followed by a 20min incubation. In control 
test tubes, the samples were treated with equal volumes of 1.2M NaOH 
(vehicle). Aliquots were taken for Western blot analysis and determination of 
cathepsin D enzymatic activity. 
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As for the in vitro protein nitration in cell culture, 3-
Morpholinosydnonimine hydrochloride (SIN-1. Sigma-Aldrich, Steinheim, 
Germany) was used. It was resuspended in DMEM up to a concentration of 
100mM. MCF-7 cells grown in 6cm diameter plates at 70% confluence, were 
treated with different concentrations of SIN-1 in a time dependent manner. 
The final concentrations of SIN-1 were 1mM, 2mM, 3mM for 24h, to determine 
the appropriate SIN-1 concentration. Once the appropriate concentration of 
SIN-1 was determined, incubation times were reduced to 5, 10, 30min, 1 and 
4h in order to determine early biological activity.  
 
18. CATHEPSIN D ENZYMATIC ASSAY 
 
Cathepsin D protease activity was measured using the commercially 
available cathepsin D assay kit (Sigma-Aldrich) following the method of 
Yasuda et al (Yasuda et al, 1999). Briefly, 5µg of protein obtained from 
mammary gland tissue of lactating rats and mice, at different times of 
weaning, were added to the assay buffer (pH3.5), followed by the addition of 
the quenched fluorimetric substrate 7-methoxycoumarin-4-acetic acid at a 
final concentration of 20 µM. The fluorescence released by the action of the 
enzyme was measured at 37°C in the SPECTRAmax GEMINI XS Microplate 
Spectrofluorometer (Molecular Devices, Inc.  Sunnyvale, CA. USA) during 
60min of incubation in a kinetic reaction. To prove that the substrate was 
hydrolysed by cathepsin D only, the specific inhibitor pepstatin A (Sigma) was 
added to parallel samples at a final concentration of 0.2mg/mL to inhibit the 
cathepsin D activity. Samples (at least n=3) were assayed in triplicate. The 
assay was also performed for 2.4µg/mL human cathepsin D (Sigma-Aldrich) 
treated with ONOO− to induce tyrosine nitration, in order to determine whether 
this post-translational modification could affect the protease activity.  
 
19. NUCLEAR EXTRACT ISOLATION 
 
Isolation of nuclei from mouse mammary gland (WT and NOS2-KO) and 
different weaning conditions was carried out with the Nuclear Extract Kit from 
Active Motif (Belgium) following instructions by manufacturer. Briefly, 0,3g of 
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mammary gland tissue was treated with 750µL of hypotonic buffer 
supplemented with 1µL/mL DTT 1M, 1µL/ml detergent and 50µL/mL of 
phosphatase inhibitor (Sigma) and homogenized in a pre-chilled loose 
Dounce homogenizer. After incubation on ice for 15min the samples were 
centrifuged for 10min at 850g at 4ºC. The pellet was re-suspended in 500µL 
of 1x hypotonic buffer (supplemented with 1mM DTT, 10µL/mL  protease and 
50µL/mL phosphatase inhibitors from Sigma) and incubated on ice for 30 
minutes with gentle shaking. The samples were then centrifuged at 14000g 
for 10min at 4ºC.The supernatant fraction (the nuclear protein extract) was 
stored at -80ºC or used immediately. 
 
20. DETERMINATION STAT3 AND NF-ΚB NUCLEAR BINDING ACTIVITY 
 
After obtaining the nuclear extract, the determination of NF-κB and 
STATs DNA-binding activity was carried out using TransAM™ STAT family or 
NF-κB p65 chemi kits both from Active Motif, also following the instructions 
from manufacturer. The protocol is based on ELISA-assay to detect and 
quantify transcription factor activation. The assay is performed on a 96-well 
plate on which an oligonucleotide containing an NF-ΚB or STAT3 consensus 
site has been immobilized. The active form of these transcription factors 
contained in the nuclear extract will bind specifically to the oligonucleotide 
after 1h incubation at room temperature. After three washes with the specific 
buffer provided, 50µL of NF-κB or STAT3 primary antibody; that detects the 
activated transcription factor bound to its target (dilution 1:1000 in antibody 
biding buffer); is added and the plate incubated for 1h. Then, a series of 
washes follows and a Horse Radish Peroxidase (HRP)-conjugated secondary 
antibody is added, providing a sensitive chemiluminiscent read out that can be 
quantified. Assays were performed using 5µg of nuclear extracts, and to 
check specificity, incubation was carried out in absence or presence of 
20pmol of competitor oligonucleotide that contains either a WT or mutated 
STAT3 or NF-κB consensus binding site. The WT oligonucleotide prevents 
the NF-κB or STAT3 binding to the probe immobilized on the plate, acting as 
a negative control, while the mutated consensus oligonucleotide has no effect 
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on the transcription factor binding. The plate was read using a microplate 
luminometer (SPECTRAmax Plus 384, Molecular Devices). 
21. MEASUREMENT OF CASPASE 3 ACTIVITY 
 
Caspase 3 activity was measured in mammary tissue lysates using the 
Caspase-3/CPP32 Colorimetric Assay Kit (BioVision). Mammary gland was 
homogenized in lysis buffer, incubated on ice for 10min and centrifuged at 
10000g for 15min. Supernatants from tissue homogenates were used to 
measure caspase 3 activity following the manufacturer's instructions. First, 
total protein concentration was measured and 200µg of protein were diluted in 
50µL of Cell Lysis Buffer provided in the assay. 50µL of 2X Reaction Buffer 
(containing 10mM of DTT) were added to each well, followed by the addition 
of 5µl of the DEVD-pNa substrate (200µM final concentration). This mixture 
was incubated at 37°C for 1 hour before reading the plate with a Multiskan FC 
plate reader (Thermo Scientific) at 405nm. 
 
22. GELATINE ZYMOGRAPHY (MMP9 AND MMP2 ACTIVITY) 
 
Protein lysates (150µg) were electrophoresed on SDS/PAGE 10% mini-
gels containing 1mg/mL gelatin (Bio-Rad Laboratories) using a non-reducing 
SDS sample buffer (62.5mM Tris/HCl, pH6.8, 25% glycerol, 4% SDS and 
0.001% Bromophenol Blue). After electrophoresis, the gels were washed for 
30min at room temperature (25°C) in re-naturing buffer (10mM Tris/HCl, 
pH7.5, and 2.5% Triton X-100) followed by 36 hour incubation in enzyme 
reaction buffer (50mM Tris/HCl, pH7.6, 200mM NaCl, 5mM CaCl2 and 0.02% 
Brij-35) for 36h at 37°C. Gels were stained with Coomassie Brilliant Blue R-
250 and gelatinolytic activities were detected after destaining by clear bands, 
indicating lysis of the substrate. 
 
23. STATISTICAL ANALYSIS 
  
Results are reported as means± S.E.M. The control and weaned rat 
data, as well as WT and NOS2-KO mice experiments data within the same 
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genotype were analysed by a one-way ANOVA. The homogeneity of the 
variances was analyzed by the Levene test; in those cases where the 
variances were unequal, the data were adequately transformed before 
ANOVA. Significant differences were determined by a Tukey-Kramer test. The 
letter ‘a’ always represents the lowest value within the group. Differences 
were considered significant at p<0.05.  
 
A two-tailed Student’s t test with the Bonferroni correction was used for 
comparison of two groups. Differences were also considered significant at * 
p<0.05. Independent studies were conducted with a minimum of three 
replicates per condition to allow for statistical comparison. 
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RESULTS 
 
1. GLOBAL ROLE OF NITRIC OXIDE DURING INVOLUTION OF MAMMARY 
GLAND AFTER WEANING.CHARACTERIZATION OF MAMMARY 
GLAND INVOLUTION IN NOS2-KO MICE 
 
1.1 MOUSE GENOTYPING  
 
Wild-type and NOS2 knock-out mice were purchased from Taconic with a 
C57BL/6 background. The genotype of the NOS2-KO strain was verified by 
PCR as explained in the Materials and Methods section. Figure 12 shows the 
PCR amplification product for both WT and NOS2-KO mice. It can be observed 
that there was an amplification product for WT and KO, but for NOS2-KO the 
product was smaller, around 300 base pairs (bp) while the WT showed a ≈ 
400bp product. This is due to the fact that the NOS2-KO mice did have the 
NOS2 gene, but in a truncated form, and hence it resulted in a truncated non-
functional protein. 
 
 
 
  
 
 
 
 
 
 
Figure 12. Genotyping of WT and NOS2-KO mice. Agarose gel electrophoresis 
showing the amplification product for NOS2 gene (410 bp) in the WT mice (A) 
or NOS2-KO animals (≈300 bp) (B).   
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1.2 NITRITE DETERMINATION IN THE WEANED MAMMARY GLAND 
 
Our group had previously established that NOS2 expression is induced in 
weaned rats as early as 8h after litter removal (Zaragoza et al, 2005). NOS2 
has been implicated in many pro-inflammatory processes, inducing higher and 
more steady levels of NO than those obtained with NOS1 and NOS3. This, 
added to the previous works that define mammary gland involution after 
weaning as a pro-inflammatory model, gave rise to question exactly which role 
did NO exert in this setting. To answer this question we used a NOS2-KO 
mouse model since, if during mammary gland involution the major source of NO 
is NOS2, the lack of this enzyme would result in lower NO levels during the 
physiological process of involution. In this sense, the first step to take was to 
confirm the increase in NO levels in the involuting mammary gland compared to 
lactation, and if in fact, NOS2-KO had lower levels of NO after weaning.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Nitrite levels measured in control and weaned mammary glands of 
WT and NOS2-KO mice. Results are displayed as means ± S.E.M. * and # 
indicate statistically significant differences (p<0.05).  
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Nitrite levels as an end-product of NO were measured in the mammary 
gland of control lactating and 24h weaned mice both in WT and NOS2-KO 
strains. It can be observed in figure 13 that NO production was increased 
significantly in the involuting mammary gland after 24h of pup removal 
compared with control lactating glands in both WT (0.98±0.02 and 1.5±0.03µM 
respectively; n=5) and NOS2-KO (0.79±0.06 and 1.06±0.05µM respectively; 
n=5) mice. However, nitrite levels in NOS2-KO mice were statistically lower 
than in WT littermates either in control lactating glands or in weaned glands (#).  
 
In order to explain the increase in nitrite levels in the mammary gland of 
NOS2-KO mice, endothelial NOS (eNOS/NOS3) levels was determined by 
western-blotting in mammary gland extracts in NOS2-KO at the peak of 
lactation and at different times during weaning. Figure 14 demonstrates that, 
after an initial decrease in the early times of weaning, NOS3 levels increase 
from 24h onwards. This augmentation in NOS3 levels during weaning could 
explain the increase in nitrite levels observed in NOS2-KO mice. In fact, other 
works have already demonstrated that both NOS3 and NOS1 expression is 
increased during mammary gland involution after weaning (Islam et al, 2009). 
 
Figure 14. Western Blot to determine the expression of NOS3 in WT and NOS2-
KO mice at the peak of lactation (0h) and during weaning (6h, 24h, 48h and 
72h).  
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1.3 HISTOLOGICAL CHANGES IN THE MAMMARY GLAND 
 
The mammary gland undergoes a series of changes during involution that 
have two clear stages, a reversible phase that lasts up to 48h and an 
irreversible phase that will remodel the structure of the mammary gland into a 
pre-pregnant like state. Since it was clear that NO levels (inferred by nitrite 
levels) were lower in the NOS2-KO mice, this model is optimal to study the 
possible role of NO in both stages of involution. The first approach was to 
determine if there were any structural differences between NOS2-KO and WT 
mice by means of histological studies. The inguinal mammary glands of these 
mice were blind-analyzed by an experienced pathologist at day 10 of lactation, 
and at 6, 24, 48 and 72h of involution. Histological analysis of tissue sections 
from WT mice (figures 15 and 16 panels I, iii, v, vii, and ix) showed a loss of 
epithelial cells that were shed into the alveolar lumen with concomitant loss of 
the glandular structure together with alveoli collapse and reappearance of 
adipose tissue from 24h of involution onward. 
 
When comparing KO with WT mice, it was observed that on day 10 of 
lactation, NOS2-KO mice showed no significant differences in mammary gland 
development, and, as in the WT, they showed prominent secretory alveoli 
(Figure 15 and 16 panels i and ii). However, histological analysis of NOS2-KO 
mice during involution revealed a clear delay in mammary gland regression. 
After 24h weaning (figures 15 and 16 panel vi), KO mice showed the same 
condensed lobulo-alveolar structures that WT mice presented earlier, at 6h 
(figures 16 and 17 panel iii). Further on, at 48 h weaning, the mammary gland 
from WT mice showed and evident regression that was not present at the same 
time point in KO mice (panels vii and viii). In fact, the pattern of involution that 
the KO mice presented at 48h was similar to that of the 24h weaned WT mice 
(figures 15 and 16 panels v and viii). Surprisingly, at 72h weaning, both WT and 
KO mice presented similar levels of regression, hence it could be concluded 
that lack of NOS2 delayed but did not impair mammary gland involution after 
weaning. In fact, panels ix and x show a similar image, with adipocytes already 
differentiated and replacing the mammary gland alveolar structures in both WT 
and NOS2-KO mice.  
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Figure 15. Histological study of mammary gland in WT and NOS2-KO mice. 
Haematoxylin and eosin-stained sections showing mammary gland morphology 
from WT (panels i, iii, v, vii and ix) and NOS2-KO (panels ii, iv, vi, viii and x) 
mice at the peak of lactation (panels i and ii) and 6h (panels iii and iv), 24h 
(panels v, vi), 48h (panels vii, viii) and 72h (panels ix and x) after induced 
involution as described in the methods section. Magnification 10X. 
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Figure 16. Histological study of mammary gland in WT and NOS2-KO mice. 
Haematoxylin and eosin-stained sections of mammary gland tissue from WT 
(panels i, iii, v, vii and ix) and NOS2-KO (panels ii, iv, vi, viii and x) mice at the 
peak of lactation (panels i and ii) and 6h (panels iii and iv), 24h (panels v, vi), 
48h (panels vii, viii) and 72h (panels ix and x) after induced involution as 
described in the methods section. Magnification 40X. 
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1.4 RATIO MAMMARY GLAND/MOUSE WEIGHT 
 
To establish if the differences between WT and KO mice were already 
present during lactation, and to further confirm the delay in involution observed 
in the pathology studies, the ratio between inguinal mammary gland weight and 
total mice weight was determined. In figure 17 it can be observed that this ratio 
was increased in the first 24h for both WT and NOS2-KO mice. After 24h there 
is a rapid loss of gland weight. The explanation for this is that regression does 
not occur immediately. It has been noted in other works (Monks et al, 2008) that 
milk secretion continues for a period of time and that, as it has been explained 
in the introduction, involution in the mouse is reversible for up to 24-48h after 
weaning. In the KO mice, this ratio was significantly higher after 6 and 24h of 
weaning when compared with WT mice. This effect could be either the result of 
an increased milk secretion in the NOS2-KO mice due to a hormonal factor, or 
the result of a delay in mammary gland regression, which would support the 
hypothesis that NO deficiency can influence mammary gland involution.  
 
 
 
 
 
 
 
 
   
 
 
 
 
Figure 17. Ratio between inguinal mammary gland wet weight and total body 
weight in WT and NOS2-KO mice, at the peak of lactation and after different 
times of litter removal. Results are means ± S.E.M (n=6). To compare between 
the different conditions in WT or KO mice, ANOVA was performed for the 
statistical analysis where different superscript letters indicate significant 
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differences, p<0.05; the letter ‘a’ always represents the lowest value within the 
group. A Student’s t test with the Bonferroni correction was used for comparison 
between WT and KO at each experimental time point; *p <0.05.  
 
1.5 SERUM PROLACTIN LEVELS 
 
As it has been pointed out in the previous section, the variation found in 
the tissue slides as well as the statistical difference found in the 
mouse/mammary gland weight ratio could be due, not only to the decreased 
NO levels during weaning, but also in the lactating period (see figure 13 where 
nitrite levels are lower in the KO controls when compared to the WT mice). 
Given this possibility, we characterized other regulatory pathways that influence 
lactation and mammary gland involution, namely, serum PRL levels, since PRL 
is the main regulatory hormone in the lactating phase. This was an important 
point too because NO has been described to exercise an inhibitory control on 
calcium (Ca2+)-dependent PRL release in the adenohypophyis (Andric et al, 
2003; Duvilanski et al, 1995).  
 
Thus, serum prolactin was determined in six WT and NOS2-KO mice at 
day 10 of lactation. For the WT mice the plasma concentration of PRL was 
165±27ng/mL and for the KO mice it was 213±16ng/mL, this difference being 
statistically significant. The higher PRL should translate into higher milk 
production in the NOS2-KO mice, hence, milk yield (in mL/pup; litters where 
normalized to seven-eight pups) was calculated according to the equation from 
Sampson and Jansen specified in the methods section. This equation takes into 
account pup weight and weight gain. Figure 18 shows that, in correlation with 
higher PRL levels, the milk production was slightly higher in the NOS2-KO mice, 
being this difference statistically significant around the peak of lactation (days 8 
to 11).  
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Figure 18. Milk production graph. NOS2-KO mice compared with WT mice. The 
start of the graph represents day 1 of lactation (first day post-partum). Results 
are means ± S.E.M (n=6).  *p<0.05 when comparing WT and NOS2-KO mice at 
the same time point.  
 
To see if this difference in milk production had any repercussion in pup 
nourishment, the daily weight gain by pups was also registered and a 
comparison between the WT and the NOS2-KO was performed. Figure 19 
shows the graph comparing the weight gain between pups nourished by a WT 
or a NOS2-KO mother. The pups fed by KO mice increased weight during the 
lactating period significantly more that those fed by WT mice, although there 
were no weight differences at birth. This is also in line with the increased milk 
production in the KO mice, which is plausible with higher PRL levels and higher 
mammary gland weight/ total weight ratio. 
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Figure 19. Graph representing the day by day weight gain of pups nourished by 
WT or NOS2-KO mice. The start of the graph represents day 1 of lactation (first 
day post-partum). Results are means± S.E.M. (n=6).  *p<0.05 when comparing 
WT and NOS2-KO mice at the same time point.  
 
1.6  STAT5 PATHWAY ACTIVATION IN WT AND NOS2-KO MICE 
  
After establishing that NOS2-KO mice have a delay of around 48h in 
mammary gland involution, with higher PRL levels and higher milk output, the 
first pathway to be explored for regulatory effects was the STAT5 pathway, 
since it is the downstream effector of PRL during lactation. PRL exerts its 
function on the mammary gland epithelial cells via STAT5, which is a 
transcriptional factor down-stream of PRL receptor and JAK2. Stat5 is encoded 
by two different genes, giving rise to STAT5a and STAT5b. STAT5 has been 
demonstrated to be crucial for regulation of milk protein gene expression. For 
example, the transcription of milk components such as whey acidic protein 
(WAP) and β-casein is regulated by STAT5 (Happ & Groner, 1993; Li & Rosen, 
1995).  
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The next step was to determine whether there was a difference in the 
STAT5 activation.  STAT5 activated state (phosphorylated) was evaluated by 
means of western blotting. Figure 20 shows a comparison between the STAT5 
phosphorylation (P-STAT5 a/b) status at different time points of lactation and 
weaning for WT and NOS2-KO mice. Total STAT5 (STAT5a) was used as a 
control. As involution progresses total STAT5 is degraded, but its active form 
disappears much earlier after weaning. When comparing WT with NOS2-KO 
animals, it is clear that phosphorylated STAT5 levels diminish at an earlier 
stage in WT mice, whereas in NOS2-KO mice, p-STAT5 is still observed up to 
48h involution. Considering that activated STAT5 is key during lactation, these 
findings are in agreement with the involution delay observed in the KO mice.   
 
Figure 20. Western blot to determine STAT5 (STAT5a) and phosphorylated 
STAT5 (P-STAT5 a/b). α-Tubulin was used as a loading control.  
  
When phosphorylated, STAT5 acts as a transcriptional factor during 
lactation inducing milk protein gene expression Hence, its activation was 
corroborated indirectly through the evaluation of β-casein gene transcription 
(see figure 21). As expected, β-casein mRNA levels drop dramatically with 
involution. STAT5 is no longer functional and hence it cannot activate milk 
protein gene transcription, this translates into the decline of this milk protein 
mRNA levels. Still, this decline is slightly delayed in NOS2-KO mice (see 24h 
and 48h time points) since at these time points p-STAT5 was still present in the 
KO mice (seen in the previous figure 20).  	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Figure 21. Real-time qPCR for β-casein gene expression. β-casein mRNA 
levels were normalized to 18S for each sample. Results are mean ± S.E.M 
relative amounts of the replicate tissue samples. ANOVA was performed for the 
statistical analysis where different superscript letters indicate significant 
differences, p<0.05; the letter ‘a’ always represents the lowest value within the 
group. * p<0.05 when comparing WT and NOS2-KO mice at the same time 
point.   
 
1.7 STAT3 ACTIVATION DURING WEANING IN WT AND NOS2-KO MICE 
  
During weaning, milk stasis and the decrease in lactogenic hormones 
induce mammary gland involution. On a molecular level, this concept is 
determined, at least in part, from a change of the governing STAT 
transcriptional factor. STAT5 was crucial for lactation, but with weaning there is 
an “involution switch” where STAT3 takes over and triggers apoptosis as well as 
the transcription of pro-inflammatory factors. Therefore, STAT3 is essential for 
the initiation of apoptosis and remodelling following forced weaning. In fact, in 
vivo experiments with conditional deletion of stat3 have proved that stat3 
inactivation results in delay of at least 3 days in mammary gland involution 
(Chapman et al, 1999). Given this crucial role in weaning, STAT3 
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phosphorylation at the peak of lactation and during involution was analyzed by 
Western blotting. Figure 22 shows that p-STAT3 levels were induced after 24h 
of weaning and declined thereafter in WT mice. STAT3 phosphorylation was not 
delayed in NOS2-KO mice, with a peak also at 24h, but clearly of lower 
magnitude. Total STAT3 protein levels were constant during lactation and 
involution in both WT and NOS2-KO mice, as shown in figure 22 (middle panel). 
 
 
Figure 22. Western blot analysis of phospho-Tyr705-STAT3 (p-STAT3) and total 
STAT3 (STAT3) in lysates derived from WT and NOS2-KO mice mammary 
glands at day 10 of lactation (0h) and at 6, 24, 48 and 72h of involution.	  α-
tubulin was used as loading control. 
 
Once seen that the levels of phosphorylated STAT3 were increased at 24h 
weaning, the STAT3 DNA-binding activity was tested by means of an ELISA-
assay described in the materials and methods section. Figure 23 confirms that 
STAT3 was activated to a considerably lesser extent in NOS2-KO mice (5 ± 0.5 
fold increase in WT compared with 3 ± 0.4 fold increase for KO after 24h of 
weaning).  
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Figure 23. Graph showing STAT3 activity in nuclear extracts from WT and 
NOS2-KO mice at the peak of lactation (time point 0) and at different times of 
weaning. To compare between the different conditions in WT or KO mice, 
ANOVA was performed for the statistical analysis where different superscript 
letters indicate significant differences, p<0.05; the letter ‘a’ always represents 
the lowest value within the group.  *p<0.05 when comparing WT and NOS2-KO 
mice at the same time point.  (n=4 for each genotype and time point).  
 
Having found this difference in STAT3 phosphorylation and activation in 
WT and NOS2-KO animals, the next logical step was to determine at which 
point NO might play a regulatory role in STAT3 functionality, hence the 
upstream regulation was furthered studied to seek for differences between WT 
and NOS2-KO mice. The identified in vivo upstream regulator for STAT3 is the 
leukemia inhibitory factor (LIF). LIF binds to the specific LIF receptor (LIFR-α) 
which forms a heterodimer with a specific subunit common to all members of 
that family of receptors, the GP130 signal transducing subunit. This leads to 
activation of the JAK/STAT (Janus kinase/signal transducer and activator of 
transcription). After observing the activation of STAT3 at 24h weaning, the 
levels of LIF were quantified to explore any differences that could explain the 
divergence between STAT3 activity in WT and NOS2-KO mice. LIF mRNA 
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levels were examined using real-time PCR in lactating and 24h weaned glands, 
when STAT3 activation is maximal, in NOS2-KO and WT mice. LIF mRNA 
levels were not quantified at different time points because it has been described 
that once activated, Stat3 promotes the expression of the receptor for 
oncostatin M (OSMR) that substitutes LIF in its role of STAT3 activation, hence, 
levels of LIF decline from that point onward (Watson & Brown, 2008). As it is 
displayed in figure 24, LIF was substantially up-regulated in involution 
compared with lactation in WT mice. In NOS2-KO mice, LIF was also 
statistically increased when compared with control lactating, but the fold 
increase was significantly smaller than in WT littermates at the same time of 
weaning. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Reat-time qPCR to determine LIF expression in the mammary gland 
of control and 24h weaned mice. Each PCR was normalized against the 
housekeeping gene 18S. Results are means± S.E.M. relative amounts of the 
replicate tissue samples. *p<0.05 when comparing WT and NOS2-KO mice at 
the same time point also WT and KO 0h vs 24h.   
 
Finally, in order to determine the physiological relevance of a lower STAT3 
activity in NOS2-KO mice, the expression pattern of bcl-3, a known STAT3 
transcriptional target (Clarkson et al, 2006), was analyzed. Figure 25 shows that 
bcl-3 was induced after 24h weaning in both WT and NOS2-KO mice. 
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Nevertheless, bcl-3 mRNA levels where increased significantly more in WT than 
in KO mice (6.5±0.4 fold increase in WT compared with 3.3±0.1 fold increase in 
NOS2-KO mice), reaching the same steady-state mRNA levels after 72h 
weaning.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Real-time qPCR to determine bcl-3 expression during lactation and 
at different timepoints after weaning. Each PCR was normalized against the 
housekeeping gene 18S. Results are presented as means ± S.E.M. relative 
amounts of the replicate tissue samples. To compare between the different 
conditions in WT or KO mice, ANOVA was performed for the statistical analysis 
where different superscript letters indicate significant differences, p<0.05; the 
letter ‘a’ always represents the lowest value within the group. *p<0.05 when 
comparing WT and NOS2-KO mice at the same time point.  
 
1.8 AKT REGULATION BY NO DURING MAMMARY GLAND INVOLUTION 
  
The PI3K/AKT pathway is one of the main hubs that controls mammary 
gland involution. It has been described that during the apoptotic phase of the 
process AKT levels are clearly decreased, but most of all, its activation is 
abrogated. Since AKT is a pro-survival pathway, its inhibition is logical. Beyond 
the first 48 hours, in the context of tissue remodelling, AKT becomes activated 
again (Baxter et al, 2007). Having observed the delaying effects a lower 
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concentration of NO has on the involution process globally, a more specific 
analysis on its effects on the AKT pathway was performed.  
 
 
Figure 26. A) Western blot to determine phosphorylated AKT (pAKT) and total 
AKT (AKT) in WT and NOS2-KO mice during different time points: peak of 
lactation (0h) and 6, 24, 48 and 72h post-weaning (6h, 24h, 48h and 72h 
respectively). The figure is representative of at least 3 experiments for each 
time point. B) Analysis of the ratio between phosphorilated AKT (pAKT) and 
total AKT (AKT) in NOS2-WT and NOS2-KO mice (at different weaning time 
points (control 0h, 6h, 24h, 48h and 72h). To compare between the different 
conditions in WT or KO mice, ANOVA was performed for the statistical analysis 
where different superscript letters indicate significant differences, p<0.05; the 
letter ‘a’ always represents the lowest value within the group. T-student test was 
performed to compare WT with KO mice within the same timepoint. *p<0.05.   
 
Figure 26 shows a western blot to compare phosphorilated AKT (pAKT) 
and total AKT throughout different times of involution (panel A). Although total 
AKT levels were diminished, p-AKT increased during the second phase of 
involution in both WT and KO mice. To confirm AKT phosphorylation and 
activation, quantification was performed in order to compare phosphorylated 
AKT with respect to total AKT for both WT and NOS2-KO mice. Panel B is the 
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graphical representation of this quantification. It can be observed that the pAKT 
levels increase dramatically (50 fold with respect to control 0h) for the WT 
beyond the first 48h, coinciding with the start of the remodelling phase. The 
results are in concordance with the literature, since an increase in AKT 
activation has been described after the first 48h of weaning (Baxter et al, 2007). 
As for the KO mice, although a trend towards increase is seen, this is not 
statistically significant (5 fold increase when comparing the 72 hour time point 
with control lactating mice). This evidence further supports that NO has a role in 
the regulation of the weaning process, also in this specific pathway. 
 
1.9 MODULATION OF NF-κB ACTIVITY BY NO DURING MAMMARY GLAND 
INVOLUTION 
 
The other main regulator of mammary gland involution that has also been 
linked to pro-inflammatory processes is NF-κB. We investigated whether this 
factor could be modulated by NO and be responsible, at least in part, for the 
delayed involution observed in NOS2-KO mice. The differences found in NF-κB-
binding activity during lactation and early involution are known to be caused by 
the modulation of its nuclear translocation (Geymayer & Doppler, 2000) and do 
not affect the p65/p50 protein levels. Thus we analysed by western blotting the 
decrease in the cytoplasmic levels of IκBα protein, indicative of IκBα 
degradation and, indirectly, of NF-κB activation. As shown in Figure 27(A), IκBα 
degradation, while maximal after 24 and 48h of weaning in WT mice, was 
delayed to 48 and 72h in NOS2-KO mice. As expected, IκBβ protein levels did 
not change during weaning (Zaragoza et al, 2005). These results strongly 
suggest that NF-κB is differentially activated in WT and NOS2-KO mice. 
 
NF-κB activation was further assessed through analyzing its DNA binding 
activity at lactation and during weaning, again, using an ELISA-based assay. 
Panel B in figure 27 shows that NF-κB activity was increased at 24h after 
weaning, reaching a maximum after 72h in WT mice. This pattern of increased 
activity was also evident in the NOS2-KO mice, but delayed in time, in 
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agreement with the delay in involution seen in the histological changes, the 
Stat5 inactivation and the IκBα degradation seen before.  
 
 
Figure 27. A) Western blot analysis for IκBα and IκBβ in mammary gland 
extracts obtained from WT and NOS2-KO mice at day 10 of lactation (0h), and 
6, 24, 48 and 72 hours of involution. B) Graph to show assessment of NF-ΚB 
p65 activation. Nuclear extracts from WT and NOS2-KO mammary gland 
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extracts were assayed for NF-κB p65 activation (n=4 for each genotype and 
time point). The results are presented as means ± S.E.M. To compare between 
the different conditions in WT or KO mice, ANOVA was performed for the 
statistical analysis where different superscript letters indicate significant 
differences, p<0.05; the letter ‘a’ always represents the lowest value within the 
group. A Student’s t test with the Bonferroni correction was used for comparison 
between WT and KO at each experimental time point; *p <0.05.  
 
1.10 ROLE OF NO IN THE MODULATION OF NF-κB ASSOCIATED GENES 
DURING WEANING 
 
On the basis of the results of NF-κB activation, the expression of 84 
genes, known to be associated with NF-κB pathway, was analyzed using super-
array technology. The results showed that, for WT condition, when comparing 
48h weaning with peak of lactation, 30 genes were up-regulated and 13 were 
down-regulated. Table 7 shows the genes that were differentially regulated in 
weaned mammary gland with respect to lactating controls in WT mice. The 
expression pattern found was similar to the values described previously by 
microarray studies (Clarkson et al, 2004; Stein et al, 2004). For the NOS2-KO 
mice (table 8), although the expression pattern was similar to that of the WT 
mice, only 21 genes were up-regulated at 48h involution with respect to peak of 
lactation.  
 
Table 7. Summary of the NF-κB pathway related genes that are differentially 
expressed in WT mice at 48h weaning with respect to peak of lactation. The 
table shows the genes that were differentially regulated (p<0.05). Out of the 84 
genes tested, 30 were up-regulated and 13 down-regulated. 
 GenBank®	  accession	  number	  	   Gene	  Symbol	   Description	   Fold	  change	  NM_009652	   Akt1	   	  Thymoma	  viral	  proto-­‐oncogene	  1	  	  	   0,51	  NM_007497	   Atf1	   	  Activating	  transcription	  factor	  1	  	  	   0,68	  NM_009740	   Bcl10	   	  B-­‐cell	  leukemia/lymphoma	  10	  	  	   0,26	  NM_033601	   Bcl3	   	  B-­‐cell	  leukemia/lymphoma	  3	  	  	   2,97	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NM_009778	   C3	   	  Complement	  component	  3	  	  	   7,11	  NM_130859	   Card10	   	  Caspase	  recruitment	  domain	  family,	  member	  10	  	  	   0,43	  NM_009807	   Casp1	   	  Caspase	  1	  	  	   3,15	  NM_011333	   Ccl2	   	  Chemokine	  (C-­‐C	  motif)	  ligand	  2	  	  	   5,16	  NM_007700	   Chuk	   	  Conserved	  helix-­‐loop-­‐helix	  ubiquitous	  kinase	  	  	   0,13	  NM_001025432	   Crebbp	   	  CREB	  binding	  protein	  	  	   1,69	  NM_009971	   Csf3	   	  Colony	  stimulating	  factor	  3	  (granulocyte)	  	  	   0,34	  NM_010336	   Edg2	   	  Endothelial	  differentiation,	  lysophosphatidic	  acid	  G-­‐protein-­‐coupled	  receptor,	  2	  	  	   0,49	  NM_010177	   Fasl	   	  Fas	  ligand	  (TNF	  superfamily,	  member	  6)	  	  	   2,32	  NM_010493	   Icam1	   	  Intercellular	  adhesion	  molecule	  	  	   3,97	  NM_019777	   IκBke	   	  Inhibitor	  of	  kappaB	  kinase	  epsilon	  	  	   4,29	  NM_010547	   IκBkg	   	  Inhibitor	  of	  kappaB	  kinase	  gamma	  	  	   2,28	  NM_010548	   Il10	   	  Interleukin	  10	  	  	   2,23	  NM_010554	   Il1a	   	  Interleukin	  1	  alpha	  	  	   2,5	  NM_008361	   Il1b	   	  Interleukin	  1	  beta	  	  	   0,54	  NM_008363	   Irak1	   	  Interleukin-­‐1	  receptor-­‐associated	  kinase	  1	  	  	   0,33	  NM_008390	   Irf1	   	  Interferon	  regulatory	  factor	  1	  	  	   2,2	  NM_010591	   Jun	   	  Jun	  oncogene	  	  	   5,84	  NM_010736	   Ltbr	   	  Lymphotoxin	  B	  receptor	  	  	   1,76	  NM_011952	   Mapk3	   	  Mitogen	  activated	  protein	  kinase	  3	  	  	   3,37	  NM_010851	   Myd88	   	  Myeloid	  differentiation	  primary	  response	  gene	  88	  	  	   6,35	  NM_008689	   Nfkb1	   	  Nuclear	  factor	  of	  kappa	  light	  chain	  gene	  enhancer	  in	  B-­‐cells	  1,	  p105	  	  	   2,14	  NM_019408	   Nfkb2	   	  Nuclear	  factor	  of	  kappa	  light	  polypeptide	  gene	  enhancer	  in	  B-­‐cells	  2,	  p49/p100	  	  	   2,56	  NM_020005	   Pcaf	   	  P300/CBP-­‐associated	  factor	  	  	   0,42	  NM_009045	   Rela	   	  V-­‐rel	  reticuloendotheliosis	  viral	  oncogene	  homolog	  A	  (avian)	  	  	   2,07	  NM_009046	   Relb	   	  Avian	  reticuloendotheliosis	  viral	  (v-­‐rel)	  oncogene	  related	  B	  	  	   4,04	  NM_138952	   Ripk2	   	  Receptor	  (TNFRSF)-­‐interacting	  serine-­‐threonine	  kinase	  2	  	  	   2,62	  NM_015747	   Slc20a1	   	  Solute	  carrier	  family	  20,	  member	  1	  	  	   0,49	  NM_030682	   Tlr1	   	  Toll-­‐like	  receptor	  1	  	  	   4,4	  NM_126166	   Tlr3	   	  Toll-­‐like	  receptor	  3	  	  	   0,42	  NM_133212	   Tlr8	   	  Toll-­‐like	  receptor	  8	  	  	   5,58	  NM_031178	   Tlr9	   	  Toll-­‐like	  receptor	  9	  	  	   2,76	  NM_013693	   Tnf	   	  Tumour	  necrosis	  factor	  	  	   5,67	  NM_020275	   Tnfrsf10b	   	  Tumour	  necrosis	  factor	  receptor	  superfamily,	  member	  10b	  	  	   2,22	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NM_011610	   Tnfrsf1b	   	  Tumour	  necrosis	  factor	  receptor	  superfamily,	  member	  1b	  	  	   4,33	  NM_011611	   Cd40	   	  CD40	  antigen	  	  	   2,78	  NM_019418	   Tnfsf14	   	  Tumour	  necrosis	  factor	  (ligand)	  superfamily,	  member	  14	  	  	   2,51	  NM_011632	   Traf3	   	  Tnf	  receptor-­‐associated	  factor	  3	  	  	   0,42	  NM_009539	   Zap70	   	  Zeta-­‐chain	  (TCR)	  associated	  protein	  kinase	  	  	   3,87	   	  	   	  
 
Table 8. Differentially regulated genes (p<0.05) when comparing control with 
48h weaned NOS2-KO mice.  
 GenBank®	  accession	  number	  	   Gene	  Symbol	   Description	   Fold	  change	  NM_009652	   Akt1	   	  Thymoma	  viral	  proto-­‐oncogene	  1	  	  	   0.32	  NM_007497	   Atf1	   	  Activating	  transcription	  factor	  1	  	  	   0.53	  NM_009740	   Bcl10	   	  B-­‐cell	  leukemia/lymphoma	  10	  	  	   0.37	  NM_033601	   Bcl3	   	  B-­‐cell	  leukemia/lymphoma	  3	  	  	   2.53	  NM_009778	   C3	   	  Complement	  component	  3	  	  	   2.68	  NM_011333	   Ccl2	   	  Chemokine	  (C-­‐C	  motif)	  ligand	  2	  	  	   4.92	  NM_007700	   Chuk	   	  Conserved	  helix-­‐loop-­‐helix	  ubiquitous	  kinase	  	  	   0.17	  NM_009969	   Csf2	   	  Colony	  stimulating	  factor	  2	  (granulocyte-­‐macrophage)	  	  	   0.05	  NM_009971	   Csf3	   	  Colony	  stimulating	  factor	  3	  (granulocyte)	  	  	   0.25	  NM_010336	   Edg2	   	  Endothelial	  differentiation,	  lysophosphatidic	  acid	  G-­‐protein-­‐coupled	  receptor,	  2	  	  	   0.54	  NM_007913	   Egr1	   	  Early	  growth	  response	  1	  	  	   3.65	  NM_010175	   Fadd	   	  Fas	  (TNFRSF6)-­‐associated	  via	  death	  domain	  	  	   0.51	  NM_010177	   Fasl	   	  Fas	  ligand	  (TNF	  superfamily,	  member	  6)	  	  	   0.41	  NM_008311	   Htr2b	   	  5-­‐hydroxytryptamine	  (serotonin)	  receptor	  2B	  	  	   2.04	  NM_010493	   Icam1	   	  Intercellular	  adhesion	  molecule	  	  	   2.3	  NM_008337	   Ifng	   	  Interferon	  gamma	  	  	   0.27	  NM_031168	   Il6	   	  Interleukin	  6	  	  	   4.82	  NM_008363	   Irak1	   	  Interleukin-­‐1	  receptor-­‐associated	  kinase	  1	  	  	   0.3	  NM_172161	   Irak2	   	  Interleukin-­‐1	  receptor-­‐associated	  kinase	  2	  	  	   0.5	  NM_010591	   Jun	   	  Jun	  oncogene	  	  	   4.93	  NM_011952	   Mapk3	   	  Mitogen	  activated	  protein	  kinase	  3	  	  	   1.82	  NM_010851	   Myd88	   	  Myeloid	  differentiation	  primary	  response	  gene	  88	  	  	   6.77	  NM_010907	   Nfkbia	   	  Nuclear	  factor	  of	  kappa	  light	  chain	  gene	  enhancer	  in	  B-­‐cells	  inhibitor,	  alpha	  	  	   0.54	  NM_020005	   Pcaf	   	  P300/CBP-­‐associated	  factor	  	  	   0.39	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NM_029780	   Raf1	   	  V-­‐raf-­‐leukemia	  viral	  oncogene	  1	  	  	   1.71	  NM_009045	   Rela	   	  V-­‐rel	  reticuloendotheliosis	  viral	  oncogene	  homolog	  A	  (avian)	  	  	   1.74	  NM_009046	   Relb	   	  Avian	  reticuloendotheliosis	  viral	  (v-­‐rel)	  oncogene	  related	  B	  	  	   5.53	  NM_138952	   Ripk2	   	  Receptor	  (TNFRSF)-­‐interacting	  serine-­‐threonine	  kinase	  2	  	  	   2.05	  NM_030682	   Tlr1	   	  Toll-­‐like	  receptor	  1	  	  	   3.8	  NM_133212	   Tlr8	   	  Toll-­‐like	  receptor	  8	  	  	   4.56	  NM_013693	   Tnf	   	  Tumour	  necrosis	  factor	  	  	   3.39	  NM_020275	   Tnfrsf10b	   	  Tumour	  necrosis	  factor	  receptor	  superfamily,	  member	  10b	  	  	   5.72	  NM_011609	   Tnfrsf1a	   	  Tumour	  necrosis	  factor	  receptor	  superfamily,	  member	  1a	  	  	   2.72	  NM_011610	   Tnfrsf1b	   	  Tumour	  necrosis	  factor	  receptor	  superfamily,	  member	  1b	  	  	   3.2	  NM_011611	   Cd40	   	  CD40	  antigen	  	  	   4.02	  
 
 A comparison between the WT and NOS2-KO mice during weaning 
revealed that 24 genes where significantly down-regulated in weaned NOS2-
KO mice compared with WT and none was up-regulated (Table 9). The fact that 
all genes found to be differentially regulated in the KO animals compared with 
the WT were down-regulated further supports that the NF-κB signalling pathway 
during weaning is delayed in KO mice and thus NO could be an important 
signal involved in the mechanisms that trigger NF-κB response.  
 
Table 9. Fold down-regulation in genes associated with the NF-ΚB signalling 
pathway during weaning in NOS2-KO compared with WT mice. The 23 genes 
that were differentially expressed (p<0.05) are listed above.  
 GenBank®	  accession	  number	  	   Gene	  symbol	  	   Description	  	   Fold	  change	  NM_033601	  	  	  	   Bcl3	   B-­‐cell	  leukaemia/lymphoma	  3	   0.70	  NM_009778	   	  C3	  	   Complement	  component	  3	  	   0.47	  NM_130859	  	   Card10	  	   Caspase	  recruitment	  domain	  family,	  member	  10	  	   0.43	  NM_009807	  	   Casp1	  	   Caspase	  1	  	   0.61	  NM_001025432	  	   Crebbp	  	   CREB	  (cAMP-­‐response-­‐element-­‐binding	  protein)-­‐binding	  protein	  	   0.64	  NM_009969	  	   Csf2	  	   Colony-­‐stimulating	  factor	  2	  (granulocyte-­‐macrophage)	  	   0.20	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NM_009971	  	   Csf3	  	   Colony-­‐stimulating	  factor	  3	  (granulocyte)	  	   0.39	  NM_007922	  	   Elk1	  	   ELK1,	  member	  of	  Ets	  oncogene	  family	  	   0.53	  NM_010169	  	   F2r	  	   Coagulation	  factor	  II	  (thrombin)	  receptor	  	   0.56	  NM_010177	  	   Fasl	  	   FasL	  (tumour	  necrosis	  factor	  superfamily,	  member	  6)	  	   0.21	  NM_008311	  	   Htr2b	  	   	  5-­‐Hydroxytryptamine	  (serotonin)	  receptor	  2B	  	   0.56	  NM_010493	  	   Icam1	  	   Intercellular	  adhesion	  molecule	  	   0.45	  NM_008337	  	   Ifng	  	   Interferon	  γ	  	   0.3	  NM_019777	  	   IκBke	  	   	  IKKε	  	   0.45	  NM_008362	  	   Il1r1	  	   Interleukin	  1	  receptor,	  type	  I	  	   0.42	  NM_008390	  	   Irf1	  	   Interferon	  regulatory	  factor	  1	  	   0.61	  NM_010735	  	   Lta	  	   Lymphotoxin	  A	  	   0.47	  NM_011952	  	   Mapk3	  	   Mitogen-­‐activated	  protein	  kinase	  3	  	   0.59	  NM_019408	  	   Nfkb2	  	   Nuclear	  factor	  of	  κ	  light	  polypeptide	  gene	  enhancer	  in	  B-­‐cells	  2,	  p49/p100	  	   	  0.52	  NM_029780	  	   Raf1	  	   V-­‐raf-­‐leukaemia	  viral	  oncogene	  1	  	   0.62	  NM_013693	  	   Tnf	  	   Tumour	  necrosis	  factor	  	   0.65	  NM_009397	  	   Tnfaip3	   Tumour	  necrosis	  factor	  α-­‐induced	  protein	  3	  	   0.62	  NM_011610	  	   Tnfrsf1b	   Tumour	  necrosis	  factor	  receptor	  superfamily,	  member	  1b	  	   0.67	  NM_009539	  	   Zap70	  	   ζ	  -­‐Chain	  (T-­‐cell	  receptor)-­‐associated	  protein	  kinase	  	   0.39	  
 
 
1.11 CASPASE 3 ACTIVITY 
 
In order to correlate the phases of mammary gland involution seen in the 
histology preparations with apoptosis and analyze the existence of differences 
between WT and NOS2-KO mice, the activity of caspase 3 was measured. After 
24h of weaning, no difference in caspase activity was observed (figure 28) but 
after 48h of weaning, caspase 3 activity was clearly increased in the WT mice, 
but this increase was not observed in the KO mice until the 72h time point.  
Hence, apoptosis levels, in terms of caspase 3 activation, are also ‘delayed’ in 
NOS2-KO mice. From these results, we can hypothesize that NO is not only 
responsible for the changes observed at the early stages of involution, but that 
the effect of this molecule is extended far beyond the first phase of apoptotic 
cell death, somehow regulating the second phase of tissue remodelling. 
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Figure 28. Caspase 3 activity in mammary tissue at different times of involution. 
Results are means ± S.E.M. relative amounts of the replicate tissue samples, 
for three different experiments performed in triplicate * p<0.05 when comparing 
WT and NOS2-KO mice at the same time point. . To compare between the 
different conditions in WT or KO mice, ANOVA was performed for the statistical 
analysis where different superscript letters indicate significant differences, 
p<0.05; the letter ‘a’ always represents the lowest value within the group.  
 
1.12 PROTEASE ACTIVITY IN WT AND NOS2-KO MICE 
 
Second phase involution is intimately related with the first, and some of its 
principal actors are also modulated by key regulators of the first phase. In fact, 
the extent of apoptosis has been reported to correlate with an increase in MMP 
activity during the second phase of involution (Clarkson & Watson, 1999; Lund 
et al, 1996). MMPs are essential in the remodelling of the ECM that takes place 
during the second phase mammary gland involution (Lund et al, 1996). MMP-9 
is a key protease in the degradation of basement membrane collagen and 
different types of gelatine (Green & Lund, 2005) and accumulating evidence 
suggests that the activation of NF-κB is one of the most important signalling 
events required for the inducible expression of MMP-9 in response to different 
stimuli (Li et al, 2009). 
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We next wanted to assess whether the functional consequences of 
delayed first phase involution had also functional consequences during the 
second phase in NOS2-KO mice. This question was addressed through the 
analysis of MMPs expression and function.  
Real-time PCR analysis was performed in WT and NOS2-KO mice at the peak 
of lactation and in weaned animals. Figure 29 shows that the mRNA levels of 
MMP-2 and MMP-9 were significantly higher after 48h of weaning than those 
mice at the peak of lactation. The maximal induction of both MMP-2 and MMP-9 
was observed after 72h of weaning. While no difference in MMP-2 mRNA up-
regulation was observed between WT and KO mice under all conditions studied 
(panel A); MMP-9 induction was more pronounced during weaning of WT mice 
vs NOS2-KO mice (panel B).  
 
Figure 29. Real-time qPCR for both gelatinase genes, MMP-2 and MMP-9 
(Panels A and B respectively). Expression levels were compared at each time 
after weaning (0, 6, 24, 48 and 72h) between WT and NOS2-KO mice. Each 
PCR was normalized against the housekeeping gene 18S. Results are means ± 
S.E.M. *p <0.05 when comparing WT and NOS2-KO mice at the same time 
point.  
 
Taking into consideration the fact that NF-κB activation is delayed in the 
KO mice, the question rose whether NF-κB was the transcriptional factor 
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inducing MMP-9 translation during the involution process. In order to answer 
this question, a ChIP assay was performed. The ChIP assay consists on 
immunoprecipitating all the chromatin that is linked to a specific protein at a 
specific time. Beforehand, the DNA is cross-linked with the attached proteins by 
means of formaldehyde. After the cross-linking, the chromatin has to be 
sonicated into smaller fragments of around 500 bp (a size that will allow the rest 
of the experiment to run adequately). Following sonication, immunoprecipitation 
is carried out, this way, only the DNA attached to a specific protein such as a 
transcription factor will be recovered. Finally, the DNA will be purified and a 
PCR performed using primers of the promoter region of the specific gene 
sought. Should there be an amplification product, it will mean that the specific 
transcription factor immunoprecipitated was attached to the promoter region of 
the specific gene, which increases the chances of it being transcribed at the 
moment of the initial chromatin extraction.  
 
In this experiment, chromatin was immunoprecipitated with anti-p65 and 
anti-p50 antibodies, the most frequent NF-κB dimer. Primers specific to the 
promoter region for MMP-9 gene were used to amplify the DNA isolated from 
the ChIP assay. Panel A in figure 30 shows the average size of the chromatin 
fragments obtained (∼500 bp).  Panel B shows that p65/p50 was bound to the 
MMP-9 promoter at 48h of involution in WT mice. On the other hand, the NOS2-
KO mice showed no binding of the NF-κB on the MMP-9 promoter. This finding 
is in accordance with the delayed activation of this transcriptional factor that 
was observed in the previous ELISA experiment and with the lower levels of 
MMP-9 mRNA observed by RT-qPCR. For positive control, an aliquot of the 
input chromatin was used. For negative control, an unrelated IgG antibody was 
used.  
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Figure 30. A) Size of the chromatin fragments obtained after isolation and 
sonication of chromatin from mammary gland samples in lactating controls and 
after 48h of weaning in both WT and NOS2-KO mice. B) In vivo association of 
p65/p50 with the MMP-9 promoter during weaning. Results of a representative 
ChIP experiment, performed in samples from control lactating mammary gland, 
and 48 h weaned WT and NOS2-KO mice are shown.  
 
MMP activation was analyzed by zymography studies. The zymography 
assay is an electrophoretic technique that includes a substrate copolymerised 
with the polyacrylamide gel for the detection of enzymes and their activity. 
Gelatine is the most commonly used substrate, and is useful for demonstrating 
the activity of gelatine-degrading proteases, such as MMPs. Following 
electrophoresis, the gel is washed with a re-naturing buffer followed by 
incubation in an enzyme activation buffer. This allows the enzymes present in 
the sample to become active and digest the gelatine substrate copolymerised in 
the gel. The zymogram is subsequently stained and the areas of enzyme 
activity and digestion become visible. 
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Figure 31. Gelatine zymography measuring MMP-2 and -9 activation. Protein 
extracts from lactating (0h) and weaned glands (48 and 72h) of both WT and 
NOS2-KO genotypes were used.  
 
Figure 31 shows that in WT mice, MMP-9 proteinase activity (105KDa) 
appeared faintly after 48h of weaning, increasing after 72h of weaning. On the 
other hand, the activation of pro-MMP-2 (70KDa band) to an active form 
occurred after 72h of weaning. The increased enzymatic activity correlated with 
MMPs mRNA levels in the weaned mammary tissue. When comparing MMPs 
activity, the intensity of the bands for MMP-2 and -9 is lower after 72h of 
weaning in KO when compared with WT mammary glands. Also, no band was 
observed for MMP-9 at 48h of involution in NOS2-KO mice which would 
correlate with the absence of histological changes seen in the hematoxilin-eosin 
pathology sections studied in figures 15 and 16.  
 
2. ROLE OF NO IN SPECIFIC POST-TRANSLATIONAL MODIFICATIONS 
DURING MAMMARY GLAND INVOUTION 
 
Given the differences observed in mammary gland involution between 
NOS2 WT and KO mice, nitric oxide (NO) seems to play an important regulatory 
role in the involution of mammary gland after weaning. It is noteworthy that NO 
has been characterized as highly reactive molecule that can play contradictory 
signalling roles depending on concentration and temporal exposure. In general, 
lower NO concentrations promote cell survival and proliferation, while higher 
levels favour cell cycle arrest, apoptosis and senescence (Thomas et al, 2008). 
More specifically, it can induce a series of nitrosative post-translational 
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modifications on proteins and lipids that play a key signalling mechanism in cell 
physiology, with a clear role in pathophysiology (White et al, 2010). In proteins, 
these modifications occur in two main forms, either as S-nitrosylation of cystein 
thiols or as nitration of tyrosine residues. A set of experiments were performed 
in order to further explore the possible role protein nitration in the mammary 
gland involution setting. The modification sought was tyrosine nitration, but a 
possible role of protein s-nitrosylation in mammary gland involution is more than 
plausible, since s-nitrosylation is highly dependant on the redox-status of the 
cell and mammary gland involution entails the depletion of glutathione (GSH), 
hence altering the redox status in the weaned gland (Zaragoza et al, 2003). The 
chosen animal model for these experiments was rat, for technical reasons and 
in order to further confirm that the role of NO in weaning was a generalized 
phenomenon and not species-specific.  
 
2.1 NITROPROTEOMIC ANALYSIS OF LACTATING AND WEANED 
MAMMARY GLAND FROM RATS 
 
Previous work had already revealed that protein nitration is increased 
during weaning (Zaragoza et al, 2005). Our group had established that in the rat 
model used, this nitration was maximal 72h after weaning. Hence, to ensure 
identification of differentially nitrated specific proteins in the weaned mammary 
gland, proteomic studies were performed on whole tissue extracts from lactating 
and 72h weaned mammary glands. Nitrated proteins were identified using a 
combination of procedures that included 2D-PAGE immunoblotting with specific 
antibodies against nitro-tyrosine (NO-tyr) residues and MS of proteins 
recovered from two-dimensional gels. A total of 20 proteins in the molecular 
mass range of 15-75kDa with a pI between 5 and 8 were identified by 2D-IEF 
and matrix-assisted laser-desorption ionization–time-of-flight MS (MALDI-TOF-
MS). Since milk stasis plays an important role in the process of involution, milk-
depleted mammary tissue was not used for proteomic analysis. This way, a 
complete nitrated protein profile could be obtained. The caveat of this was that, 
among the nitrated proteins identified, there were relative abundance of 
albumin, immunoglobulin chains and casein fragments. This higher proportion 
of albumin and other milk-secreted proteins probably impaired the recognition of 
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low abundance proteins. Nevertheless, it is possible that these fragments of 
nitrated albumin could play a more important role than one might think at first. 
Indeed, it has been described that the injection of small peptides derived from 
milk into the mammary gland accelerates the process of involution (Shamay et 
al, 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Protein expression profiles of control lactating and 72h weaned 
mammary glands separated by IEF 2D-PAGE and silver stained (A) or staining 
of nitrated proteins by immunoblotting with anti-nitro-tyrosine antibody (B). 
Figure B shows an increase of nitrated proteins (NO-tyr) in the weaned gland 
when compared to the lactating control. One of the proteins found differentially 
nitrated was cathepsin D (spotted on right hand panels fig A and B).  
 
Still, within these other more abundant proteins, a 48kDa nitrated protein 
was identified, with coverage of 2.5%, as Cathepsin D. Differential nitration can 
be seen in figure 32 that shows representative silver stained gels and nitrated 
proteins (panels A and B respectively) in control and 72h weaned mammary 
glands.  
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2.2 CONFIRMATION OF CATHEPSIN D NITRATION IN WEANED MAMMARY 
GLAND 
 
2.2.1 Immunoprecipitation of Cathepsin D with Specific Cathepsin D 
Antibody 
 
To further confirm the nitration of this enzyme after 72h weaning, 
immunoprecipitation with anti-cathepsin D antibody, followed by immunoblotting 
against NO-tyr residues was performed. Two different forms of cathepsin D 
immunoprecipitated from the lactating mammary gland homogenates were 
found to be nitrated. One was the mature single-chain cathepsin D above the 
43kDa molecular mass marker. The other corresponded to the heavy 34kDa 
chain from the mature double-chain form. These results of the 
immunoprecipitation and blotting can be seen in figure 33. Equal loading of both 
samples was assessed by loading on to the gel 1% of control or weaned 
mammary gland homogenate (input). Besides, to corroborate that cathepsin D 
was immunoprecipitated, Western blotting against cathepsin D was performed 
on the immunoprecipitate from 72h weaned mammary gland (Figure 33, right-
hand panel).  
 
 
 
 
 
 
 
 
 
 
 
Figure 33.  Immunoprecipitation of Cathepsin D. Tissue homogenates from 
control lactating or 72h weaned (‘72h W’) mammary glands were 
immunoprecipitated (IP) by anti-(cathepsin D) antibody, and the precipitates 
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were then immunoblotted (IB) with anti-nitro-tyrosine antibody or anti-(cathepsin 
D) antibody. Input represents an equal amount of starting homogenate. 
 
2.2.2 Immunoprecipitation of Cathepsin D with Specific Pepstatin- 
Coated Beads 
 
Furthermore, in order confirm the previous results, purification of cathepsin 
D from the mammary gland samples was performed, this time using an 
approach with pepstatin A. Pepstatin A is a cathepsin D inhibitor that binds 
specifically to this protease. Pepstatin A-coated agarose beads were used to 
specifically precipitate cathepsin D from weaned mammary gland homogenates 
to be thereafter blotted against cathepsin D and NO-tyr, as shown in figure 34. 
This experiment corroborated that cathepsin D was in fact nitrated during 
weaning. As a positive control, an equal amount of starting homogenate (Input) 
was also loaded onto the electrophoresis gel. 
 
 
 
 
 
 
 
 
 
 
Figure 34. Immunoprecipitation of cathepsin D with pepstatin beads. Mammary 
gland homogenates from 72h weaned rats (‘72h W’) were incubated with 
pepstatin A-coated agarose beads. After elution, the bound fraction was 
analysed by Western blotting, including an equal amount of starting 
homogenate (named Input). The membrane was immunoblotted (IB) with anti-
(cathepsin D) antibody and then stripped and reprobed with anti-nitrotyrosine to 
verify protein nitration. 
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2.3 EFFECT OF WEANING ON THE EXPRESSION AND ACTIVITY OF 
CATHEPSIN D IN RAT LACTATING MAMMARY GLAND 
 
Having spotted cathepsin D as a protein that becomes nitrated during 
weaning, and knowing its role in the involution process, we sought to further 
explore the implications of this post-translational modification on its function. 
Nevertheless, before this, mRNA and protein levels of this protease were 
analyzed.  
 
Figure 35 shows the results of mRNA expression levels for cathepsin D in 
control and weaned (W) rat mammary gland at different time points (panel A). 
The mRNA levels peaked at 8h after litter removal and decreased thereafter. 
This finding correlated with the data obtained in the western blot analysis of 
lactating and weaned mammary gland lysates, which revealed two major 
cathepsin D-related bands that correspond to the enzymatically inactive 
precursor of ≈ 52KDa and the mature single-chain form of ≈ 48KDa. Figure 35 
panel B shows that the amount of the latter (mature single chain) is increased 
after 8h of pup removal and remains elevated 3 days later, being barely 
detectable thereafter.  
 
Since we had found that cathepsin D was differentially expressed during 
weaning when compared to lactation, differences in its activity were sought. Its 
proteolytic activity was measured by the hydrolysis of the fluorigenic substrate 
7-methoxycoumarin as described in the materials and methods section. Panel 
C in figure 35 shows cathepsin D proteolytic activity at control and different 
weaning time points. Even thought the mRNA levels and protein levels elevated 
as early as 8h after weaning the protease activity is not increased until 48h after 
pup removal in the rat model. These results point to a possible post-
translational modification needed for the protease to become active.  
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Figure 35. A) Cathepsin D mRNA expression in rat mammary tissue at the peak 
of lactation (control) and at different times of weaning, measured by real-time 
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RT–PCR. Each PCR was normalized against the housekeeping gene 18S. B) 
Western-blot for cathepsin D using control and weaned rat mammary gland 
homogenates. Two immunoreactive bands, corresponding to pro-cathepsin D 
(proCD) and mature single-chain cathepsin D (CD msc) forms of cathepsin D 
were visualized in control and weaned rats using anti-(cathepsin D) antibody. 
The position of the molecular mass markers (kDa) is shown on the right. W= 
weaning. C) Cathepsin D activity in mammary gland from control lactating and 
weaned rats by measurement of the hydrolysis of the fluorigenic substrate 7-
methoxycoumarin-4-acetic acid. Results are means± S.E.M. relative amounts 
for three independent experiments. ANOVA was performed for the statistical 
analysis where different superscript letters indicate significant differences, 
p<0.05; the letter “a” always represents the lowest value. 
 
2.4 EFFECT OF IN VITRO ONOO— INDUCED NITRATION ON CATHEPSIN D 
ACTIVITY: STUDIES IN RAT MAMMARY GLAND HOMOGENATES AND IN 
RECOMBINANT CATHEPSIN D 
 
So far, from the previous studies, it could be concluded that cathepsin D is 
induced during weaning as early as 8 hours after pup removal, but it does not 
become active until 48h after weaning. Also, cathepsin D was found to present 
tyrosine nitration as a post-translational modification at 72h weaning. Hence, it 
could be that this post-translational modification played a role in the activation 
of the protease.  
 
To further explore this possibility, in vitro induced nitration experiments 
were performed using both mammary gland homogenates from lactating rats 
and human recombinant cathepsin D. After inducing protein nitration in vitro, 
cathepsin D activity was measured to directly confirm whether this post-
translational modification was responsible, at least in part, for the protease 
activation.  
 
Mammary gland homogenates from control lactating rats were incubated 
with different concentrations of ONOO- (PN) (ranging from 0 to 100µM). In 
figure 36 (panel A) it can be seen that at 20µM of ONOO- cathepsin D activity 
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was 50% higher when compared to the control. At concentrations higher than 
50µM of ONOO-, there was a linear decreased activity (probably due to the 
oxidative effects of ONOO- on a variety of amino acid residues in addition to 
nitration of aromatic acids). After corroborating that, in order to achieve the 
highest activity of Cathepsin D, the optimal dose of ONOO- was 20µM, it was 
also studied whether this activation was due to ONOO- by means of incubation 
of the mammary gland homogenates with ONOO-. This  increase was abolished 
in the presence of the flavonoid epicatechin that has been shown to interfere 
with protein tyrosine nitration by intercepting the tyrosyl radical (Schroeder et al, 
2001) (Figure 36, panel B). 
 
 
Figure 36. Cathepsin D activity in rat mammary gland homogenates. A) The 
graph shows the increase in cathepsin D activity in the nitrated samples of rat 
mammary gland homogenates (ONOO- concentrations ranging from 5 to 100µM 
to 100µM PN) when compared with control (treated with vehicle). Results are 
means ± S.E.M. of three different experiments. B) The graph shows cathepsin 
D activity in mammary gland homogenates treated with PN (20µM PN) or PN 
and epicatechin (PN+Epic) when compared with control (treated with vehicle). 
*p <0.05. 
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Western blotting with anti-NO-tyr antibodies showed that protein nitration 
was enhanced after the incubation with 20µM ONOO- and was undetectable in 
control lactating rats treated with vehicle or with ONOO- and epicatechin. The 
results of this experiment can be seen in figure 37A. It was also demonstrated 
that the different treatments (vehicle, ONOO−  and ONOO− + epicatechin) had 
no effect on the amount cathepsin D protein levels.  In order to assess whether 
cathepsin D was nitrated after the incubation with 20 µM ONOO-, 
immunoprecipitation of control and nitrated samples with cathepsin D antibody 
was performed. Cathepsin D was immunoprecipitated from tissue lysates 
incubated with vehicle or 20µM ONOO-, and analyzed for tyrosine nitration by 
western blotting. The results in figure 37 (panel C) show that nitrated cathepsin 
D was increased after ONOO- induced nitration.  
 
The prior results pointed to two possibilities: the first, direct nitration of 
cathepsin D as a post-translational modification enhances its activity. The 
second is that NO activates cathepsin D through indirect mechanisms, such as 
nitration of other proteins that modulate cathepsin D activity. To gain further 
understanding of the mechanisms by which protein nitration might affect directly 
cathepsin D activity, as well as to test the first hypothesis, in vitro experiments 
with recombinant cathepsin D from human liver were performed. As seen in 
figure 38, commercial human cathepsin D reacted with 0 or 20µM ONOO- (PN) 
in the presence or absence of 30µM epicatechin (Epic.). This recombinant 
cathepsin D from human liver corresponds mainly to the heavy chain of the 
mature cathepsin D form (34kDa). Samples were analyzed for tyrosine nitration 
or cathepsin D activity. Panel A in figure 40 shows that when human cathepsin 
D is treated with 20µM ONOO-, an increase in nitro-tyrosine residues can be 
clearly observed. This increase in tyrosine nitration was abolished when 30µM 
epicatechin was added. On the other hand, the direct effect of ONOO- on 
cathepsin D activity was measured (figure 38 panel B). A significant increase in 
the activity of this protease was observed when ONOO-  (PN) was added, with a 
subsequent abolishment when treated also with epicatechin. Also, as expected, 
the activity of cathepsin D was completely abolished when incubating the 
recombinant human cathepsin D with its specific inhibitor pepstatin A (PspA). 
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Figure 37. A) Western blot (IB) against tyrosine-nitrated residues (upper panel) 
or cathepsin D (lower panel) in samples from mammary tissue after treatment 
with ONOO− with or without epicatechin  (20µM ONOO− and 20µM ONOO− + 
Epic respectively). B) Immunoprecipitation (IP) in tissue homogenates from 
control lactating mammary glands treated with vehicle (control) or with ONOO- 
(20µM PN) by anti-cathepsin D antibody and immunoblot(IB) with anti-cathepsin 
D antibody. C) Immunoprecipitation (IP) in tissue homogenates from control 
lactating mammary glands treated with vehicle (control) or with ONOO- (20µM 
PN) by anti-cathepsin D antibody and immunoblot (IB) with anti-NO-tyr 
antibody. Molecular mass markers (kDa) are indicated on each blot.  
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Figure 38. A) Western blot (IB) to analyze tyrosine nitration (NO-tyr) of human 
recombinant cathepsin D (CD) control, after treatment with 20µM ONOO- (20µM 
PN) and after treatment with both 20µM ONOO- and epicatechin (20µM PN+ 
Epic). The lower panel shows that equal amounts of cathepsin D (IB: CD) were 
loaded. Immunoblots are representative of three separate experiments. The 
position of molecular mass markers (KDa) is shown on the right. B) Effect of 
ONOO- on human cathepsin D activity. Treatment with 20µM ONOO- with or 
without 30µM epicatechin and with or without pepstatin A (20 µM PN, Psp, 
PN+Epic and PN+Psp A respectively). *p<0.05.  Pepstatin A was used to verify 
the specificity of the assay. 
 
Having found the same results for both rat cathepsin D (in mammary gland 
homogenates) and human recombinant, it proved that this specific action of 
ONOO- was an inter-species phenomenon. To further consolidate this concept, 
the effect of ONOO- was studied in bovine cathepsin D. Figure 39 shows that 
addition on ONOO- to bovine cathepsin D also results in a significant 
enhancement of this protease’s activity; which is in turn abolished with the 
addition of epicatechin.  
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Figure 39. Effect of 20µM ONOO- with or without 30µM epicatechin and with or 
without pepstatin A on bovine cathepsin D (20 µM PN, Psp A, PN+Epic and 
PN+Psp A respectively). *p<0.05.  
 
2.5 IDENTIFICATION OF THE CATHEPSIN D NITRATION SITE 
 
From our previous results, it can be concluded that NO induces tyrosine 
residue nitration on cathepsin D. It can also be concluded that this post-
translational modification has an effect on its activity, since we observed a 50% 
increase in activity when treating recombinant human cathepsin D with ONOO-. 
Finally, In order to identify the tyrosine residue targeted by ONOO-, tryptic 
digests of nitrated and non-nitrated human recombinant cathepsin D were 
characterized by MS. The doubly charged ion with m/z 823.92 was assigned as 
the nitrated form of peptide L159VDQNIFSFYLSR171. All y ions from y4 showed 
the extra 45Da, suggesting the nitration of Tyr168. In contrast, no nitration was 
detected when tryptic digests from control cathepsin D were analysed. In 
particular, a doubly charged ion with m/z 801.42 was assigned as the non-
nitrated L159VDQNIFSFYLSR171 peptide (figure 40). Nevertheless, although 
most of the tyrosine residues present in the protein (13 tyrosine residues out of 
19), were sequenced, we were unable to sequence more than 40% of human 
cathepsin D, therefore it cannot be ruled out the possibility that other tyrosine 
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residues could also be nitrated. As shown in figure 41, tyrosine168 is found in the 
heavy chain of cathepsin D and is highly conserved among species and other 
proteases, such as human renin, porcine pepsin and bovine chymosin. In fact, 
detailed protein sequence analysis reveals a possible nitration domain with the 
sequence F-S-F/V-Y-X-X-R/S. 
 
Figure 40. Representative MS/MS spectra of tryptic digests from human cathepsin D 
(A) vehicle or (B) ONOO--treated are shown. The mass/charge value of 823.92 for the 
peptide 159LVDQNIFSFYLSR171 from CD treated with ONOO- contains a +45 Da 
adduct when compared to the vehicle-treated enzyme (m/z of 801.42), suggesting the 
nitration of Tyr168.  
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Figure 41. Sequence alignments for the mammalian aspartic proteases: 
cathepsin D, cathepsin E, renin, pepsin, and chymosin. The possible nitration 
domain, which is highly conserved among different proteinases, is bolded in 
grey.  Key: CD, cathepsin D; CE, cathepsin E; REN, renin; CHY, chymosin; 
PEP, pepsin. Sequence sources: Cathepsin D: Swissprot entries 
CATD_HUMAN, MOUSE and RAT. Cathepsin E: Swissprot entries 
CATE_HUMAN, MOUSE and RAT. Renin: Swissprot entries RENI_HUMAN. 
Chymosin: Swissprot entries CHYM_BOVIN. Pepsin: Swissprot entries 
PEPA_PIG. 
 
2.6 EVALUATION OF THE EXPRESSION AND ACTIVITY OF CATHEPSIN D 
IN NOS2-KO AND WT MICE 
 
Our results establish that NO plays a role in the involution process after 
weaning and that, although cathepsin D has increased expression early on in 
the process, its activity only increases after 48h of weaning (irreversible phase), 
and it undergoes tyrosine nitration in specific sites. Therefore, the data 
presented so far pointed to our initial hypothesis, tyrosine residue nitration as a 
post-translational modification does play a role in the activation of this protease. 
Of course, this does not mean that NO is solely responsible for the activation of 
cathepsin D, since this protease has to undergo many post-translational 
modifications in order to become active. Still, the increase in activity observed in 
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both mammary gland homogenates and human recombinant cathepsin D 
treated with ONOO- is evident.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42. A) Gene expression of cathepsin from WT and NOS2-KO mice during 
lactation and weaning. To compare between the different conditions in WT or KO 
mice, ANOVA was performed for the statistical analysis where different 
superscript letters indicate significant differences, p <0.05; the letter ‘a’ always 
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represents the lowest value within the group. A Student’s t test with the Bonferroni 
correction was used for comparison between WT and KO at each experimental 
time point. *p<0.05. B) Western blot analysis of cathepsin D at the peak of 
lactation (control) and during mammary gland involution (weaning) in WT and 
NOS2-KO mice. The blot shows the presence of precursor (proCD) and mature 
single-chain (CD msc) forms of cathepsin D and the two degradation products of 
∼30 kDa (CD heavy chain; CD hc) and ∼14 kDa (CD light chain; CD lc).  
 
In the first objective of the present work, it has been established that lack 
of NOS2 implies a delay in mammary gland involution in the first phase of the 
process. In this second objective, it seemed plausible to demonstrate whether 
our in vivo model of NOS2-KO had also differences in cathepsin D activity, 
which would imply that NOS2 did play a role also in the second phase of 
mammary gland involution. First, a possible role in cathepsin D expression 
regulation was explored but no changes were found in mRNA and protein levels 
of cathepsin D between WT and KO mice, as seen in figure 42 (A). Protein 
levels were also checked and compared in WT vs NOS2-KO animals. In figure 
42 (panel B) it can be observed that cathepsin D protein levels increased during 
weaning in a time-dependent manner for both WT and KO mice. This protein 
increase was maximal for the pro-cathepsin D 2 days after weaning.  
 
 After discarding a role of NO in cathepsin D expression regulation, its 
possible role in function modulation in this in vivo model was studied. For this, 
cathepsin D activity was measured in WT and NOS2-KO mice. Figure 43 shows 
that cathepsin D activity is significantly lower in NOS2-KO mice when compared 
with WT mice at 2 days and 3 days after weaning (2dW, 3dW) when cathepsin 
D is normally activated. NOS2-KO mice showed decreased protease activity 
throughout involution when compared to WT animals. 
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Figure 43. Cathepsin D activity measured in control and weaned mammary 
gland for both WT and NOS2-KO mice.  To compare between the different 
conditions in WT or KO mice, ANOVA was performed for the statistical analysis 
where different superscript letters indicate significant differences, p<0.05; the 
letter ‘a’ always represents the lowest value within the group. A Student’s t test 
with the Bonferroni correction was used for comparison between WT and KO at 
each experimental time point; *p <0.05.  
 
Recapitulating the in vitro and in vivo work in this second part of the 
project; the magnitude of the increase in cathepsin D activity seen in the in vitro 
work is of the order of 0.5 fold increase. This is much lower than the increase in 
activity seen between the WT and NOS2-KO mice (2.5 fold maximal difference). 
This difference was expected, since in the in vitro model only the direct effect of 
tyrosine-residue nitration on activity was measured. Of course, in the in vivo 
model many other factors will influence cathepsin D activation. These factors 
range from the delay in the first phase due to NO decreased levels, the many 
post-translational changes that cathepsin D undergoes, physiological inhibitors 
of cathepsins, etc, all of which could also be influenced by NO variation in 
concentration, that add to the direct effect of NO on the protease activity.  
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3. ROLE OF NITRIC OXIDE IN A LUMINAL BREAST CANCER MODEL.  
PRELIMINARY DATA AND FUTURE DIRECTIONS. 
 
The third objective was to explore which of the studied physiological 
mechanisms did a transformed epithelial neoplastic cell recruit when exposed to 
high doses of NO. For this, we used a very well characterized breast cancer cell 
line of the luminal lineage, MCF-7, and we exposed it to varying concentrations 
of a NO donor, SIN-1, as described in the material and methods section.  
 
3.1 NITRITE CONCENTRATIONS IN MCF-7 MEDIA AFTER SIN-1 
TREATMENT 
 
The first step in this part was to establish that indeed, higher 
concentrations of SIN-1 translated into higher nitrite concentrations. This was 
analysed by means of a colorimetric assay, as described in the materials and 
methods section. Figure 44 represents the quantitative results of this analysis 
and it can be observed that increasing concentrations of SIN-1 in the mM range 
(1 to 3mM) for 24h translate into a significant increase in nitrite concentrations. 
The time point of 24 hours was chosen because it is biologically plausible to 
think that NO concentrations are stable in a pro-inflammatory environment and 
we sought to study stable modifications, rather than fast signalling changes.   	  	  	  	  	  	  	  
 
 
 
 
Figure 44. Nitrite concentration achieved in MCF-7 culture after treatment with 
different concentrations of the NO donor SIN-1 (Control, 1mM, 2mM, 3mM) 
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during 24h. T-test was performed to compare nitrite concentrations between 
control samples and treated with different SIN-1 concentrations. *p< 0.05. 
 
3.2 MCF-7 VIABILITY AFTER EXPOSURE TO HIGH NO CONCENTRATIONS 
 
It has been amply described that high concentrations of NO can induce 
apoptosis. To address this point, a MTT cell viability assay was performed. 
Figure 45 shows that increasing concentrations of SIN-1 resulted in a decrease 
of cell viability. In fact, when treating MCF-7 cells with 2 and 3mM 
concentrations of SIN-1, a significant decrease in cell viability was observed 
(20% and 34% decrease respectively).  	  
 	  	  	  	  	  	  	  	  	  
 
 
Figure 45. Cell viability in control and SIN1 treated MCF-7 cells. Treated cells 
were incubated with different concentrations of SIN1 for 24h and viability was 
measured using the MTT method as described in the materials and methods 
sections. T-test was performed to compare viability between control and treated 
samples. *p< 0.05. 
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3.3 EVALUATION OF AKT ACTIVATION IN MCF-7 CELLS AFTER NO 
EXPOSURE 
 
AKT is a well described hub in both mammary gland involution and 
cancer signalling, the next exploratory step was to find if AKT was activated, 
hence phosphorylated, after MCF-7 exposure to high concentrations of NO. 
Figure 46 (panel A) shows a representative western blot were it can be seen 
that with increasing NO concentrations, there is an increase in pAKT, with 
stable concentrations of AKT. This is, to our knowledge, the first time that AKT 
activation has been described after long exposure to high concentration of NO. 
This increase in pAKT was consistent throughout repeated experiments and 
confirmed to be significant with a semi-quantitative method, as described in the 
materials and methods section (figure 46 panel B).  
 
	  
Figure 46. A) Western blot to determine AKT and phosphorilated AKT (pAKT). β-
Actin was used as a loading control. The western blot is representative of at 
least three experiments.  B) Analysis of pAKT/AKT ratio. T-student was 
performed to compare the pAKT/AKT ratio between the control experiment and 
after treatment with different concentrations of SIN-1. *p<0.05.  	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3.4 EVALUATION OF NF-κB ACTIVATION 
 
After corroborating that NO had an effect on AKT phosphorylation in 
epithelial breast cancer cells, we also wanted to explore the possible effects on 
another of the major hubs controlling mammary gland involution. NF-κB, as well 
as being a major regulator of the involution after weaning process, plays an 
important role in tumour progression. Since it had been established that NO is a 
regulator of its activity during the physiological process of weaning it seemed 
logical to explore its possible effects on the regulation of this transcription factor 
in cancer cells. In this sense, levels of the NF-κB negative regulator, IκBα were 
evaluated by means of western blotting. Figure 47 (panel A) shows that the 
levels of IκBα clearly decrease after 24h exposure of MCF-7 cells to increasing 
concentrations of the NO donor SIN-1. When quantifying this decrease, a clear 
reduction pattern can be seen (figure 47 panel B).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47. A) Western blot showing the decrease of IκBα in MCF-7 cells after 
24h exposure to increasing concentrations of SIN-1 (0 to 3mM). β Actin was 
used as a loading control. The blot is representative of western blots with at 
least 3 samples per condition. B) Relative quantification of IκBα levels in MCF-7 
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normalized with β actin. The levels are relative to IκBα levels in control (non-
exposure) conditions. A t-test was performed to compare IκBα levels after 
exposure to increasing concentrations with respect to MCF-7 non-exposure 
IκBα levels. *p<0.05 
 
Another indirect approach used to further prove the possible activation of 
NF-κB was to evaluate the expression of MMP-9. Since we had established that 
MMP-9 is a transcriptional target of activated NF-κB in physiological weaning 
conditions in mice, we wanted to explore if MMP-9 expression was also up-
regulated after treating MCF-7 cells with a high concentration of NO. The breast 
cancer cell line was treated with 2mM SIN-1 for 24h. Figure 48 shows up-
regulation of MMP-9 gene expression after exposing MCF-7 to high 
concentrations of NO. This increase was statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48. Real-time qPCR that analyzes de expression of MMP-9 in MCF-7 
cells after treatment with high concentrations of a NO donor for different periods 
of time (SIN-1 2mM during 24h). The expression is related to baseline RNA 
levels of MMP-9 (control). *p<0.05 
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All in all, our preliminary data point clearly to the possibility that breast 
tumour cells, upon NO stimulation, activate the same mechanisms observed 
during weaning and that, as in this physiological process, also seem to depend 
on NO exposure.  	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DISCUSSION 
 
Mammary gland is a highly dynamic and specialized tissue. Its 
development takes place mainly post-natally and its terminal functional 
differentiation is reached during pregnancy and lactation. This final 
differentiation process is regulated mainly by E, Pg, GH, glucocorticosteroids, 
insulin and PRL, being the most important Pg and PRL. During pregnancy, 
the branched ductal system subdivides into decreasingly smaller ductules, 
which terminate in lobules. These lobules, composed of various alveoli, 
consist of secretory epithelial cells that will undergo final differentiation upon 
parturition. When lactation ends, the excess of secretory epithelium has to be 
removed, in order to return the gland to a virgin-like state. This implies the 
need for massive apoptosis and tissue remodelling. Hence, it involves two 
distinct steps: a first step which is reversible and where apoptosis is the main 
event; and a second irreversible step that involves a change in structure, the 
remodelling of the ECM and an infiltration of adipocytes, so the mammary 
gland returns to a quiescent pre-pregnant state, ready for the next pregnancy. 
Selective teat sealing studies have concluded that the first phase is probably 
triggered by local factors such as milk accumulation, rather than by a fall of 
systemic lactogenic hormones (Li et al, 1997b; Marti et al, 1997). Apoptosis is 
thought to be initiated by anoikis (loss of cell adhesion), although this is still 
speculative, and the signal that initiates the extrusion of the epithelial cells to 
the alveolar lumen remains unknown (Monks & Henson, 2009). Involution is 
regulated by four main regulatory pathways, PI3K/AKT, NF-κB, STAT3 and 
TGFβ, which have also been implicated in cancer progression (Karin et al, 
2002; Massague, 2008; Yu et al, 2009). 
 
Gene expression studies have enabled researchers to define multiple 
phases of the controlled regulatory response to forced weaning on the basis 
of the transcriptional profile. In fact, they have allowed for a definition of three 
distinct phases within the first stage of involution (Clarkson & Watson, 2003; 
Stein et al, 2007); namely, a transitory change in gene expression within the 
first 24h, a prolonged change by 24h, and an increase in expression by 48h. 
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The analysis of the genes that make up these subsets identifies a correlation 
between involution-related genes and genes associated with an inflammatory 
response. It is of note that pro-inflammatory mediators are transiently 
activated as early as 12h post-weaning. This up-regulation is followed by an 
increase in APR genes including C/ebpδ and serum amyloids. Finally, by 48h, 
there is a significant increase in immune-related genes which indicates a 
macrophage and plasma cell infiltration. Beyond the 96h mark, apoptosis has 
passed its peak, the gland is being remodelled and apoptotic cells are being 
removed. The involution profile is characterized by expression of genes 
related with wound-healing and tissue metalloproteases as well as 
carboxypeptidases (Clarkson & Watson, 2003; Stein et al, 2007; Zaragoza et 
al, 2005). All in all, these published data demonstrate that gland involution 
utilizes some of the same tissue remodelling programs activated during 
wound healing. Specifically, immune cell infiltration and provisional wound 
healing matrix components. Hence, involuting mammary gland may present a 
window of opportunity for tumour cell progression. In fact, recent studies have 
shown that the involuting mammary gland stroma can promote tumour 
development and metastasis (Lyons et al, 2011; McDaniel et al, 2006). 
 
Among the mechanisms activated in inflammatory processes, NO has 
been found to be generated by macrophages that take part in any such 
process. NO is a well-studied signal transduction agent that exerts a wide 
variety of functions, depending on the concentration and time of exposure.  In 
a pro-inflammatory ambience NO is produced, mainly in macrophages, and it 
can reach steady concentrations of the µM range (Carcillo et al, 2003; Lee & 
Lee, 2005; Stadler et al, 1994). At these high concentrations, NO exerts its 
reactions mainly through indirect mechanisms, which require NO reacting with 
O2 or superoxide, thus generating RNS. These RNS subsequently react with 
specific biological targets. In an inflammatory context, the vast majority of this 
NO is derived enzymatically form inducible NOS (NOS2). It has been 
previously described that NO is generated at a low rate during lactation, via 
NOS3 activity, but our group described a switch during involution, when NOS3 
levels declined and NOS2 protein levels were increased at 24h after weaning 
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(Zaragoza et al, 2005). It was also established that NF-κB is bound to the 
promoter of this gene as early as 8 hours after weaning, and this results in the 
actual transcription of the gene. Taking into consideration this background, 
the main objective of this thesis was to further explore the role of NO in 
mammary gland involution, on a global level and on specific post-translational 
protein modifications. Our interest in further deepening on the role of NO was 
because NO rises in pro-inflammatory environments (such as our model of 
post-lactational involution), which in turn, facilitates tumour progression, 
hence, it is logical to think that a deregulation in the mechanisms where NO 
might play a role, could influence on tumour development.  
 
1. GLOBAL ACTION OF NO IN THE INVOLUTING MAMMARY GLAND. 
 
NO might be a signalling modulator not only during involution, but also 
during pregnancy and lactation where proliferation and differentiation of the 
mammary gland epithelial cells is maximal. Indeed, the three isoforms, NOS1, 
NOS2 and NOS3 are expressed in normal mammary epithelium (Khalkhali-
Ellis & Hendrix, 2003); being up-regulated during involution (Islam et al, 2009; 
Zaragoza et al, 2005). In our model, nitrite levels as an end-product of NO did 
significantly increase in mammary tissue of both WT and NOS2-KO mice, but 
these were significantly higher in the WT animals (figure 13). The increment 
observed in the KO mice may be due to the activation of constitutive NOS 
forms, as we and others have demonstrated (figure 14) (Islam et al, 2009). 
 
The difference in NO production between the WT and the NOS2-KO 
mice correlated with a different involuting phenotype, being delayed in the 
genetically modified animals. This is the first evidence that NO can have a 
role in the physiologic process of involution. Corroborating this hypothesis, 
mammary gland weight/total weight ratio was significantly higher in the KO 
mice (figure 17), the milk production was higher as was the mean pup weight 
(figures 18 and 19). These differences where also established in the 
pathology studies, where we saw that NOS2-KO mice displayed a 24h delay 
in the changes mammary gland goes through after weaning (figures 15 and 
16). This difference could be due to alterations in the control of either lactation 
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or involution. Given these two possibilities, we performed further experiments 
to elucidate when NO was acting, taking into account that both physiological 
processes could be altered by the failure to increment NO levels.  
 
The main regulatory hormone in lactation is PRL which acts in the 
epithelial cells of the mammary gland through binding to its receptor (PRLR) 
and this will activate the JAK-STAT5 pathway. Upon activation, STAT5 
becomes phosphorylated in specific tyrosine residues. This phosphorylation 
results in the dimerization of STAT5 which translocates to the nucleus and 
binds to its recognition site, where it activates transcription of many genes, 
among which feature milk proteins such as β-casein (Miyoshi et al, 2001). It 
has been established in other works that NO has an inhibitory control on Ca2+ 
dependent PRL release in the adenohypophysis (Andric et al, 2003; 
Duvilanski et al, 1995), which could mean that a decrease in circulating NO 
levels would allow for further PRL release, thus prolonging lactation. This 
hypothesis was the basis to deepen on the STAT5 pathway, the downstream 
effector of PRL, in our experimental model. In our involution model we found 
that lack of functional NOS2 implied persistence of phosphorylated STAT5 up 
to 48h after weaning (figure 20). Of course, the increased PRL levels 
observed in NOS2-KO mice could be modulating the JAK/STAT signalling 
pathway avoiding p-STAT5 down-regulation during the first phase of 
involution. However, it is important to highlight that NO might also have a 
direct effect on STAT5 activity, that could account for the diminished p-STAT5 
observed in WT mice after weaning. Indeed, NO has been described to inhibit 
Stat5 signalling pathway in macrophages either by decreasing STAT5a and 
STAT5b protein levels (Starzynski et al, 2006) or by reducing tyrosine 
phosphorylation (Bingisser et al, 1998). We also decided to check whether 
this lesser down-regulation was influencing STAT5 final function in mammary 
gland tissue. Since the levels of STAT5 expression and activation have been 
demonstrated to affect the extent of milk protein expression and secretion 
during lactation (Clarkson et al, 2006; Geymayer & Doppler, 2000; Watson & 
Brown, 2008) and the casein promoter is more sensitive to STAT5 
transactivation than other milk proteins (Iavnilovitch et al, 2002); we studied 
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the pattern of β-casein expression at the peak of lactation and during the time 
course of involution. Increased mRNA levels of this gene were observed at 
the peak of lactation and after 6h of weaning (figure 21). This is not surprising 
since the β-casein mRNA half-life is approximately 9h (Kuraishi et al, 2002); 
and it has been described that levels of mRNA for α, β and γ-caseins remain 
high for at least 12h after weaning, decreasing thereafter (Wiens et al, 1992). 
However, accompanying the inactivation of STAT5, the β-casein gene 
expression was decreased after 24h of weaning in the WT mice, but this was 
not the case for NOS2-KO mice. Although decreased, we found that β-casein 
mRNA levels were significantly higher after 24 and 48h of weaning, in 
accordance with the sustained activation of STAT5 we had previously 
observed. The findings in this first set of experiments could explain, in part, 
the increased milk production in KO mice, the higher ratio in mammary gland 
weight/ total weight and the higher pup weight gain. Furthermore, these 
results support our initial hypothesis that the NOS2-KO mammary tissue is 
held in a functional stasis during early involution despite the loss of the 
suckling stimulus. Since teat-sealing experiments demonstrated that 
involution is triggered not only by decay of serum PRL levels, but rather by 
loss of the sucking stimulus, this would further support the idea that NO does 
have a direct effect in the first phase of involution, and not all of its effects are 
due to sustained PRL levels (Cross & Silver, 1956; Vina et al, 1981). 
 
As it has been explained amply in the introduction, there are four main 
regulatory pathways in mammary gland involution: STAT3, NF-κB, PI3K/AKT, 
and TGFβ. Hence, the next step was to study the effect of NO on these. It has 
been reported that STAT5 and STAT3 are inversely activated during the 
course of a lactation/involution cycle (Clarkson et al, 2006; Watson & Brown, 
2008). It has also been demonstrated that blocking STAT3 activation induces 
a strong delay in mammary gland involution (Chapman et al, 1999). Thus we 
analyzed STAT3 phosphorylation at the peak of lactation and during 
involution, finding that even if STAT3 activation was not delayed in NOS2-KO 
mice as compared to WT animals, the phosphorylation was clearly weaker 
(figure 22). The apparent lower phosphorylation observed by western blotting 
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was concordant with a significantly lower DNA-binding activity of STAT3 in the 
NOS2-KO mice (figure 23). Although we cannot rule out the possibility that 
NO could have a direct effect on STAT3 activation, it is predictable that 
activated STAT5 has a regulatory role in this pathway. This hypothesis is in 
agreement with a previous report demonstrating that over-expression or 
forced activation of STAT5 in transgenic mice promotes a lower level of 
STAT3 activation (Iavnilovitch et al, 2002).  
 
We set out to determine the physiological relevance of a lower STAT3 
activity in the NOS2-KO. We analysed bcl-3 expression pattern since it is a 
known target of the STAT3 pathway (Clarkson et al, 2004). Although the 
functional role of this protein is still unclear, it is known to be strongly induced 
in mice mammary glands after 24h of weaning (Clarkson et al, 2006). Indeed, 
bcl-3 expression was increased at 24h weaning, in accordance to literature, 
but this increase was significantly higher in the WT mice (figure 25). It is worth 
emphasizing that the magnitude of bcl-3 up-regulation after 24h of weaning is 
the same as that found for STAT3 activity in both animal types at that time 
point which further supports that STAT3 is involved in the modulation of bcl-3 
expression at this time point. However, the pattern of bcl-3 expression after 48 
and 72h of weaning does not correlate with the STAT3 activation we found. 
Therefore, from our results we cannot discern the particular contribution of 
STAT3 to bcl-3 expression during the time course of the experiment. Our data 
clearly show that, at least after 24h of weaning, STAT3 is phosphorylated, its 
DNA binding activity is increased and bcl-3, one of its target genes, is up-
regulated to a higher level in WT compared with NOS2-KO mice. Hence, we 
can conclude that NO seems to play a role in the modulation of those signals 
leading to STAT3 molecular and functional activation in mammary tissue after 
24h of involution.    
 
Another of the main regulatory pathways involved in involution 
regulation is the NF-κB pathway. NF-κB is a key transcription factor in the 
modulation of different stages of mammary gland development and has been 
suggested to act as a checkpoint modulator of apoptosis (Clarkson & Watson, 
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1999). NF-κB is activated during pregnancy, almost completely suppressed 
during lactation and reactivated in early involution (Clarkson et al, 2000; 
Zaragoza et al, 2005). In different experimental models, NO has been shown 
to indirectly up-regulate NF-κB binding activity, via IκBα degradation through 
its phosphorylation (Fernandez-Martinez et al, 2004) or nitration (Yakovlev et 
al, 2007). We investigated if in our model, this factor could be regulated by 
NO and be responsible, at least in part, for the delayed involution seen in 
NOS2-KO mice.  
 
Since the differences found in NF-κB binding activity during lactation 
and early involution are known to be caused by the modulation of its nuclear 
translocation (Geymayer & Doppler, 2000) and do not affect the p65/p50 
protein levels, we analyzed by western blotting the decrease in cytoplasmic 
IκBα levels, which is an indirect form of measuring NF-κB activation. We 
found that IκBα degradation was maximal after 24 and 48h of weaning in WT 
mice and delayed to 48 and 72h in the KO mice. These results strongly 
suggest that NF-κB is differentially activated in WT and NOS2-KO mice 
(figure 27 A). This observation was further confirmed by the analysis of NF-κB 
DNA-binding activity at lactation and during weaning. Indeed, NF-κB binding 
activity started to increase at 24h after litter removal in the WT mice, reaching 
a maximum after 72h of involution, whereas, in the NOS2-KO mice, NF-κB 
activity was also increased but to a significantly lesser extent (figure 27 B) in 
agreement with the 24h delay in IκBα degradation. Of note, in the WT 
animals, at 72h after weaning, IκBα was re-synthesized, whereas the p65 
subunit of NF-κB was still active. This is in line with the fact that NF-κB 
modulates the expression of its own negative regulator, this way, the negative 
feedback loop controls the extent of the NF-κB-dependent response. Once 
IκBα has accumulated again, it would interact with p65 within the nucleus and 
facilitate its export back to the cytoplasm. In our experimental model, our 
results after 72h of weaning most probably reflect the final step of this NF-κB 
signalling pathway, where NF-κB is involved in IκBα expression and therefore 
is still active. However, it is interesting to remark that this process is known to 
be more complicated than a simple stoichiometric-dependent regulation. For 
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example, the binding of p65 to IκBα and its subsequent nuclear export to the 
cytoplasm is modulated by deacetylases/acetyltransferases activated by 
different stimuli. In this way, acetylation of p65 would block its interaction with 
IκBα and therefore would be still active within the nuclear compartment (Chen 
et al, 2002; Neumann & Naumann, 2007). 
 
On the basis of the result that NF-κB activation during weaning was 
delayed in NOS2-KO mice, we investigated the extent of this effect on those 
pathways known to be associated with the NF-κB response. We therefore 
analyzed the expression of 84 genes associated with NF-κB using super-
array technology. In WT mice, the expression pattern found after 48h of pup 
removal was similar to that described in previous microarray expression 
studies (Clarkson et al, 2004; Stein et al, 2004). Out of the 84 genes included 
in the study, 30 where found to be up-regulated when compared with the 
lactation point. In the KO mice, even if the expression pattern was also similar 
to the WT at 48h of weaning, we only found 21 genes to be up-regulated. 
Furthermore, when comparing WT and NOS2-KO mice at 48h of weaning, 23 
genes were significantly down-regulated in weaned NOS2-KO mice compared 
with the WT mice, and none was up-regulated. The detailed study of the data 
shown in table 9 provides additional and important information on the role of 
NO in the regulation of mammary gland involution. That is, (i) the fact that all 
genes found to be differentially regulated in KO animals compared with WT 
were down-regulated, suggests that the NF-κB signalling pathway during 
weaning is delayed in KO mice, and thus, NO could be an important signal 
involved in the mechanisms that trigger the NF-κB response. Since none of 
these genes was up-regulated, we conclude that NO does not participate in 
the silencing of any NF-κB associated genes. Also (ii) some of the down-
regulated genes, such as caspases, bcl-3, colony-stimulating factors, elk-1 or 
tnf, are largely considered to be pro-apoptotic (Gouon-Evans et al, 2000; 
Varela & Ip, 1996). For instance, an 80% decrease in fasl expression in 
NOS2-KO mice would suggest a protection from apoptosis in these mice. In 
fact, no apoptotic cells were found during the first 3 days of involution in fasl 
deficient mice (Song et al, 2000). Moreover, the authors of that study suggest 
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a defect during the first phase of involution that does not affect the second 
phase. And (iii), some other genes are know to be anti-apoptotic, and one 
would expect them to be up-regulated in a process with less severe apoptosis 
as in the NOS2-KO mice. Strikingly, those genes where also down-regulated. 
This is the case of intercellular adhesion molecule 1 (ICAM-1), which is 
reduced 55% in NOS2-KO compared with WT mice. It has been suggested 
that the response of adjacent cells to localized apoptosis is to induce the 
expression of cell adhesion molecules such as ICAM-1 to maintain survival. 
Nevertheless, a correlation between the extent of apoptosis and the 
expression of ICAM-1 has been demonstrated (Clarkson & Watson, 1999). 
Therefore, it would be reasonable to think that a less severe apoptosis during 
the first phase of involution would induce a poorer response in terms of ICAM-
1 expression. This could also apply to the poorer activation seen of the pro-
survival signal exerted by AKT (figure 26). The definition of the first stage of 
involution can explain this apparent functional contradiction. On the whole, 
involution is the addition of both pro- and anti-apoptotic signals that, upon 
persistence of forced weaning, will unbalance the response towards the 
irreversible phase of apoptosis and remodelling of the gland; but the 
remaining surviving cells will recruit survival pathways in a controlled manner 
in order to ensure the adequate remodelling. Finally, the data suggest that, 
although NF-κB is in some way involved in the modulation of all of the genes 
listed, there is not a solely specific pathway that can be affected by the 
absence of NOS2 expression after 48h of weaning.  
 
Given the amount of pathways intervening and all the events that take 
place as well as the strict order they take place in, it can be inferred that, like 
in any physiological process, mammary gland involution has to be extremely 
well orchestrated. This way, nothing is left to chance. The characteristics of 
the process and the early differences seen between WT and NOS2-KO mice 
suggest that, although NO targets are at the very onset of involution, including 
the PRL receptor/JAK/STAT pathway, the nature of the mammary gland 
allows the amplification of the signal through the modulation of several 
pathways. This means that NO does not seem to only affect one pathway, but 
many.    
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As explained, mammary gland involution has two distinct phases, the 
first phase, characterized by apoptosis, and the second phase, characterized 
by gland remodelling. This second phase is intimately related with the first, 
because, although the second can happen without the first (Chapman et al, 
2000) some of its principal actors are also modulated by key regulators of the 
first phase. Such is the case of metalloprotases (MMPs). Activation of NF-κB 
can induce apoptosis, with concomitant loss of extracellular matrix contacts 
(Gukovskaya et al, 1997). The rise in NF-κB binding activity in our model 
coincided with an increased rate of apoptosis in the mammary gland. On the 
other hand, the extent of apoptosis has been reported to correlate with an 
increase in MMP activity at the onset of major remodelling of the gland during 
the second phase of involution (Clarkson & Watson, 1999; Lund et al, 1996). 
In fact, MMPs are synthesized as latent zymogens, which have to be 
biologically activated by cleavage of their proenzyme peptide. Accumulating 
evidence suggests that the activation of NF-κB is one of the most important 
signalling events required for the inducible expression of MMP-9 in response 
to different stimuli (Li et al, 2009). Consequently, we explored the functional 
consequences of delayed NF-κB activation in NOS2-KO mice during the 
second phase of involution. Since we found that MMP-9 induction was 
significantly more pronounced during weaning in WT than in NOS2-KO mice 
(figure 29), concordant with the delay found in NF-κB binding activity in the 
latter, we hypothesized that MMP-9 transcription could be directly dependent 
on NF-κB. Our hypothesis was confirmed by ChIP assay (figure 30), were we 
found that, in WT mice, at 48h after weaning, NF-κB was in fact bound to the 
MMP-9 promoter, and this was not the case for NOS2-KO mice.  
 
MMPs are essential in the remodelling of the ECM that takes place 
during mammary gland involution (Lund et al, 1996). In fact, MMP-9 is a key 
protease governing degradation of basement membrane collagen as well as 
different types of gelatine (Green & Lund, 2005). Our results suggest that the 
effect of NO in the regulation of mammary gland involution is not limited to the 
first phase of involution. Therefore, it seems that by the modulation of either 
PRL signalling and transcriptional factors activities and/or their interactions, 
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the signal generated by NO during the first phase of involution is amplified 
throughout the cascade of events triggered during the second phase.  
 
2. SPECIFIC ROLE OF NO IN REGULATION OF MAMMARY INVOLUTION 
AFTER WEANING. NITRATION AS A POST-TRANSLATIONAL 
MODIFICATION.  
 
As said before, NO at high concentrations exerts its functions through 
the reaction with O2 or superoxide to generate reactive nitrogen oxide species 
(RNS) that subsequently react with biological targets, inducing nitrosative 
modifications. Nitrosative modifications are selective processes that target 
precise molecular sites in proteins or lipids for gain or loss of function, in a 
manner somewhat analogous to the better-known phosphorylation or 
acetylation signal transduction mechanisms (White et al, 2010). 
Tyrosine nitration is a post-translational modification of protein tyrosine 
residues that is mediated by ONOO-. Nitration of tyrosine or tyrosyl groups of 
a protein modulates protein function and its involved in signal transduction, 
which leads to an alteration of cellular metabolism and function. In particular, 
ONOO- -induced protein oxidation often leads to a loss of protein activity 
(Gorg et al, 2007; MacMillan-Crow et al, 1998), seldom to activation (Ji & 
Bennett, 2003; Ji et al, 2006; Rebrin et al, 2007). Because of its recognized 
significance, there is an increasing interest in identifying nitrated proteins in 
order to gain a better understanding of their involvement in different biological 
processes, as is the case for mammary gland remodelling.  
So far, in our work, we have established that NO concentration rises 
with weaning, and this is due, at least in part, to an up-regulation of NOS2. 
We have also established that NO targets are at the very onset of the 
process, but given the dynamic nature of the mammary gland tissue and the 
multiple interconnected pathways that partake in involution, the specific 
changes/signals induced by NO are amplified throughout the whole process. 
We have established that a decrease in its concentration translates into a 
global delay in involution; still, we also wanted to assess if NO induced 
specific post-translational modifications.  
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In order to approach this question, proteomic studies were performed 
using mammary gland homogenates from lactating rat and after 72h weaning. 
From the 2D gel studies (figure 32), it was confirmed that protein nitration is 
increased during weaning. The differentially nitrated proteins were recovered 
and from the gel and identified using MALDI-TOF-MS. As explained before, 
mammary glands were not milk-depleted because milk stasis plays an 
important role in involution and we were interested in the complete protein 
profile. As a consequence, low abundance proteins could not be detected, 
hence it cannot be ruled out that more proteins could be nitrated after 
weaning. The analysis of the protein map showed a relative abundance of 
albumin, immunoglobulin chains and casein which is expected, due to milk 
stasis. Nevertheless, it is possible that these fragments of nitrated albumin 
could play a more important role since it has been described that the injection 
of small peptides derived from milk into the mammary gland accelerates the 
process of involution (Shamay et al, 2002). However, a 48KDa nitrated protein 
was identified, with coverage of 2.5% as cathepsin D in mammary gland 72h 
after weaning.  
 
Cathepsin D is a major aspartic protease of endosomes and lysosomes 
and member of the pepsin family of proteases (Tang & Wong, 1987). 
Cathepsin D is increased during weaning, playing a key role in protein 
degradation during mammary gland apoptosis; indeed, cathepsin D is known 
to be involved in the mitochondrial caspase-dependent intrinsic pathway of 
cell death (Castino et al, 2007). Despite the relevance of this protease in 
physiological and pathological events, little data exists on the factors that 
modulate its secretion, activity and extracellular function in lactating mammary 
tissues. It is known that cathepsin D undergoes a complex series of post-
translational modifications from its pre-pro form to its fully activated double-
chain mature form, and recently it has been proved that these changes may 
vary depending on the physiological process it participates in (Margaryan et 
al, 2010). Finding cathepsin D among the nitrated proteins oriented to the 
possibility of tyrosine nitration as an added post-translational modification.  
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Indeed, the stagger between the rise of mRNA and protein levels and 
the increase in the protease activity (figure 35), pointed to a possible post-
translational modification. Immunoprecipitation studies (figures 33 and 34) 
confirmed cathepsin D nitration in mammary gland homogenates after 72h 
weaning; hence rose the hypothesis that this post-translational modification 
was, at least in part, responsible for its activation. As presented in the results 
section, cathepsin D of rat, human and bovine origin does become more 
active after exposure to ONOO-. This increase in activation was of the order of 
0.5 fold in the in vitro studies (figures 37, 38 and 39). With these results we 
can conclude that tyrosine nitration does play a role in cathepsin D activity 
enhancement and that this post-translational modification is conserved among 
different species. Of course, even though we have described in this work 
cathepsin D nitration for the first time, and that post-translational modification 
seems to play a direct role in its increased catalytic activity, other proteins, 
also affected by NO, could be modulating cathepsin D activity indirectly. Also, 
this protease needs of other modifications that could also be modulated by 
NO, in order to become fully activated, this could explain the 2 fold difference 
observed between the WT and the NOS2-KO mice experiments  (figure 42 A).  
 
The next question raised by the results obtained was how nitration of a 
tyrosine residue can affect cathepsin D activity. Immature cathepsin D can be 
partially auto-activated, leading to the mature form of the enzyme; therefore a 
specific nitration could be somehow accelerating or interfering with the 
autoprocessing of the immature form of cathepsin D. However, our 
experiments with WT and KO animals show the same pattern of proteolytic 
cathepsin D cleavage (figure 42B). It has been shown that pro-cathepsin D 
requires lysosomal cysteine proteases for the final processing of its pro part 
and we have demonstrated that recombinant human cathepsin D undergoes 
in vitro nitration and activation in a cysteine protease-free buffer (figure 38). 
Therefore it can be excluded that auto-processing is the mechanism by which 
nitration increases activity in cathepsin D. Intriguingly, in the rat mammary 
gland homogenates, we found that both the 48kDa mature single chain and 
the 34kDa heavy chain of the mature two-chain enzyme had tyrosine nitration 
(figures 33, 34 and 37 panel C), which points to the possible cellular 
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compartment this nitration could occur in, and this also suggests that 
cathepsin D becomes nitrated at an earlier step of the maturation process 
along the endosomal-lysosomal pathway. 
 
Our results strongly suggested the existence of nitration domain 
conserved among species, since both rat, human and bovine cathepsin D can 
be nitrated by ONOO- (figures 37, 38 and 39). Moreover, the fact that this 
nitration induced a slight increase in enzyme activity compared with non-
nitrated cathepsin D suggests that NO can modulate cathepsin D activity in a 
direct manner. One could argue that the protein context surrounding 
cathepsin D or the conformation of cathepsin D in vivo could be other than 
that favoring the nitration. Nevertheless, we have shown that cathepsin D 
from extracts of control lactating mammary gland can also be nitrated in vitro, 
and that this nitration induces an increase in the enzymatic activity (figure 36). 
 
On the whole, our experiments show that low degree of nitration 
increases cathepsin D catalytic activity, not only in recombinant human 
cathepsin D, but also in tissue homogenates, suggesting that direct nitration 
of this enzyme is responsible for the enhanced activity observed. Also, the 
specific tyrosine nitration site was sought. Figure 40 shows MS 
characterization of human recombinant cathepsin D before and after ONOO- 
treatment. After being exposed to ONOO-, the tyrosine residue in the 168 
position appeared nitrated. Although most of the tyrosine residues present in 
cathepsin D structure were sequenced (13 residues out of 19), we were 
unable to sequence more than 40% of human cathepsin D, hence, it cannot 
be ruled out that other tyrosine residues could be nitrated. Tyr168 is found in 
the heavy chain of cathepsin D and it is highly conserved among species 
(figure 41).  In fact, a detailed protein sequence reveals a possible nitration 
site within the sequence F-S-F/V-Y-X-X-R/S. Further studies would be needed 
in order to determine if other proteases with the same conserved domain can 
also undergo in vitro and in vivo nitration.    
 
It has been amply described by other groups that tyrosine nitration can 
induce profound changes in protein structure and function due to a shift in the 
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pKa of the tyrosine hydroxyl group (Sokolovsky et al, 1967). Also, the 
importance of pH in the modulation of cathepsin D activity has been 
extensively documented (Beaujouin & Liaudet-Coopman, 2008; Khalkhali-Ellis 
et al, 2008; Matsuyama et al, 2000). Indeed, while an acidic pH leads to a fully 
active enzyme, at pH 7.5 a molecular bond between specific tyrosine residues 
and the catalytic aspartate residues stabilizes the protein structure in an 
inactive conformation (Masa et al, 2006). Although Tyr168 is 17.76 Å 
(1 Å=0.1 nm) away from the active site and such a distance is not compatible 
with a direct hydrogen bond with the catalytic residues, it would be 
conceivable that the nitration of Tyr168 could favor an irreversible active 
conformation of the enzyme by blocking a molecular bond crucial for 
cathepsin D folding. Moreover, an inhibitory domain has been localized at the 
N-terminus of cathepsin D (Masa et al, 2006); at pH 7.5 the mature N-
terminus is repositioned into the active site cleft, interacting with the catalytic 
residues. Since we cannot exclude the possibility of nitration in other non-
identified tyrosine residues, the in vivo nitration of a specific tyrosine at this 
site could block the binding of the inhibitory pro-peptide and allow free access 
of the substrate. 
 
In our work we find that levels of cathepsin D mRNA are highly up-
regulated in the first day of involution, while its catalytic activity is delayed and 
it increases in days 2-3 of involution, this further supports the importance of 
post-translational modifications in protein function (figures 35, 42 and 43).  In 
line with our finding, another published paper studied mammary cathepsin D 
protein levels and proteolytic activity in a mouse model from late pregnancy 
and throughout lactation and involution (Margaryan et al, 2010). The authors 
also find cathepsin D protein levels to be elevated from the initial stages of 
involution, but in the first three days they find primarily a mixture of 
procathepsin D and active single-chain in the tissues. On day 4 of involution, 
a large quantity of mature, double chain cathepsin D appears. So it seems 
that cathepsin D does not have a single function or state, but rather, it holds a 
highly plastic activity. In the same paper, another observation is the potential 
role of the glycosilation pattern of this protease as a regulatory tool. Indeed, 
changes in glycosilation are unlikely to impact catalytic activity or substrate 
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specificity of cathepsin D (Beyer & Dunn, 1996), but alterations in glycosilation 
may contribute to altered trafficking and compartmental localization of pro-
cathepsin D and cathepsin D, thus dictating changes in biological functions 
(Erickson et al, 1981; Fortenberry et al, 1995; Varela & Ip, 1996). 
 
Finally, we present a schematic figure on the global role NO exerts 
during post-lactational mammary gland involution. As discussed, we have 
found that NO in this pro-inflammatory setting can modulate certain key 
pathways (STAT5, STAT3, NF-κB and AKT) as well as induce specific protein 
modifications that will add to the perfect orchestration of this highly dynamic 
process.  
 
 
Figure 49. Global effect of NO during weaning. Upon weaning, involution 
starts and initial activation of Stat3 and NF-κB occurs.  NF-κB induces NOS2 
which will activate NO formation. NO, by means of formatting RNS will 
modulate the involution process, having an impact on Stat, NF-κB and AKT 
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function. Also, it will induce specific nitrosative modifications, eg, tyrosine 
nitration of cathepsinD, which will enhance its activity, having an impact on 
the tissue remodelling process. The NO source has also been proved to be 
activated macrophages that invade the mammary tissue upon pro-
inflammatory signalling, exerted by STAT3 and NF-κB activation. 
Macrophages phagocyte apoptotic cells and suppress inflammation, allowing 
for adequate tissue re-structuring. 
 
3. ROLE OF NO IN THE REGULATION OF PATHWAYS INVOLVED IN 
BOTH INVOLUTION AND CANCER PROGRESSION: PRELIMINARY 
DATA 
 
Understanding the relationship between the physiological functions of 
different molecules during development and their pro-tumorigenic functions in 
carcinogenesis is critical for developing appropriately targeted therapeutics. 
The relevance of our findings is granted by the fact that the main regulatory 
pathways in mammary gland involution: STAT3, NF-κB and PI3K/AKT 
pathways are related with pro-survival mechanisms in cancer. This means 
that physiological processes have to be very well orchestrated, the signalling 
pathways that are recruited have to be switched on and off at the appropriate 
times and that depending on the context, transcription factors can have pro-
survival or pro-apoptotic functions. An error in the regulation may facilitate an 
oncogenic event that, in the appropriate microenvironment, can progress and 
give rise to a neoplasm.  
 
Breast cancer incidence is rising among young women, and this is due 
to many factors, but one is delay in age of the first conception (Lord et al, 
2008). This might seem a paradox, since it is a well established 
epidemiological fact that pregnancy is associated with a reduction in a 
woman’s lifetime risk of developing breast cancer (Albrektsen et al, 1994; 
MacMahon et al, 1973; Rosner et al, 1994). However, it is also recognized 
that the protective effect of pregnancy is neither immediate nor constant, and, 
while parity is associated with a lifetime reduction in breast cancer risk, 
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studies in breast cancer incidence have demonstrated a transient increase in 
breast cancer risk in the years immediately following pregnancy, 
independently of age (Albrektsen et al, 2005; Chie et al, 2000; Lambe et al, 
1994). This increase has been shown to persist for at least ten years for a 
woman under the age of 25 at delivery (Lambe et al, 1994). Also, delaying 
pregnancy further increases this transient risk, and a maternal age greater 
than 30 at first birth results in both an increase in incidence and a longer 
increased risk that persists for up to 30-50 years post-partum (Albrektsen et 
al, 2005; Chie et al, 2000; Dupont & Page, 1987; Lambe et al, 1994; Liu et al, 
2002). Hence, pregnancy might both suppress and promote breast cancer, 
since, the initial effect of any completed pregnancy is an increased risk, but a 
cross-over to long term protection is seen in women of younger maternal age, 
and high parity (Lord et al, 2008). This protective cross-over effect is lost 
when the age of first birth is above 35 (Lyons et al, 2011; Lyons et al, 2009; 
Rosner et al, 1994; Schedin, 2006). 
 
There are two main hypotheses to explain this transient increased risk 
in breast cancer associated with pregnancy. The first, exposure to pregnancy 
related hormones such as E, Pg, GH and IGF-1 are associated with 
promotion of breast cancer cell proliferation (Schedin, 2006). The second 
hypothesis postulates that mammary gland involution, which goes hand-in-
hand with a terminated pregnancy implies the activation of certain 
mechanisms that resemble pro-tumorigenic wound-healing environment. In 
fact, the latter theory seems to better explain the worse prognosis of patients 
when breast cancer is diagnosed after birth in comparison to those who are 
diagnosed during pregnancy (Guinee et al, 1994; Schedin, 2006). 
 
To further support the hypothesis that the involuting mammary gland 
drives breast cancer progression, a recent work published by the Schedin 
group (Lyons et al, 2011) proved that tumour cell exposure to the involuting 
mammary microenvironment promotes breast cancer metastasis and this is 
via ECM proteins, such as fibrillar collagen, and COX-2. The authors 
demonstrate that COX-2 activity in the normal involuting gland is required for 
the deposition of fibrillar collagen and that this collagen up-regulates COX-2 
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expression in tumour cells which promotes invasion. Notably, COX-2 inhibition 
by NSAIDs during normal post-partum mammary gland regression blocked 
the production of fibrillar collagen so it is hypothesized that NSAIDs taken 
during mammary gland involution could be an effective chemoprevention 
strategy for women who are at higher risk of developing breast cancer (Lyons 
et al, 2011). In agreement with this, epidemiological studies have correlated 
COX-2 inhibition with NSAIDs with decrease breast cancer recurrence and 
related deaths (Holmes et al, 2010; Kwan et al, 2007).  
 
Having reviewed the argument for the use of NSAIDs in this context, 
we postulate that the use of anti-inflammatory drugs could also have an 
impact on the NO regulated mechanisms we have described in the present 
work. Indeed, NO activates COX-2 (Cahlin et al, 2000; Kim et al, 2005) and 
aspirin-like drugs have been described to inhibit both NOS2 expression and 
catalytic activity (Amin et al, 1995). However, other influencing factors cannot 
be ruled out. 
 
In the final part of the present work, we raised the question of whether 
high concentrations of NO had a specific impact on the pathways that are 
regulated by this molecule during mammary gland involution, but in an 
epithelial breast cancer model. The effect we have found in our model 
supports that high doses of NO could be having a dual effect: on one side, the 
induction of apoptosis, which is in concordance with other studies (Borutaite & 
Brown, 2006; Cleeter et al, 1994; Thomas et al, 2004). MCF-7 cells where 
less viable when exposed to increasing concentrations of NO (figure 45); on 
the other, high concentrations of NO seem to be activating pathways clearly 
related with survival such as AKT and NF-κB (figures 46 and 47) and 
interestingly, there is a parallelism with the physiological process of involution.  
 
4. FUTURE WORK 
 
All in all, our data point to the possibility that breast tumour cells upon 
NO stimulation activate the same mechanisms observed during weaning; and 
that, like in the physiological process, the activation of these pathways also 
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seem to depend, at least in part, on NO exposure. Of course, these are only 
very preliminary data. Indeed, the direction to take this would be to further 
corroborate activation of the PI3K/AKT/mTOR pathway through the analysis 
of activation of downstream effectors and the quantification of expression of 
targets genes of this pathway. Another interesting set of experiments would 
be to specifically address at which point of the signalling pathway does NO 
interfere, does it activate AKT directly, or through the activation/inhibition of 
up-stream regulators? Or on the contrary, does it become phosphorylated 
through the loss of the negative feed-back loop exerted by mTOR should 
mTOR be inhibited by direct or indirect effects of NO? 
 
Although other works have amply proved that NF-κB can be activated 
by NO through mechanisms that implicate direct IκBα tyrosine nitration 
(Yakovlev et al, 2007) or its phosphorylation (Gochman et al, 2011), it would 
be interesting to know if at these high concentrations, NF-κB is activated and 
which target genes does it have. In this line of thought, it would be important 
to corroborate if the up-regulation in MMP-9 expression we have observed in 
our MCF-7 model (figure 45) is due to NF-κB transactivation.  
 
It would also be pertinent to study these pathways in more 
physiological conditions, since the nitrite concentrations achieved with the 
amount of SIN-1 used in our work model are above physiological (figure 41), 
even when the microenvironment is that of an inflammatory status. But all in 
all, we believe that the data provided so far, does support the hypothesis that 
the same regulatory activity exerted by NO in different pathways implicated in 
mammary gland involution after weaning is also seen in malignant breast 
epithelial cells. Of course, many studies have already been published on the 
role of NO in cancer, and most of these works support the hypothesis that a 
concentration of NO in the µM range, such as the concentrations achieved in 
pro-inflammatory environments, promote tumour regression and cell death 
(Singh & Gupta, 2011). This has been the rational for the development of 
drugs such as NO donating NSAIDs (NO-NSAIDs) (Williams, 2011). Still, 
many questions are still pending on the real anti-tumour effects of these 
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drugs, their safety and whether if their anti-tumour effects are really 
dependant on the NO-donating part or, just on the anti-inflammatory effects of 
these agents (Rigas & Williams, 2008).  
 
Understanding the relationship between physiological functions of a 
particular process during normal development and homeostasis is crucial, 
since all physiological processes are a finely balanced mix of signalling 
pathways that can be contradictory in their functions. Indeed, in our NOS2-KO 
mouse model there is a de-regulation in this balance during mammary gland 
involution. This is due to an alteration of NO concentration which gives rise to 
a delayed apoptosis, but also to a down-regulation of pro-survival-related 
genes. This phenomenon could be due to the fact that losing NO pro-
apoptotic stimulus also alters the pro-survival counter-back. Hence, in a pro-
inflammatory microenvironment such as post-lactational regression, NO will 
induce apoptosis, but could also facilitate proliferation in the remaining cells 
via the activation of pathways such as the PI3K/AKT pathway.  
 
We know that a normal cell, on its way to neoplastic transformation will 
recruit already existing mechanisms in order to survive, only that these 
mechanisms will be de-regulated and adapted in order to meet the cell’s new 
needs. Indeed, in our in vitro preliminary data in a breast cancer luminal 
model, we found that, after exposure to high concentrations of NO, 
transformed cells recruited some of the specific mechanisms used during the 
physiological process of involution. Of note, these mechanisms have been 
amply described as pro-survival in a neoplasic setting, which could mean that, 
although high concentrations of NO imply cell death, the surviving cells could 
be ensuring their endurance activating pro-survival mechanisms that use the 
apoptosis-inducing noxa in their own benefit, and this concept has deep 
therapeutical implications.  
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CONCLUSIONS 
 
The present study emphasizes the importance of NOS2 up-regulation and of 
NO concentration increase in the fine-tuning of the coordinated changes that 
occur during mammary gland involution.  We conclude that maintaining the 
correct levels of NO, together with other regulatory factors in the mammary 
gland, is essential for the modulation of transcription factor activities, post-
translational modifications and interactions that lead to the involution and 
remodelling of the mammary tissue once lactation is terminated. 
 
1. In the present work we have studied the effects of the absence of 
NOS2 in mammary gland involution after lactation. This absence 
results in lower NO levels in NOS2-KO mice, which in turn delays 
involution. We have evaluated this delay by means of 
immunohistochemistry studies, milk production and caspase 3 
activation.   
2. In order to gain a deeper knowledge on the differences observed at a 
macroscopic and histological level, molecular studies were carried out. 
The main signalling pathways that control post-lactational regression 
are clearly delayed in NOS2-KO mice. The most remarkable 
differences have been observed after 48 hours of weaning, specifically 
in the activation of the Stat5/Stat3 switch and the activation of NF-κB. 
This results in a de-regulation of their direct transcriptional targets (e. g. 
β-casein, Bcl-3, MMP-9); affecting the first phase of the process, where 
apoptosis is mainly involved, and also the ECM remodelling that takes 
place during the second phase of involution.  
3. NO not only plays a role on the fine tuning of the global process of 
involution, but also induces specific post-translational modifications that 
impact on protein function. In our model we found a specific tyrosine-
nitration in cathepsin D, a lysosomal aspartic endopeptidase, crucial for 
tissue remodelling. Our in vitro and in vivo experiments demonstrate 
that this tyrosine nitration results in cathepsin D activation.  
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4. Concerning breast cancer, in vitro exposure to high concentrations of 
NO reduces viability of epithelial breast cancer cells; but the remaining 
cells recruit some of the specific mechanisms activated during the 
physiological process of involution. In our work we found that high 
concentrations of NO induced cell death but also AKT phosphorylation  
and NF-κB activation, which are pro-survival  signals. 	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INTRODUCCIÓN 
 
La glándula mamaria es un tejido complejo y muy especializado que, a 
lo largo de la evolución se ha ido modificando para proveer al recién nacido 
de leche, alimento básico en la primera etapa del desarrollo de los 
mamíferos, que aporta nutrientes y protección inmunológica (Vorbach et al, 
2006). El tejido mamario sufre una extensa remodelación  en cada ciclo de 
embarazo/lactancia. Durante el embarazo, se produce una proliferación y 
diferenciación del epitelio ductal y alveolar para adquirir un fenotipo secretor 
(Benaud et al, 1998). Cuando cesa la succión, al final de la lactancia, se 
produce la muerte de las células epiteliales secretoras por apoptosis y se 
induce la diferenciación de los adipocitos circundantes de modo que la 
glándula mamaria queda preparada para un nuevo ciclo embarazo/lactancia. 
Este fenómeno fisiológico, conocido como involución, está estrechamente 
regulado y se produce en dos fases; la primera fase tiene lugar hasta las 48h 
del destete, es reversible y se caracteriza por la apoptosis del epitelio 
secretor alveolar, sin que se produzcan grandes cambios en la estructura de 
la glándula. Conforme avanza la involución, entramos en la segunda fase, de 
carácter irreversible, en la que se produce la activación de proteasas que 
degradarán la membrana basal y la matriz extracelular (Reinhardt & Lippolis, 
2009). A su vez, en esta segunda fase, se produce la adipogénesis, o 
rediferenciación de los adipocitos, de modo que la glándula se remodela 
hasta llegar a un estado similar al que tenía antes del embarazo (Baxter et al, 
2007; Green & Streuli, 2004).  
 
Este proceso fisiológico y secuencial está sometido a una estrecha 
regulación para que se produzca la perfecta coordinación entre cada una de 
las fases. Diversos estudios han demostrado que muchos de los genes 
sometidos a importantes cambios de expresión en la glándula mamaria 
durante la involución participan también en el proceso y desarrollo de la 
transformación neoplásica del tejido mamario (Watson, 2006). Por lo tanto, la 
glándula mamaria en el ciclo de lactancia/destete se puede considerar un 
excelente modelo fisiológico para establecer las bases moleculares de la 
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regulación de expresión de genes que, en condiciones patológicas como el 
cáncer de mama, se encuentra alterada. 
 
En cuanto a las vías de señalización que regulan las diferentes fases de 
involución, dos estudios de microarray de expresión génica han revelado que 
existen hasta cuatro perfiles transcripcionales que se suceden y se solapan 
parcialmente en las 96 primeras horas tras el destete. Un primer grupo 
presenta un perfil de expresión que alcanza su pico máximo a las 12 horas 
(grupo 1) y contiene genes relacionados con la vía de los death receptors 
(DR) y genes de respuesta de fase aguda (APR) de clase II; en el que se 
incluyen genes activados por NF-κB. Un segundo grupo que presenta un pico 
de expresión a las 12h de destete pero que se mantiene al menos hasta las 
96h. Este segundo grupo de expresión se caracteriza por estar compuesto 
por genes regulados por el factor de transcripción STAT3. Un tercer grupo 
cuya expresión máxima se da a las 24h de destete con un perfil similar al del 
grupo 2. Finalmente, el cuarto grupo, cuyo máximo pico de expresión se da a 
las 96h del destete. Este grupo también se caracteriza por genes de APR 
clase II, pero sobretodo se caracteriza por la expresión de genes 
relacionados con la inmunidad innata, inflamación y la regulación de la 
fagocitosis (Clarkson et al, 2004; Stein et al, 2004). Lo sorprendente de estos 
estudios es que han ligado íntimamente la involución post-lactancia con 
respuestas inflamatorias y de fase aguda. Las principales vías de 
señalización que se activan durante el destete son la vía de STAT3, NF-κB, 
TGFβ y PI3K/AKT.  
  
En modelos murinos, tras la retirada de las crías se inicia el proceso de 
involución con la inducción de apoptosis en las primeras 12h (Lund et al, 
1996). El inicio de la involución se caracteriza a nivel molecular por la 
activación de varias vías de señalización que deben estar bien orquestradas 
para que el proceso se dé de manera regulada. Es de señalar el cambio en 
actividad que se da en dos de los componentes de la familia STAT de 
factores de transcripción. Si durante la lactancia, una de las principales vías 
de señalización activadas era la de STAT5, que actuaba como efector de la 
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prolactina (PRL) regulando la transcripción de genes esenciales para la 
proliferación alveolar, diferenciación y síntesis de leche; durante la involución 
el estado de fosforilación (activación) de STAT5 cae mientras que aumenta la 
fosforilación de STAT3 activando la transcripción de genes pro-apoptóticos y 
pro-inflamatorios (ver tabla 2; página 26) (Clarkson et al, 2006; Li et al, 
1997b; Liu et al, 1996).  
 
Otra de las vías de señalización que regula la involución post-lactancia 
es la vía de NF-κB, grupo de factores de transcripción diméricos que regulan 
procesos de inmunidad, inflamación, proliferación y apoptosis (Sen & 
Baltimore, 1986). NF-κB se encuentra activo en varias fases de la evolución 
de la glándula mamaria. Su actividad es elevada durante el embarazo, 
momento en el que regula la proliferación epitelial (Baxter et al, 2007; Cao et 
al, 2001), pero se encuentra inactivo durante la lactancia (Clarkson et al, 
2000; Geymayer & Doppler, 2000). Durante la involución, NF-κB se activa 1h 
tras el destete y su actividad aumenta considerablemente a las 24h, siendo 
su pico máximo a las 72h post-destete (Clarkson et al, 2000). Su activación 
se da a través de la vía canónica y el perfil de expresión génica que activa 
está relacionado con respuesta de fase aguda e inmune (ver tabla 3 página 
31) (Clarkson & Watson, 2003). 
 
La vía de PI3K/AKT es una vía pro-proliferativa y de supervivencia. Se 
encuentra inactiva en las primeras 48h post-destete (Schwertfeger et al, 
2003), pero más allá de estas 48h, la glándula mamaria inicia la fase de 
remodelado y la vía PI3K/AKT se activa nuevamente. Además, AKT es un 
nodo no sólo de PI3K, sino que también lo es de la vía NF-κB y STAT3, lo 
que sugiere que AKT tiene una función de regulador central del proceso de 
involución. También es interesante señalar que si bien las células del epitelio 
alveolar entran en apoptosis durante la involución, algunas de ellas 
sobreviven, siendo biológicamente plausible que activen esta vía de 
supervivencia para evitar la apoptosis (Baxter et al, 2007). 
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Como se ha mencionado anteriormente, la involución de la glándula 
mamaria post-lactancia es un proceso dinámico en el que no sólo se da una 
fase de apoptosis para retirar el exceso de epitelio, sino que en último lugar 
se da un proceso de profunda remodelación que dará lugar a una estructura 
similar a la de antes de la concepción, de forma que la mama quedará lista 
para un nuevo ciclo embarazo/lactancia. Esta remodelación es llevada a cabo 
por una serie de proteasas como las metaloproteasas (MMPs) y las 
catepsinas, que contribuirán a la degradación de la matriz extracelular y la 
membrana basal y con ello, a una mayor apoptosis de las células luminales, 
favoreciendo así a la involución y remodelación  glandular (Green & Lund, 
2005). A medida que la involución progresa, aumenta la actividad de las 
MMPs, a la par que se facilita la invasión del estroma por adipocitos y se 
remodela el árbol ductal. Las principales MMPs que intervienen en este 
proceso son MMP-2, MMP-3, MMP-9 y uPA (Benaud et al, 1998; Lund et al, 
2000; Talhouk et al, 1992). 
 
Por otra parte, otra familia de proteasas relacionadas en la segunda 
fase de la involución es la familia de las catepsinas, que son hidrolasas 
lisosomales que degradan proteínas en un medio ácido, actuando como 
endopeptidasas en el compartimento endolisosomal (Liaudet-Coopman et al, 
2006). Se piensa que las catepsinas modulan la involución a través de tres 
mecanismos: i) muerte celular mediada por lisosomas (necroptosis); ii) 
autofagia; y iii) remodelación tisular. En la actualidad no existen estudios 
concluyentes acerca de los roles específicos que cada miembro de esta 
familia ejerce durante este proceso fisiológico específico, pero estudios de 
expresión génica han demostrado un aumento en la expresión de las 
catepsinas B, K, S, L y D durante el destete. Es importante anotar que 
aunque su expresión aumenta a las 12h de destete, su actividad no aumenta 
hasta cierto tiempo después, dado que estas proteasas deben sufrir una serie 
de cambios post-traduccionales antes de estar activas (Clarkson et al, 2004; 
Watson & Kreuzaler, 2009). 
 
La catepsina D presenta un proceso de maduración desde su síntesis 
en la forma de pre-pro-catepsina D (412 amoniácidos) hasta su forma madura 
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final compuesta por dos cadenas, una pesada de 196 aminoácidos y otra de 
141 aminoácidos. A este proceso hay que añadir otras modificaciones como 
la formación de puentes disulfuro, la fosforilación y la glicosilación en 
diferentes residuos. El procesamiento de esta peptidasa tienen lugar en el 
compartimento endo-lisosomal (Minarowska et al, 2008). Durante el ciclo 
lactancia/involución, la catepsina D se ha visto que ejerce múltiples 
funciones: Es secretada como pro-catepsina D en la leche, se cree que para 
facilitar la digestión en el tracto digestivo del recién nacido. También es 
secretada por las células luminales hacia el lado basal, donde podría 
participar en el procesado de la PRL (Benes et al, 2008; Castino et al, 2008). 
Durante la involución, tal y como se ha mencionado, su función principal es 
como una endopeptidasa con un papel importante en la remodelación tisular 
y la necroptosis.  
 
Como se ha descrito, el proceso de involución de la glándula mamaria 
integra una compleja serie de mecanismos de señalización que deben estar 
reguladas para asegurar un resultado final que permita a la glándula estar 
preparada para un nuevo embarazo y lactancia. Es evidente que los actores 
que intervienen en este proceso son múltiples. Nuestro grupo, en un trabajo 
previo, estableció que la transcripción de Óxido Nítrico Sintasa Inducible 
(NOS2) era regulada por NF-κB (Zaragoza et al, 2005). NOS2 está implicada 
en muchos procesos pro-inflamatorios a través de la formación de óxido 
nítrico (NO) a concentraciones más elevadas y estables que las obtenidas 
con las formas constitutivas NOS1 y NOS3. NO es una molécula altamente 
reactiva que, dependiente de la concentración y del tiempo de exposición, 
tiene propiedades tóxicas o protectoras en las células. De hecho, se ha 
demostrado in vivo que en microambientes pro-inflamatorios las 
concentraciones de NO pueden alcanzar el rango µM; siendo la mayor fuente 
de NO los macrófagos, que juegan un papel fundamental en las respuestas 
inmunes e inflamatorias. El NO a concentraciones altas induce parada de 
ciclo celular e inhibición de la respiración mitocondrial. El NO a 
concentraciones elevadas ejerce sus acciones a través de la generación de 
radicales libres como las especies reactivas de nitrógeno (RNS) (ver figura 
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10; página 46) que reaccionan con otras moléculas, induciendo 
modificaciones nitrosativas como la s-nitrosilación de tioles de cisteína y la 
nitración de residuos de tirosina (Hess et al, 2005; Ischiropoulos, 2003). Si 
bien estas modificaciones proteicas no son dependientes de una reacción 
enzimática, sí son procesos altamente selectivos pudiendo ejercer un papel 
importante en la regulación de diferentes vías de señalización. Por ejemplo, 
se ha descrito que las modificaciones nitrosativas regulan la activación de las 
vías de NF-κB y AKT (Nomiyama et al, 2004; Yakovlev et al, 2007). Tomando 
en consideración todos estos datos, se concluye que el NO es un mediador 
de la señalización celular que puede influir en múltiples vías. Dado que su 
concentración aumenta en ambientes pro-inflamatorios como la involución de 
la glándula mamaria post-destete, su rol específico en este proceso debería 
ser caracterizado en mayor profundidad.  
 
El estudio de los mecanismos moleculares que intervienen en la 
regulación de la involución de la glándula mamaria revela diferentes procesos 
biológicos que se suceden en el tiempo, y a su vez, se superponen. La 
proliferación celular se da, no sólo durante el desarrollo puberal y el 
embarazo, sino que también sucede durante la involución post-lactancia 
(Wiesen & Werb, 2000). La inducción concomitante de señales de apoptosis, 
inflamación y proliferación podrían suponer un conflicto para la célula. En 
condiciones fisiológicas, un balance adecuado de todas estas vías de 
señalización condicionan la homeostasis tisular. Es importante recalcar, que 
la mayor parte de las proteínas y de las vías de señalización que regulan este 
proceso también han sido identificadas como oncogenes y factores de 
transcripción que se activan durante la transformación neoplásica. De hecho, 
STAT3 y NF-κB no sólo modulan la proliferación y la muerte celular, también 
han sido implicados en el desarrollo neoplásico a través de la inducción de 
ambientes pro-inflamatorios que en parte simulan el microambiente que se da 
durante la involución tras el destete (Chariot, 2009; Torres et al, 2011). De 
hecho, trabajos ya publicados sugieren que la des-regulación del proceso de 
involución post-lactancia puede facilitar la progresión tumoral (Lyons et al, 
2011; Radisky & Hartmann, 2009; Torres et al, 2011). 
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OBJETIVOS 
 
1. Nuestro grupo ha establecido que NOS2 es inducida por NF-κB a 8h del 
destete (Zaragoza et al, 2005). NOS2 está implicada en muchos procesos 
pro-inflamatorios, induciendo altas concentraciones de NO de manera más 
estable que las alcanzadas con NOS1 y NOS3. Estos datos, junto con los 
trabajos que definen la regresión mamaria post-lactancia como un modelo 
pro-inflamatorio, suscitaron la pregunta acerca del papel exacto de NO en el 
proceso de involución. Nuestro primer objetivo es establecer el papel de NO 
como molécula de señalización en el proceso de involución, específicamente 
en la regulación de dos de las principales vías implicadas en la involución, 
STAT3 y NF-κB. 
 
2. NO es una molécula altamente reactiva que produce especies reactivas 
nitrosativas. NO puede ejercer roles contradictorios dependiendo de la 
concentración y la exposición temporal (Thomas et al, 2008). NO puede 
inducir una serie de modificaciones nitrosativas post-traduccionales en 
proteínas y lípidos que juegan un papel clave en la fisiología celular y 
patogénesis (White et al, 2010). En proteínas, estas modificaciones se 
manifiestan de dos formas, como s-nitrosilación de tioles de cisteína o como 
nitración de residuos de tirosina. El segundo objetivo del presente trabajo es 
explorar el posible papel de modificaciones nitrosativas específicas en la 
involución de la glándula mamaria y cómo estas modificaciones post-
traduccionales afectan la función proteica. 
 
3. El embarazo se asocia con una reducción del riesgo de desarrollar cáncer 
de mama  a lo largo de la vida de una mujer (Albrektsen et al, 1994; 
MacMahon et al, 1973; Rosner et al, 1994). Sin embargo, estudios sobre la 
incidencia de cáncer de mama han demostrado que existe un aumento 
transitorio en el riesgo de cáncer de mama en los años que siguen al 
embarazo (Albrektsen et al, 2005; Chie et al, 2000; Lambe et al, 1994). Así 
pues, el embarazo puede suprimir o promover la carcinogénesis mamaria, 
dado que el efecto inicial de cualquier embarazo a término es de aumento de 
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riesgo, pero existe un efecto protector a largo plazo en mujeres de edad joven 
en el primer embarazo y un mayor número de gestaciones (Lord et al, 2008). 
Una de las hipótesis que explica este aumento de riesgo transitorio postula 
que la involución de la glándula mamaria que se da necesariamente tras una 
gestación a término, implica la activación de una serie de mecanismos que 
remedan un microambiente pro-inflamatorio y pro-carcinogénico (Schedin, 
2006). NO es una de las moléculas inducidas en ambinentes pro-
inflamatorios, y se ha demostrado que tiene efectos pro-apoptóticos o pro-
supervivencia celular en función de la dosis y el tiempo de exposición 
(Thomas et al, 2008). El tercer objetivo es explorar en un modelo celular de 
cáncer de mama luminal las vías de señalización específicas que se activan 
tras la exposición a NO a concentraciones elevadas. El objetivo principal en 
este apartado es determinar qué mecanismos fisiológicos estudiados en los 
dos objetivos previos son reclutados por las células epiteliales transformadas 
cuando son expuestas a altas concentraciones de NO.  
 
RESUMEN DE LAS PRINCIPALES TÉCNICAS UTILIZADAS EN 
MATERIALES Y MÉTODOS 
 
1. OBTENCIÓN DE TEJIDO MAMARIO DE RATAS Y RATONES     
Para la consecución de este trabajo se emplearon ratas wistar 
embarazadas (Harlan) y ratones hembra de la cepa C57BL/6  de Taconic, 
“wild type” (WT) y knock out para el gen NOS2  (NOS2-KO). En todo 
momento los animales fueron tratados siguiendo estrictamente la legislación 
vigente. Los protocolos experimentales fueron aprobados por la Comisión de 
Ética en la Investigación Experimental de la Universidad de Valencia.  
 
Para la obtención de muestras tisulares  los animales fueron 
anestesiados con  tiopental sódico por inyección intraperitoneal (60 mg.Kg-1 
de peso corporal, en ClNa 0.9 %). Después las glándulas mamarias 
inguinales  se extrajeron rápidamente, se lavaron con suero fisiológico y e 
inmediatamente se congelaron por la técnica del freeze-clamped. 
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Posteriormente los órganos enteros y  congelados se almacenaron a -80 ºC 
hasta su procesado.  
Una parte de la glándula mamaria de ratones de cada condición se fijó en 
paraformaldehído 4%(w/v) y se conservó en parafina para realizar cortes 
histológicos, tinción con hematoxilia-eosina y estudio microscópico.   
 
2. CULTIVO CELULAR 
 
La línea celular utilizada para los estudios in vitro fue MCF-7, obtenida 
de la American Type Culture Collection (ATCC). Los diferentes experimentos 
fueron realizados cuando las placas de cultivo alcanzaban una confluencia 
del 70%. Los experimentos con donantes de NO se realizaron utilizando 
hidrocloruro de 3-Morfolinosidnonimina SIN-1 (sigma-aldrich) a diferentes 
concentraciones y con tiempos de exposición crecientes. Los estudios de 
viabilidad celular se realizaron con MTT (Bromuro de 3-(4,5- dimetiltiazol-2-
ilo)-2,5-difeniltetrazol), un tetrazol amarillo que se reduce a formazán (color 
lila) en células viables.  
 
3. CUANTIFICACIÓN DE LOS NIVELES PLASMÁTICOS DE PRL 
 
En el día 10 de lactancia se recogió sangre de ratones WT y NOS2-KO 
(n=3 para cada condición). Tras centrifugar, se recogió el sobrenadante 
(plasma) y se utilizó para medir niveles de PRL utilizando un kit comercial 
(SPIbio) basado en un inmunoensayo enzimático.  
 
4. DETERMINACIÓN POR COLORIMETRÍA Y FLUOROMETRÍA DE LAS 
CONCENTRACIONES DE NITRITOS  
 
En los estudios con líneas celulares, los niveles de nitritos se midieron 
con un kit de colorimetría (Cayman Chemical Company). Dado que este kit no 
era lo suficientemente sensible para medir la concentración de nitritos in vivo 
en tejido mamario, para este caso se utilizó un método de fluorimetría basado 
en la reacción del 2,3-diaminonaftaleno (Sigma-Aldrich) con nitrito en 
condiciones de pH ácido para formar 1-(H)-naftotriazol, un producto 
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fluorescente que cuantificamos utilizando el SPECTRAmax GEMINI XS 
Microplate Sectrofluorometer (Molecular Devices, Inc. Sunnyvale, CA. USA).  
	  
4. GENOTIPADO DE RATONES 
 
  Para determinar el genotio de los ratones WT y NOS2-KO se cortaron 
las colas que fueron incubadas en buffer TESNA (100mM Tris/HCl pH7,5; 
10mM EDTA; 2% SDS y 10mM NaCl) con proteinasa K. El producto se 
mezcló con  1 volumen de Fenol:Cloroformo:Isoamil Alcohol (25:24:1) y se 
centrifugó. Se recuperó la fase acuosa a la que se añadió 500µL de para 
realizar una segunda centrifugación. Finalmente el pellet se lavó con etanol 
80% y resuspenddido en 65µL de H20. Posteriormente se realizó una PCR 
utilizando los primers mencionados en la tabla 4 de la página 68. El uso de 
tres oligonucleótidos se debió a que los ratones NOS2-KO sí presentan el 
gen, pero en una forma truncada, por lo que el primer forward para WT era 
diferente del primer para KO.  
Condiciones de la PCR: 95°C (1min); [95°C (30s); 63°C (30s); 72°C (30s)] 
repeat for 40 cycles; 72°C (10min); 4°C(∝).  
 
El producto de amplificación se cargó en un gel de agarosa al 1.5% 
agarosa y la lectura se realizó utilizando un sistema de análisis de imagen 
UVIdoc (UVITEC Limited, Cambridge, UK). 
 
6. EXTRACCIÓN DE RNA 
 
    RNA total de tejido de glándula mamaria y de pellets celulares fue 
extraído utilizando el reactivo TRIzol (Invitrogen Life Technologies), 
cloroformo y  alcohol isopropílico. Tras el aislamiento, se realizó una 
purificación por columnas adicional (RNeasy, Qiagen) siguiendo las 
instrucciones del fabricante. La concentración y pureza del RNA fueron 
medidas con NanoDrop ND-2000 (NanoDrop Technologies); y su integridad 
mediante la determinación del ratio  RNA 28S/18S utilizando RNA 6000 Nano 
Labchips en un Agilent 2100 Bioanalyzer (Agilent Technologies).	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7. RT-PCR EN TIEMPO REAL 	  
	  
El RNA fue retro-transcrito a cDNA utilizando el Real-Time RT-PCR high 
capacity cDNA reverse transcription kit (Applied Biosystems). Los productos 
de cDNA fueron amplificados por qPCR utilizando la  GeneAmp Fast PCR 
Master Mix (Applied Biosystems). Se realizó una PCR cuantitativa en  
7900HT Fast Real-Time PCR System. Los primers pre-diseñados fueron 
adquiridos Applied Biosystems (ver tabla 5 página 69). 	  
 
8. ENSAYO DE INMUNOPRECIPITACIÓN DE CROMATINA (ChIP ASSAY) 
 
El ensayo de inmunoprecipitación de la cromatina (ChIP assay) permite 
identificar la unión de una determinada proteína o factor de trascripción a un 
promotor específico. Esta técnica se realizó mediante los siguientes pasos: 
se trató con formaldehído las muestras de glándula mamaria para establecer 
enlaces carbamida entre la cromatina y cualquier proteína que estuviese 
unida a ésta en un momento específico. La cromatina fijada fue sometida a 
sonicación (15 pulsos de 10s a una amplitud del 38% con paradas de 50s) 
para obtener fragmentos de ≈500pb; y posteriormente centrifugada. Se 
determinó la concentración de la misma y su tamaño final. Esta cromatina  se 
pre-lavó con las bolas de agarosa A/G durante 4h a 4°C en rotación. Tras 
centrifugar las muestras se cogió una alícuota de los sobrenadantes y se 
incubaron con 2µg de anticuerpos específicos frente las subunidades NF-κB 
p65 y p50 durante toda la noche a 4°C en rotación. Posteriormente se 
incubaron co las bolas de agarosa previamente bloqueadas y los 
inmunocomplejos se recuperaron con una serie de lavados con tampones de 
baja y alta salinidad, LiCl y finalmente con TE (Sandoval et al, 2004). La 
cromatina inmunoseleccionada fue eluída con tampón de elución y el DNA 
fue purificado con el kit QIAquick® DNA (QIAGEN, Hilden, Germany). 
También se trató una alícuota de cromatina en presencia de anticuerpo no 
relacionado (IgG) y se guardó parte de la muestra no incubada con las bolas 
de agarosa como input. Tras la purificación del DNA, se realizó una PCR con 
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los pares de primers para amplificar la región promotora de MMP-9 (Primer 
forward: 5’- GTGAACACGGTGGCTGAAA-3’. Primer reverse: 5’-
CAGGCTCTTTGAAGCAGGATT-3’).  
 
La PCR se realizó con NETZYME® DNA Polymerase mediante el 
sistema Gene Amp PCR system 2700 (Applied Biosystems) y las condiciones 
de PCR fueron las siguientes:  
93°C (2min); [93°C (30s); 58°C (30s); 72°C (30s)] repetir 37 ciclos; 
72°C (10min); 4°C(∝).  
El producto de la amplificación fue cargado en un gel de 1.5% de 
agarosa/TAE con tampón de carga de DNA y bromuro de etidio para su 
posterior lectura.  
 
9. OBTENCIÓN DE PROTEÍNAS 
 
El tejido mamario (de ratón o rata) o los cultivos celulares se 
homogenizaron en tampón RIPA con inhibidores de proteasas y, tras 
centrifugación para eliminar restos celulares, se guardó el sobrenadante en el 
que cuantificaron las proteínas por el método Bradford. 
 
10. WESTERN BLOT E INMUNOPRECIPITACIÓN  
 
Los niveles de proteínas se analizaron mediante procedimientos 
convencionales de inmunoblotting. 15µg proteínas se desnaturalizaron con 
tampón Laemli y calentando a 95ºC. Posteriormente se  cargaron en un gel 
de acrilamida a concentraciones variables en función del peso molecular de 
la proteína que se deseaba determinar (entre 8% y 12%)  para proceder a su 
separación por tamaño. Tras la electroforesis, se transfirieron las proteínas a 
una membrana de nitrocelulosa donde se detectaron los niveles de las 
diferentes proteínas con un anticuerpo específico (ver tabla 6 página 76). Los 
inmunocomplejos formados se revelaron usando un anticuerpo secundario 
conjugado con peroxidasa y una reacción quimioluminiscente inducida por la 
peroxidasa.  
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11. INMUNOPRECIPITACIÓN DE CATEPSINA D 
 
Se utilizaron bolas de sefarosa de Proteina A y Protein G beads(GE 
Healthcare UK Limited) (50:50 v/v) bloqueadas con albúmina sérica bovina. 
1mg de proteínas obtenidos de los tejidos de glándula mamaria lisados fue 
pre-lavado con las bolas previamente bloqueadas. El sobrenadante se incubó 
con anticuerpo anti-catepsina D o con un anticuerpo no relacionado y 
posteriormente con las bolas de sefarosa. Tras la centrifugación se utilizó el 
sobrenadante de estas muestras como input y los pellets formados por los 
inmunocomplejos unidos a las bolas se lavaron y eluyeron para obtener las 
proteínas inmunoprecipitadas y posteriormente evaluarlas por inmunobloting.   
 
También se realizaron inmunoprecipitaciones de catepsina D utilizando 
un método alternativo con bolas de agarosa cubiertas con Pepstatina A 
(Sigma). Los homogenados de glándula mamaria fueron incubados con estas 
bolas durante 15h, a 4°C. Posteriormente las muestras se centrifugaron a 
20000g y el pellet se lavó con tampón 20mM citrato-fosfato. Finalmente el 
pellet se resuspendió y desnaturalizó en tampón Laemly previo al análisis por 
western-blot. 
 
12. DETERMINACIÓN DE LA ACTIVIDAD DE CATEPSINA D 
 
 La actividad proteasa de la catepsina D fue medida utilizando un kit 
comercial (Sigma-Aldrich) que se basa en el método de Yasuda (Yasuda et 
al, 1999). Brevemente, se añadió tampón del kit (pH3,5) a 5µg de proteínas 
obtenidas de tejido mamario de ratas y ratones lactantes o en diferentes 
momentos del destete. Posteriormente se añadió el sustrato fluorométrico 7-
metoxicumarina-4-ácido acético 20µM. El enzima activo actuó sobre el 
sustrato que tras ser procesado libera fluorescencia que fue medida con el 
fluorómetro SPECTRAmaz GEMINI XS Microplate (Molecular Devices, Inc. 
Sunnyvale, CA. USA) durante 60min, en una reacción cinética a 37°C. Para 
comprobar que el sustrato sólo era hidrolizado por la catepsina D, se añadió 
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el inhibidor específico pepstatina A (Sigma) en muestras paralelas. El test 
también se realizó con catepsina D humana recombinante (Sigma-Aldrich) 
tratada con ONOO- para determinar si la nitración afectaba la actividad 
proteasa.  
 
13. ANÁLISIS ESTADÍSTICO 
 
Los resultados se muestran como medias ± S.E.M. Los datos obtenidos 
en los experimentos con ratas control y en destete así como con ratones WT 
y NOS2-KO dentro del mismo genotipo fueron analizados con ANOVA de una 
vía. La homogeneidad de las variancias se analizó con el test de Levene test. 
En el caso de que las variancias fueran desiguales, los datos se 
transformaron de forma adecuada antes de realizar la ANOVA. Las 
diferencias significativas fueron determinadas por el test de Tukey-Kramer. La 
letra “a” siempre representa el valor inferior dentro del grupo. Se consideraron 
estadísticamente significativas las diferencias con p<0.05. Un test de T-
Student con la corrección de Bonferroni se utilizó para la comparación de dos 
grupos entre sí.  Las diferencias se consideraron estadísticamente 
significativas si p<0.05. Estudios independientes se realizaron con un mínimo 
de tres replicas por cada condición para permitir la comparación estadística.  
 
RESULTADOS Y DISCUSIÓN 
 
1. ACCIÓN GLOBAL DEL NO EN LA INVOLUCIÓN DE LA GLÁNDULA 
MAMARIA 
 
El NO puede ser un modulador de la señalización, no sólo durante la 
involución mamaria, si no también durante el embarazo y la lactancia, 
momento en el cual la proliferación y diferenciación de las células epiteliales 
es máxima. De hecho, las tres isoformas de óxido nítrico sintasa (NOS1, 
NOS2, NOS3) se expresan en el epitelio mamario normal (Khalkhali-Ellis & 
Hendrix, 2003) aumentando dicha expresión durante la involución post-
lactancia (Islam et al, 2009; Zaragoza et al, 2005). En nuestro modelo, los 
niveles de nitritos aumentaron significativamente en el tejido mamario tanto 
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en ratones WT como en NOS2-KO (figura 13 página 88), pero estos era 
significativamente más elevados en los animales WT. El incremento 
observado en los ratones KO puede deberse a la activación de formas 
constitutivas de NOS, como se demuestra en la figura 14 de la página 89. 
 
La diferencia en la producción de NO entre ratones WT y NOS2-KO se 
correlaciona con un fenotipo involutivo diferente, dado que en los ratones KO 
la involución se ve retrasada 24h (figuras 15 y 16). A estas diferencias en la 
histología se suman diferencias significativas en el peso de la glándula 
mamaria, la producción de leche y el peso de las crías (figuras 17, 18 y 19 
respectivamente) que era mayor en los ratones genéticamente modificados. 
Estas diferencias podían deberes a alteraciones en el control de la lactancia o 
de la involución, o de ambos procesos, por lo que realizamos una serie de 
experimentos para dilucidar el mecanismo de acción de NO en este contexto. 
  
La principal hormona reguladora de la lactancia es la PRL, que actúa en 
las células epiteliales a través de la unión con su receptor (PRLR). Esta unión 
activará la vía JAK/STAT activándose STAT5. STAT5 activo (fosforilado p-
STAT5) se trasloca al núcleo donde activa la trascripción de múltiples genes, 
entre los cuales figuran genes de proteínas de la leche como la β-caseína 
(Miyoshi et al, 2001). Otros trabajos han establecido que NO actúa inhibiendo 
de la liberación de PRL dependiente de Ca2+ en la adenohipófisis (Andric et 
al, 2003; Duvilanski et al, 1995), lo cual podría significar que una disminución 
en los niveles circulantes de NO aumentaría la liberación de PRL, 
prolongando la lactancia. Esta hipótesis fue la base de partida para 
profundizar en la vía se señalización de STAT5, el efector de PRL, en nuestro 
modelo experimental. En efecto, encontramos que la pérdida de NOS2 
implicaba la persistencia de p-STAT5 hasta 48h tras el destete (figura 20, 
página 97). Esto podría deberse en parte al aumento en los niveles 
plasmáticos de PRL que objetivamos en los ratones KO frente a los WT 
(213±16ng/mL vs 165±27ng/mL respectivamente), pero no podemos 
descartar que NO puede tener una acción directa en la actividad de STAT5. 
De hecho, otros trabajos han descrito que NO inhibe la señalización de 
RESUMEN 
 
 
184 
STAT5 en macrófagos a través de la disminución directa  de los niveles de 
STAT5a y b (Starzynski et al, 2006) o de su fosforilación (Bingisser et al, 
1998). También quisimos comprobar si este aumento en la actividad de 
STAT5 influía en su función en el tejido mamario, y para ello estudiamos el 
patrón de expresión de β-caseína en lactancia e involución; observando que 
en los ratones NOS2-KO presentaban mayores niveles de mRNA de dicho 
gen en los ratones genéticamente modificados (figura 21, página 98). Todo 
ello concordante con la activación sostenida de STAT5, el aumento de la 
producción de leche, el mayor peso de las crías y el mayor peso de la 
glándula mamaria en estos ratones con respecto a los WT. Más aún, estos 
resultados apoyan nuestra hipótesis inicial de que la glándula mamaria en los 
ratones NOS2-KO se mantiene en un estasis funcional a pesar de la pérdida 
del estímulo de succión. Dado que los experimentos de sellado de tetilla han 
demostrado que la involución se inicia, no sólo por la caída de hormonas 
lactogénicas,  sino más bién por la pérdida del estímulo de succión, esto 
apoyaría también la idea de que el NO tiene un efecto directo en la primera 
fase de la involución, y no todos sus efectos se deben a una concentraciones 
plasmáticas de PRL sostenidas (Cross & Silver, 1956; Vina et al, 1981). 
 
Ha sido descrito que STAT5 y STAT3 están inversamente activados 
durante el ciclo lactancia/involución (Clarkson et al, 2006; Watson & Brown, 
2008). También ha sido publicado que el bloqueo de la activación de STAT3 
induce un retraso en la involución de STAT3 (Chapman et al, 1999). Por todo 
ello analizamos la fosforilación de STAT3 en el pico de lactancia y durante la 
involución, encontrando que si bien la activación de STAT3 no estaba 
retrasada en ratones NOS2-KO, los niveles de la misma eran claramente 
inferiores cuando se comparaban con los niveles de ratones WT. Lo mismo 
sucedía cuando determinamos su capacidad de unión al DNA (figuras 22 y 
23, páginas 99 y 100 respectivamente). Esta diferencia en la activación de 
STAT3 puede deberse al retraso en la inactivación de STAT5 visto 
previamente en los ratones KO o a un efecto directo de NO sobre STAT3, o 
ambos. La menor activación de STAT3 se vio traducida en una menor 
expresión de bcl-3, un gen diana de este factor de transcripción (figura 25, 
página 102).  
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Otra de las vías de señalización implicadas en la regulación del proceso 
de regresión post-lactancia es la vía de NF-κB, que se encuentra activada 
durante el embarazo, casi totalmente suprimida durante la lactancia y se 
activa nuevamente durante la involución tras el destete (Clarkson et al, 2000; 
Zaragoza et al, 2005). En diferentes modelos experimentales, se ha 
demostrado que NO puede regular su actividad de forma directa o indirecta 
(Fernandez-Martinez et al, 2004; Yakovlev et al, 2007). En nuestro modelo 
estudiamos si este factor de transcripción podría estar regulado por NO y ser 
responsable, al menos en parte, del retraso en la involución observado en los 
ratones NOS2-KO. Para ello medimos los niveles citoplásmicos de IκBα, su 
inhibidor fisiológico, confirmando un retraso de 24h en su degradación en los 
ratones KO (figura 27 A, página 105), lo que significa de una manera indirecta 
un retraso de 24h en la activación de factor de transcripción en los ratones 
NOS2-KO. Esta observación se confirmó con el estudio de unión a DNA de 
NF-κB (figura 27 B, página 105) en el que se objetivó que la actividad de 
unión a DNA de NF-κB en los ratones KO era significativamente inferior con 
respecto a los WT. En base a estos resultados, investigamos el alcance de 
este retraso en la activación de NF-κB en los ratones transgénicos evaluando 
por RT-qPCR la expresión diferencial de genes involucrados en la vía de este 
factor de transcripción. La tabla 9 (página 109) muestra una relación de los 
genes diferencialmente expresados a las 48h del  destete en ratones WT y 
NOS2-KO, objetivándose que 23 genes estaban regulados a la baja en los 
ratones KO con respecto de los WT, y ninguno estaba sobreexpresado. Estos 
datos se interpretan de varias maneras: i) el hecho de que todos los genes 
diferencialmente regulados estén infraexpresados en los ratones NOS2-KO 
sugiere que la vía de señalización de NF-κB está retrasada en estos ratones 
durante el destete. ii) algunos de los genes diferencialmente expresados son 
pro-apoptóticos, como las caspasas, bcl-3, elk-1 o tnf (Gouon-Evans et al, 
2000; Varela & Ip, 1996) lo que sugiere que un déficit de NOS2 implica una 
protección de apoptosis. Por último iii) otros de estos genes son anti-
apoptóticos, y sorprendentemente estos también están infraexpresados en 
los ratones KO, lo que nos plantea que una apoptosis menos severa se 
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traduce en una activación más pobre de las señales pro-supervivencia. Este 
planteamiento concuerda con la menor activación de AKT observada en 
nuestro modelo NOS2-KO (figura 26, página 103).  
 
Estos datos sobre señales pro y anti-apoptóticas dándose 
conjuntamente pueden parecer contradictorios si uno atiende a la definición 
de la primera fase de involución (apoptosis del tejido epitelial). Sin embargo, 
globalmente la involución post-lactancia es la adición de señales pro y anti-
apoptóticas que, si persiste el destete, inclinan la balanza hacia la apoptosis y 
la remodelación, pero las células restantes que sobreviven activarán 
mecanismos de supervivencia de manera controlada para asegurar una 
remodelación adecuada. Finalmente, los datos obtenidos sugieren que, si 
bien NF-κB está involucrado en la modulación de todos los genes listados, no 
existe una única vía que se encuentre afectada por la ausencia de NOS2, 
sino múltiples.  
Finalmente, en este primer objetivo del presente trabajo, se profundizó 
en el posible papel del NO en la regulación de la segunda fase de la 
involución post-lactancia, caracterizada por la existencia de una remodelación 
tisular que depende, principalmente, de proteasas efectoras. Otros trabajos 
han descrito que la extensión de la apoptosis  se correlaciona con la actividad 
de las metaloproteasas durante la segunda fase de la involución (Clarkson & 
Watson, 1999; Lund et al, 1996) y que la activación de NF-κB es una de las 
señales más importantes requeridas para inducir la expresión de MMP-9 (Li 
et al, 2009). Por todo ello se exploraron las consecuencias del retraso en la 
activación de NF-κB en ratones NOS2-KO en la segunda fase de la 
involución. Encontramos que la inducción de MMP-9 era más pronunciada en 
el destete en ratones WT que en los KO (figura 29, página 112), y dado que 
esto concordaba con el retraso de activación de NF-κB, comprobamos 
mediante ChIP assay que la expresión de MMP-9 dependía de este factor de 
transcripción (figura 30, página 114). Todos estos hallazgos apoyan la 
hipótesis de que el efecto de NO en la regulación de la involución de la 
glándula mamaria no se limita a la primera fase. A través de la modulación de 
la señalización de PRL, los diferentes factores de transcripción y sus 
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interacciones, la señal generada por NO en la primera fase se amplifica a 
través de las cascada de eventos que se dan en la segunda fase.  
 
2. PAPEL ESPECÍFICO DEL NO EN LA REGULACIÓN DE LA 
INVOLUCIÓN POST-LACTANCIA. MODIFICACIONES POST-
TRADUCCIONALES 
 
El segundo objetivo del proyecto fue establecer si NO inducía 
modificaciones post-traduccionales concretas a nivel proteico que indujeran 
cambios funcionales a nivel molecular, y así explicar el impacto de NO en el 
proceso involutivo de forma más específica.  Se realizó un estudio de nitro-
proteómica utilizando homogenados de glándula mamaria de rata lactante o 
tras 72h de destete. En los geles 2D (figura 32, página 117) se confirmó que 
la nitración proteica aumenta con el destete. Se recuperaron las proteínas 
diferencialmente nitradas que fueron analizadas mediante MALDI-TOF-MS. 
Una de estas proteínas, de 48KDa fue identificada, como catepsina D.  
 
La catepsina D es una proteasa aspártica endolisosomal que pertenece 
a la familia de las pepsinas (Tang & Wong, 1987) que aumenta durante el 
destete, donde juega un papel importante en la degradación proteica y la 
apoptosis celular. Se sabe que hasta alcanzar su forma totalmente activa 
debe sufrir una serie de modificaciones post-traduccionales. Esto podría 
explicar el en parte retraso que encontramos entre la activación de la 
proteasa (48h post-destete) y el aumento de mRNA y  de niveles de proteínas 
(8h post-destete) (figura 35, página 121). Los estudios de 
inmunoprecipitación confirmaron la nitración de la catepsina D en 
homogenados de glándula mamaria tras un destete de 72h; de estos 
resultados se dio la hipótesis que esta modificación post-traduccional fuese, 
al menos en parte, responsable de su activación (figuras 33 y 34, páginas 
118 e 119 respectivamente) .  
 
Como se presenta en las figuras 37, 38 y 39 (páginas 125, 126 y 127 
respectivamente) tanto la catepsina D de rata como la de origen humano y 
bovino presentan un aumento de orden de 0,5 en actividad en los estudios de 
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nitración in vivo. Con estos resultados podemos concluir que la nitración de 
tirosinas tiene un papel en la actividad de la catepsina D y que esta 
modificación post-traduccional parece jugar un papel directo en el aumento 
de su actividad catalítica y que esta modificación está conservada entre 
diferentes especies.  
 
Sin embargo, no se puede descartar que el NO active otros 
mecanismos que modulen la actividad de catepsina D de forma directa o 
indirecta, esto podría explicar por qué en los estudios in vitro el NO inducía 
un aumento del orden de 0,5 en la actividad proteasa pero este aumento era 
del orden de 2 cuando comparamos los ratones WT con los NOS2-KO (figura 
42 A página X). En los estudios in vivo se descartó que la ausencia de NOS2 
y por ende, la menor concentración de NO provocara diferencias en el 
procesamiento proteolítico de la catepsina D; lo que apunta que la nitración 
del residuo tirosina no aumenta la actividad enzimática a través de un 
mecanismo de autoprocesamiento (figura 42 B, página 130) sino que tenga 
un efecto directo en la actividad catalítica. La figura 40 (página 128) ilustra la 
caracterización del punto concreto de nitración en la catepsina D humana. Se 
identificó la tirosina de la posición 168 como el residuo modificado tras la 
exposición a ONOO-, sin embargo, dado que no pudimos secuenciar más del 
40% de la proteasa, no podemos descartar la presencia de otro residuo que 
esté nitrado. La Tyr168 se encuentra en la cadena pesada de la catepsina D y 
es un residuo muy conservado entre las especies (figura 41 página X). Otros 
grupos han descrito ampliamente la importancia del pH en la modulación de 
la actividad de la proteasa (Beaujouin & Liaudet-Coopman, 2008); y que la 
nitración de tirosinas puede inducir cambios profundos en la estructura y la 
función proteica dado el cambio inducido en el pKa del grupo hidroxilo 
(Sokolovsky et al, 1967). De hecho, el pH ácido conlleva una activación de la 
proteasa, pero en un pH7,5  los enlaces moleculares entre residuos tirosina 
específicos y los residuos aspartato del dominio catalítico estabilizan la 
estructura en una conformación inactiva (Masa et al, 2006). Por todo ello, 
sería plausible que la nitración en Tyr168 favoreciera una conformación activa 
e irreversible del enzima a través del bloqueo de la formación de un enlace 
crucial en el plegamiento del la proteasa.  
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La conclusión de esta segunda parte de nuestro trabajo es que NO no 
solo juega un papel en la regulación global del proceso  de involución, 
también induce modificaciones post-traduccionales específicas que tienen un 
impacto en la función proteica. En nuestro modelo encontramos una nitración 
de tirosina específica en catepsina D, una endopeptidasa aspáritca lisosomal 
crucial para la remodelación tisular. Nuestros trabajos in vivo e in vitro 
demuestran que esta nitración de tirosina resulta en la activación de 
catepsina D.   
 
3. PAPEL DEL NO EN UN MODELO DE CARCINOMA DE MAMA 
LUMINAL. DATOS PRELIMINARES 
 
Entender la relación entre las funciones fisiológicas de diferentes 
moléculas durante el desarrollo y sus funciones pro-carcinogénicas es crítico 
para desarrollar apropiadamente terapias diana-específicas. Nuestros 
hallazgos son relevantes en la medida que algunas de las principales vías 
involucradas en la involución post-lactancia: STAT3, NF-κB y PI3K/AKT están 
a su vez, íntimamente relacionadas con mecanismos de supervivencia y 
proliferación celular en cáncer. Esto significa que los procesos fisiológicos  
tiene que estar muy bien orquestrados y las vías de señalización reclutadas 
tienen que activarse e inhibirse en los momentos adecuados para una 
adecuada progresión del proceso. Significa también que, dependiendo del 
contexto, los factores de transcripción pueden tener funciones pro- o anti-
apotóticas. Un error en la regulación de estos mecanismos podría facilitar un 
evento oncogénico que, en un microambiente adecuado, puede progresar y 
dar lugar a una neoplasia. 
 
La incidencia de cáncer de mama está aumentando en mujeres jóvenes, 
y esto se debe entre otros muchos factores al retraso en la edad de la 
primera concepción (Lord et al, 2008). Esto podría resultar una paradoja, ya 
que se sabe que el embarazo se asocia epidemiológicamente a una 
reducción del riesgo de desarrollar cáncer de mama a lo largo de la vida 
(Albrektsen et al, 1994; MacMahon et al, 1973; Rosner et al, 1994). Sin 
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embargo se sabe que el efecto protector del embarazo no es ni inmediato ni 
constante, y, mientras que la paridad se asocia  a una reducción global del 
riesgo de cáncer de mama, estudios sobre la incidencia de este tipo de tumor 
han demostrado un aumento transitorio del riesgo en los años siguientes a 
una gestación a término, independientemente de la edad (Albrektsen et al, 
2005; Chie et al, 2000; Lambe et al, 1994). Así pues, la gestación puede 
aumentar y disminuir el riesgo de cáncer de mama a la vez, dado que el 
efecto inicial es de aumento de riesgo y el global es de protección, si bien 
este efecto protector sólo se produce cuando la edad del primer embarazo es 
inferior a los 35 años (Lyons et al, 2011; Lyons et al, 2009; Rosner et al, 
1994; Schedin, 2006). Una de las hipótesis que intenta explicar este aumento 
transitorio del riesgo postula que la involución mamaria post-lactancia implica 
la activación de una serie de mecanismos que remedan el microambiente 
típico de la cicatrización, que es altamente pro-carcinogénico.  
 
En la parte final de el presente trabajo se planteó la pregunta de si la 
exposición a altas concentraciones de NO tenía un impacto específico en las 
vías de señalización que son reguladas por esta molécula durante la 
involución tras el destete, pero en un modelo de carcinoma de mama perfil 
luminal. El efecto que encontramos en nuestro modelo apoya la idea que 
altas concentraciones de NO podría tener un efecto dual. Por un lado, y en 
concordancia con otros estudios, induciría apoptosis (Borutaite & Brown, 
2006; Cleeter et al, 1994; Thomas et al, 2004). De hecho, las células MCF-7 
presentaban menor viabilidad cuando eran expuestas a concentraciones 
crecientes de NO (figura 45, página 134). Por el otro lado, concentraciones 
elevadas de NO parecen estar activando vías de señalización claramente 
relacionadas con la supervivencia, como AKT y NF-κB (figuras 46 y 47, 
páginas 135 y 136 respectivamente) y lo más interesante es que parece 
existir un paralelismo con el proceso de involución tras la lactancia. En 
conjunto, nuestros datos señalan la posibilidad de que las células de cáncer 
de mama, tras ser estimuladas con NO activen los mismos mecanismos 
observados durante ela involución post-lactancia, y que, como en el proceso 
fisiológico, la activación de estas vías parece depender, al menos en parte, 
de la exposición al NO. Por supuesto, son datos muy preliminares; de hecho, 
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sería interesante corroborar la activación de la vía PI3K/AKT/mTOR mediante 
el análisis de la expresión de genes diana  de la vía. También sería 
interesante profundizar en punto en el que la vía de AKT se activa tras 
exposición a NO.  
 
Entender la relación entre las funciones fisiológicas de un proceso 
particular del desarrollo normal y la homeostasis tisular es crucial, ya que 
todos los procesos fisiológicos son un balance finamente regulado de una 
series de vías de señalización que pueden tener funciones contradictorias. En 
nuestro modelo NOS2-KO hemos encontrado una desregulación de este 
balance durante la involución glandular post-lactancia. Esta desregulación se 
debe a una alteración en las concentraciones tisulares de NO, lo que da lugar 
a un retraso en la apoptosis, pero también una Infra-expresión de genes pro-
supervivencia. Este fenómeno podría deberse a que la pérdida del estímulo 
pro-apoptótico del NO también altera la contra-partida pro-supervivencia. Así 
pues, en un microambiente por-inflamatorio como la regresión post-lactancia, 
el NO induce apoptosis, pero también puede facilitar la proliferación de las 
células que quedan a través de la activación de vías como AKT.  
 
Sabemos que  una célula, en su camino hacia la transformación 
neoplásica reclutará mecanismos ya existentes para poder sobrevivir, sólo 
que estos mecanismos serán des-regulados y adaptados para suplir las 
nuevas necesidades de la célula. De hecho, en los datos preliminares 
obtenidos in vitro hemos visto que las células tumorales reclutan mecanismos 
específicos del proceso fisiológico de involución post-destete. Es de notar 
que estos mecanismos han sido ampliamente descritos como pro-
supervivencia en el contexto de transformación neoplásica, lo que podría 
significar que, si bien altas concentraciones de NO implican muerte celular, 
las células viables podrían estar asegurando su supervivencia activando 
mecanismos que la faciliten, y así utilizar la noxa inicialmente inductora de 
apoptosis en su propio beneficio, lo cual podría tener implicaciones 
terapéuticas importantes. 
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CONCLUSIONES 
 
Nuestro trabajo demuestra la importancia de NOS2  así como el incremento 
en la concentración de NO en la regulación de los cambios que se dan 
durante la involución mamaria post-lactancia. Concluimos que mantener los 
niveles adecuados de NO, junto con otros factores de regulación, es esencial 
para la correcta modulación de la actividad de factores de transcripción, de 
modificaciones post-traduccionales y la adecuada regulación de las 
interacciones que conducen a la involución y remodelación del tejido mamario 
cuando la lactancia finaliza.  
 
5. En este trabajo hemos estudiado los efectos de la ausencia de NOS2 
en la involución mammaria tras el destete. Esta ausencia resulta en 
una menor concentración de los niveles de NO en los ratones NOS2-
KO, que conlleva un retraso en el proceso involutivo. Hemos evaluado 
este retraso por medio de estudios de inmunohistoquímica producción 
de leche y activación de caspasa 3.  
6. Para comprender mejor las diferencias observadas a nivel 
macroscópico e histológico, realizamos estudios moleculares. Las 
principales vías de señalización que controlan la involución post-
destete se ven claramente retrasadas en los ratones NOS2-KO. Las 
diferencias más importantes se han visto a las 48h post-destete, 
específicamente en la activación STAT3 y de NF-κB. Esto conlleva 
una alteración en la regulación de sus dianas transcripcionales (por 
ejemplo β-casein, Bcl-3, MMP-9); lo cual afecta la primera fase del 
proceso, donde la apoptosis es el principal evento, pero también la 
segunda fase en la que se da la remodelación de la matriz 
extracellular. 
7. El NO no solo juega un papel en la regulación del proceso global, sino 
que también induce modificaciones post-traduccionales específicas 
que interfieren en la función proteica. En nuestro modelo objetivamos 
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que la nitración de tirosinas en la catepsina D tiene   un impacto en su 
actividad proteasa.  
8. Con respecto al cancer de mama, la exposición in vitro a altas 
concentraciones de NO reduce la viabilidad cellular; sin embargo, las 
células que sobreviven activan mecanismos específicos del proceso 
de involución post-lactancia. En nuestro trabajo objetivamos qie altas 
concentraciones de NO inducen muerte cellular pero también 
fosforilación de AKT y activación de and NF-κB, que son señales pro-
supervivencia.  
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Ooooooooh oooh oooh oooh oooh oooh oooh ooh ooh ooh ooh ooh ooh 
Don’t worry. 
Ooh ooh ooh ooh ooh ooh ooh.  
Be happy. 
Ooh ooh ooh ooh ooh 
Don’t worry, be happy. 
 
Bobby McFerrin 
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